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Abstract 
 
It is now known that at least 80% of the human genome is composed of non-coding 
DNA which has a biochemical activity and is involved in a wide range of activities 
and mechanisms. Among these, epigenetic modifications, cis-trans gene expression 
regulation, transcription factor binding sequences, are the most studied.  
Non-coding DNA is often characterised by a polymorphic and repetitive nature and it 
is composed of a high density of GC nucleotides. These polymorphic and repetitive 
regions within the population may represent either protective elements or risk 
factors, based on population studies in various diseases, for several conditions and at 
the same time have the power to shape our behaviours or wellbeing.  
The compositions of transcription factor binding sites (BSs) and epigenetic factors at 
these regions act in concert with external and environmental factors to modify gene 
function and gene expression.  
This combined effect of environmental and genetic factors capable of influence 
people’s wellbeing or disease risk is known as Gene – Environment Interaction 
(GxE) and it is a key feature that allows us to adapt to our surrounding.  
The data presented in this thesis will try to address some of the well characterised 
polymorphic variants associated with Central Nervous System (CNS) conditions, 
such as the Monoamine oxidase A (MAOA) gene, and I will show how they can 
modify gene expression in response to environmental stimuli. We also report two 
regulatory regions in the CACNA1C (Calcium Voltage-Gated Channel Subunit 
Alpha1 C) gene, strongly associated to schizophrenia by GWAS (Genome-Wide 
Association Study) investigations. Finally I will also report a novel polymorphic 
microsatellite in the promoter region of the gene that has been defined “the master 
15 
 
regulator” of transcription, the RE1-Silencing Transcription factor (REST) gene, that 
strongly suggests an association with Alzheimer’s disease. 
Therefore I demonstrate a similarity in mechanisms and in the activity of these 
repeat elements in the promoter regions of three key genes for CNS behaviour and 
illustrate the potential power of these elements as transcriptional regulatory DNA 
regions. 
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General Introduction 
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1.1 Thesis introduction 
During the early 60s the genomic loci that did not code for protein were defined 
by the scientific community as “junk DNA”. The term had been made public by Dr. 
Susumu Ohno in 1972 (Ohno, 1972). His idea was that duplications and mutations in 
various genes remained silent in our genome with the unique function of spacing the 
coding genetic regions.  
In more recent years, the international Encyclopaedia of DNA Elements (Encode) 
recognised that at least 80% of the human genome has a biochemical function 
(Encode Project Consortium, 2012). It is now known that non-coding DNA is 
involved in epigenetic mechanisms, or constitutes cis- and trans- regulatory 
sequences. Part of the non-coding DNA are telomeres, introns and retrotransposons 
or constitute the binding sequences for transcription factors (TFs). 
However, one of the most important aspects of the non-coding DNA, which I will 
also focus on in this thesis, is their potential role in the regulation of gene expression. 
Different variants of non-coding DNA sequences have been associated with 
variations in gene expression both biochemical and in genetic association.  
In Chapters 3 and 4 I will focus on the Monoamine Oxidase A (MAOA) gene and 
the two polymorphic variants termed uVNTR (Sabol et al., 1998) and dVNTR 
(Philibert et al., 2011) and their role on MAOA expression. 
The MAOA gene has been proven to be a key gene, especially through the genetic 
associations of the uVNTR, in several stages of the human life and in several 
conditions (Table 1.3).  
This MAOA polymorphism has been also shown to moderate the infant emotions 
in relation to the mother’s stress during pregnancy (Hill et al., 2013) and at the same 
time it plays a role in maternal sensitivity (Pickles et al., 2013).  
18 
 
In Chapter 5 I explore another function of the non-coding DNA: its potential to 
operate as positive and negative regulators of gene expression. The promoter region 
of the GWAS (Genome-Wide Association Study) gene associated to schizophrenia 
(Obermair et al., 2004, Gwas Consortium Bipolar Disorder Working Group, 2011) 
CACNA1C (Calcium Voltage-Gated Channel Subunit Alpha1 C) will be the subject 
of this analysis. I used the UCSC web browser to study two domains in close 
proximity that might be polymorphic, making the overall structure of the CACNA1C 
promoter region similar to the promoter region of the MAOA gene. Therefore, I will 
investigate the polymorphic nature of these regions and, if they prove to be 
polymorphic, I will try to build an association with SCZ, as well as validate their 
activity through reporter gene constructs. 
Finally in Chapter 6 I explore the role of a novel polymorphic microsatellite in the 
REST gene promoter region. REST protein levels have been found dramatically 
reduced in Alzheimer’s disease (AD) patients’ brain (Lu et al., 2014) and it has been 
hypothesised that REST has a protective role in ageing brains. Therefore, I 
genotyped selected cohorts in order to test this novel microsatellite might represent a 
risk factor for CNS diseases and in particular AD. 
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1.2 Gene Regulation 
1.2.1 Transcription 
The regulation of gene expression represents a fundamental process for every 
organism whether they are prokaryotes or eukaryotes. Regulating the expression of 
particular genes in specific moments of these organisms’ life cycles makes them able 
to adapt to their environment, thus increasing their chances of surviving by 
expressing particular proteins only when needed (Raj and van Oudenaarden, 2008). 
The transcription process starts when the complex of general transcription factors 
(GTFs) binds to a particular DNA sequence, referred to as ‘core’ promoter, forming 
the pre-initiation complex (PIC) (Kornberg, 2005). In eukaryotes there are several 
GTFs required in order to initiate the transcription. These are TFIIA, TFIIB, TFIID, 
TFIIE, TFIIF and TFIIH (Lee and Young, 2000, Orphanides et al., 1996, Sainsbury 
et al., 2015) (Figure 1.1). 
After the PIC assembles, RNA polymerase II (Pol II) binds to it to initiate the 
transcription. This process can be additionally regulated by other proteins such as 
repressors or activators which are able to modulate the formation or the activity of 
the initiation complex. There is evidence of a mechanism in which GTFs are 
recruited by enhancer sequences before the transcription is initiated. Therefore, an 
enhancer-GTFs complex would activate the transcription by creating a loop in the 
DNA, closing the gap between the core promoter sequence and the enhancer-GFTs 
complex and only afterwards recruiting the Pol II (Szutorisz et al., 2005). 
The Pol II, once anchored to the DNA core promoter, creates a transcription 
bubble, separating the two DNA strands by melting the hydrogen bonds between 
nucleotides. At this point the Pol II can start the elongation process adding RNA 
nucleotides to the complementary DNA strand (Fuda et al., 2009). 
20 
 
Finally, transcriptional termination occurs when Pol II reaches the 3ʹ-end of the 
newly generated transcript where there are present polyadenylation signals which 
contain several cleavage components that allow the transcriptional machinery to 
terminate the mRNA (Lykke-Andersen and Jensen, 2007). 
The newly formed pre-mRNA can go through a series of post-transcriptional 
modifications, including 5ʹ- capping and/or splicing processes before the mature 
mRNA is translated into protein.  
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Figure 1.1 - Schematic representation of Pol II transcription initiation. Canonical model for pre-
initiation complex (PIC) assembly from general transcription factors (various colours) and RNA 
polymerase II (Pol II; grey) on promoter DNA. The names for the intermediate complexes that form 
during the initiation–elongation transition are provided to the left of the images. TFIID or its TATA 
box-binding protein (TBP) subunit binds to promoter DNA, inducing a bend. The TBP–DNA complex 
is then stabilised by TFIIB and TFIIA, which flank TBP on both sides. The resulting upstream 
promoter complex is joined by the Pol II–TFIIF complex, leading to the formation of the core PIC. 
Subsequent binding of TFIIE and TFIIH complete the PIC. In the presence of ATP, the DNA is 
opened (forming the ‘transcription bubble’) and RNA synthesis commences. Finally, dissociation of 
initiation factors enables the formation of the Pol II elongation complex, which is associated with 
transcription elongation factors (blue). Image from (Sainsbury et al., 2015) 
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1.2.2 Chromatin organization 
In eukaryotes, all the genetic information for a whole organism is stored inside the 
nucleus of each cell. In order to fit the entire DNA length inside it, DNA is densely 
packed into a protein-DNA complex, referred to as chromatin. 
Chromatin has several functions apart from reducing the volume of DNA inside 
the cells. One of the most important is regulating gene expression by different and 
coordinated folding and unfolding of chromatin structure organizations. There are 
several degrees of possible organization for the genetic material (Figure 1.2). The 
nucleosome is a fundamental, repeating unit composing the chromatin. The DNA 
wraps around a histone octamer composed of two H2A histones, two H2B, two H3 
and two H4. One after another, several nucleosomes, form the “beads-on-a-string” 
structure, which is a lightly packed structure that modulates transcription processes. 
In order to make this structure available for transcription, two principal and 
reversible mechanisms take place. Histones can be modified by enzymes that can add 
phosphate, methyl, or acetyl groups (Fischle et al., 2003). Alternatively, histones can 
also be displaced, allowing the transcription machinery to access DNA sequences 
and start the transcription (Smith and Peterson, 2005). 
Chromatin is otherwise packed in more dense structures. For example, the 30nm 
fibres contain the linker histone H1 that makes this structure highly stable (de la 
Serna and Imbalzano, 2002). During meiosis and mitosis, the 30 nm fibres are further 
packed in the 300nm fibres that looped in themselves give rise to the characteristic 
chromosome (Felsenfeld and Groudine, 2003). 
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Figure 1.2 - Chromatin organization. Representation of DNA major structures. From top left: DNA 
double helix, single nucleosome, "beads on a string" structure (euchromatin), 30 nm fibre nucleosome 
(heterochromatin), section of a chromosome, condensed section of a chromosome, chromosome. 
Image adapted from: https://en.wikipedia.org/wiki/Chromatin#/media/File:Chromatin_Structures.png  
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1.2.3 Epigenetic modifications 
The histone modifications, briefly mentioned in section 1.2.2, are part of a vast 
category of cellular variations that can respond to external environmental factors and 
are capable of influencing gene expression (Riffo-Campos et al., 2015). Together, 
these transitory mechanisms take the name of epigenetic modifications. In general, 
epigenetic modifications can be defined as heritable changes in gene expression that 
do not involve alterations to the DNA sequences but that can switch genes on or off, 
modulating the transcribed protein levels. Thus enabling changing in the phenotype 
without altering the genotype. Age, lifestyle, disease and environment are all factors 
that can influence epigenetic modifications.  
Specific epigenetic mechanisms include imprinting: where certain genes are 
expressed in a parent-of-origin-specific manner, X chromosome inactivation: the 
process where one of the two X chromosomes is inactivated in female mammal cells. 
However, three major systems are able, through interacting within themselves, to 
modulate gene expression: DNA methylation, histone modifications and RNA 
silencing (Egger et al., 2004). 
DNA methylation in the C5 DNA residues has been long proven to be an 
epigenetic silencing mechanism (Riggs, 1975, Riggs, 2002). These cytosine residues, 
that can be methylated by DNA methyltransferase (DNMT) enzymes, assemble in 
genomic regions, usually longer than 500 bps in size, where the GC content is above 
55%, referred to as CpG islands (Takai and Jones, 2002). The methylation of CpG 
islands in gene promoter regions is often associated with gene silencing (Phillips, 
2008) and altered methylation patterns have been associated with cancer 
development (Luczak and Jagodzinski, 2006). CpG methylation prevents TFs and 
Pol II from bind the DNA, hence silencing the gene. Alternatively, methylated DNA 
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binding proteins, such as m5CpG binding (MeCP) and m5CpG-binding domain 
(MBD) proteins, can prevent the transcription machinery from binding DNA by 
creating spatial hindrance (Luczak and Jagodzinski, 2006). 
Hypermethylation of tumour suppressive gene (TSG) promoters and 
hypomethylation of proto-oncogenes have both been observed during cancer 
development and/or metastasis (Herman and Baylin, 2003, Szyf et al., 2004). 
Altered methylation patterns have also been observed in relation to neurological 
and psychiatric disorders. An example is the hereditary sensory and autonomic 
neuropathy type 1 (HSAN1) condition where a mutation in the DNA (cytosine-5)-
methyltransferase 1 (DNMT1) gene interferes with DNA methylation maintenance 
causing dementia and hearing loss in adulthood (Klein et al., 2011). Another 
example is Fragile X Syndrome (FXS) where hypermethylation of a trinucleotide 
repeat expansion in the FMR1 (fragile X mental retardation 1) gene on the X 
chromosome silences the transcription, causing a form of mental retardation (Devys 
et al., 1993). 
In close coordination, proteins that bind methylated DNA also interact with 
complexes involved in histone modifications. Histone deacetylase remove acetyl 
groups from lysine residues in histone tails. As a result the histones wrap DNA more 
tightly, silencing transcription. For example, DNMT1 has been proven to interact 
with the histone deacetylase HDAC1, promoting gene silencing (Fuks et al., 2000). 
Opposite effects are produced by histone acetylases that, adding an acetyl group, 
make the DNA more available for transcription (Choudhary et al., 2009).  
Antisense non-coding RNAs, microRNAs (miRNA) and RNA interference 
(RNAi) have also the ability to regulate gene expression by silencing transcription 
through the formation of heterochromatin (Mattick and Makunin, 2005). A well 
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characterised example is the product of the XIST gene that in mammals is responsible 
for dosage compensation in females by silencing one of the X Chromosomes (Plath 
et al., 2002). In addition, it has been proven that altered miRNA pathways are 
present in several age-dependent neurodegenerative conditions (Gascon and Gao, 
2012). 
 
 
 
Figure 1.3 - Epigenetic modifications. Schematic of the mechanisms of the three distinct 
mechanisms of epigenetic regulation. Histone modifications, RNA-mediated gene silencing, and DNA 
methylation. Image from: Sawan et al. (2008) 
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1.3 Genetic polymorphisms 
Within individual and population gene pools are present different alleles of each 
genetic region. These genetic variations are supported by individuals carrying the 
different alleles variation which are caused by differences in the nucleotide 
sequences and usually arise through mutations. Some examples of different alleles 
present in this thesis are the MAOA VNTR, where 6 different alleles of the 30bp 
repeat are present among the population, and the REST VNTR where at least 4 
variants have been identified. These different alleles, but also many others, are 
capable of sustain differential expression depending on the length of the allele.  
Random mutations are the source of genetic variation and are defined as  
permanent changes in an organism’s genome. Through genetic mutations some 
viruses become more infective, more lethal and through the same process the 
immune systems are capable of defending the host from external challenges. 
Mutations are,  however, rare events and most likely to be neutral or deleterious. 
Advantageous mutations however can be favoured by natural selection. Genetic 
variation can be categorised according to the size of the mutation, less then 1Kbp 
include single nucleotide polymorphisms (SNP) where a single nucleotide is 
modified, insertions or deletions where a larger genetic region can be deleted or 
inserted into the genome. Above 1Kbp there are duplications, copy number variants 
(CNVs) or translocations. Each of these mutations exert a different effect on the 
genome and, therefore, to all the related downstream pathways. 
These genomic variants are often considered important genetic biomarkers to 
identify the susceptibility to several disorders. Among the multitude of common 
variants with low risk, there are some rare polymorphisms with moderate to high risk 
factor. 
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Great emphasis has been put into SNP analysis for mainly two reasons: firstly if 
these polymorphisms are in fact in the protein coding regions, a mutation can 
produce an aberrant protein that lacks function, producing a clear and easily 
identifiable phenotype in patients. Secondly, these single nucleotide substitutions are 
largely used to compare individual genotype frequencies as SNPs can be inherited in 
blocks, thus easily linked to a particular phenotype or disease. This feature has been 
exploited to identify genetic loci which may give insight on disease risk factors 
among the population. Linkage disequilibrium (LD) maps are a way by which the 
inheritance of these genetic biomarkers can be assessed or predicted. The vast 
majority of these single nucleotide mutations associated to a disease are located 
either in intronic or intergenic regions, and thus are non-coding (Hindorff et al., 
2009, MacKenzie et al., 2013).  
In recent years, the scientific community has increasingly given importance to 
genomic regions that are defined as Tandem Repeats (TRs) or Simple Sequence 
Repeats (SSRs) (Breen et al., 2008). Along with a better understanding of the 
genomic structures and genetic regulatory mechanisms, microsatellites and short 
tandem repeats gained more importance in disease onsets. 
In 2001 the international human genome sequencing consortium (Lander et al., 
2001) estimated that at least 3% of the human genome contains DNA tandem repeats 
and microsatellites, three times more than the protein coding sequences (~1%) in the 
human genome. These sequences are categorised by their repeat unit length: 
microsatellites are genomic region containing repetitions of 2-5bp (base pairs) or 
nucleotides and can be repeated 5-50 times. Longer motif lengths go under the name 
of minisatellites, however they are both part of the category referred to as variable 
number tandem repeats (VNTRs). Although their location can widely vary, they are 
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particularly abundant in gene promoter regions usually around 1kb upstream of the 
transcriptional start sites (Payseur et al., 2011). VNTR structures and sequences, 
often offer high affinity and specific binding motifs to transcriptional factors (TFs), 
essential for either initiating or to simply regulate the transcription of a gene (Breen 
et al., 2008).  
Taken together, the VNTRs ability to bind TFs and the fact that their variable 
copy number can bind multiple copies of the same TF support their importance in 
modulating gene expression. These polymorphisms can affect a wide variety of 
factors. Figure 1.4 summarises some of these possible effects, depending on the 
position they are located in the genome and their effects on downstream pathways.  
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Figure 1.4 - Genetic polymorphisms and their potential effects. The positions of the polymorphisms are indicated by the stars. When located in the intergenic or promoter 
regions they can modulate the expression acting as trans or cis regulatory elements respectively. Within the transcribed region they can affect the translated protein sequence 
and therefore its activity. DNA, RNA and protein levels can be affected by these polymorphisms. Abbreviations: ncRNA, non-coding RNA; ORF, open reading frame; UTR, 
untranslated region. Figure adapted from (Hannan, 2010). 
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1.4 Variable Number Tandem Repeats (VNTRs) 
Variable Number Tandem Repeats are genomic DNA sequences that can be 
repeated several times. One of the primary causes of mutation of these VNTRs can 
be accounted for by a mechanism termed replication slippage, consisting of a 
misalignment association during the DNA replication process (King et al., 1997). 
Probably the most important characteristic of VNTRs is their ability to regulate 
gene expression depending on the motif length. In addition, and because of this 
peculiarity, they have been associated to several human behavioural traits or CNS 
disorders. Table 1.1 summarises some of the most characterised VNTRs in genes 
such as those in the serotonin transporter (SLC6A4) and the dopamine transporter 
DAT1 (SLC6A3), for association to a specific disorder. The SLC6A4 repeat length 
polymorphism (5-HTTLPR), one of the most characterised VNTRs, is located 
upstream of the coding region of SLC6A4. Of the several variants present in the 
population, the most common alleles contain 14 and 16 repetitions of a GC-rich 
sequence (Nakamura et al., 2000). The shorter allele, with 14 repetitions, has been 
associated with lower gene expression in-vitro (Heils et al., 1996). Association 
analyses have also linked the short VNTR with more severe depressive symptoms 
compared to the long allele carriers (Goldman et al., 2010). 
Another well characterised VNTR is a 30 base pairs VNTR, termed uVNTR, in 
the promoter region of the MAOA gene (Sabol et al., 1998) and 10 base pairs 
VNTR, termed the dVNTR, 500 base pairs 5’ from the uVNTR (Philibert et al., 
2011). In section 1.8 I will talk more extensively about these VNTRs. 
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Table 1.1 - VNTR behavioural association 
Gene Motif (Repetitions) Location Association Reference 
Serotonin Transporter 
(SLC6A4),              
5-HTTLPR 
22 bp 
 
(14 allelic 
variants) 
Promoter 
Region 
Anxiety-
related traits 
(Sen et 
al., 2004) 
Serotonin Transporter 
(SLC6A4) 
STin2 
17 bp 
 
(9R - 10R - 12R) 
Intron 
Susceptibility 
to bipolar 
disorder 
(Lasky-Su 
et al., 
2005) 
DNA-binding protein 
Jarid2  
4 bp 
 
(8R to 13R) 
Coding Schizophrenia 
(Pedrosa 
et al., 
2007) 
Dopamine Transporter 
DAT1             
(SLC6A3)  
40 bp 
 
(3R to 11R) 
3ʹ UTR 
Attention 
deficit 
hyperactivity 
disorder 
(Cornish 
et al., 
2005) 
Table adapted from Fondon et al. (2008) 
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1.5 Microsatellites or Simple Sequence Repeats (SSRs) 
Microsatellites or Simple Sequence Repeats (SSRs) are short genomic sequences 
with a 2-5 nucleotide motifs repeated several times. They have been shown to be 
represented across the genome in a non-random distribution (Li et al., 2007) and they 
have also been implicated in several processes such as chromatin organization and 
gene regulation (Gymrek et al., 2016, Li et al., 2007). 
In humans, several neurological disorders have been associated with SSR 
expansions that frequently, as in the case of Huntington’s disease (HD), disrupt the 
protein activity by modifying the translated sequence when the expansion is located 
within a coding exon. The normal huntingtin (htt) protein contains a run of 6–35 
glutamines encoded by CAG repeats. Expansion of this glutamine run causes 
misfolding and/or abnormal cleavage of the resulting protein (Gusella and 
MacDonald, 2006). The altered protein is, in turn, responsible for progressive cell 
dysfunction and neuronal death which causes the symptoms of the pathology, such as 
cognitive deficits and dementia. 
In the case of the Fragile X mental retardation syndrome (FRAXA), an expansion 
located in the 5ʹ UTR of the gene causes a dramatic reduction in gene expression. 
Table 1.2 highlights some of these expansions where the disease outcome can be 
predicted by the length of the VNTR. 
However, despite the fact that most of these expansions coincide with severe 
diseases, it has been demonstrated that the vast amount of genetic variability that 
arise from all the VNTRs, especially the SSRs, present in the genome may play an 
important role in evolution contributing to a wide morphological and phenotypic 
variation within species (Fondon and Garner, 2004, Kashi and King, 2006).  
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Table 1.2 - VNTR disease association 
Disease Motif 
Expansion Length 
Location Reference 
Normal Pathology 
 
Huntington’s 
disease (HD) 
 
CAG 6 – 35 36 – 250 Exon 
(Gusella and 
MacDonald, 
2006) 
 
Fragile X mental 
retardation 
syndrome 
(FRAXA) 
 
CGG 6 – 53 >200 5ʹ UTR (Garber et al., 2006) 
 
Fragile X 
tremor/ataxia 
syndrome 
(FXTAS) 
 
CGG 6 – 53 55 – 200 5ʹ UTR (Loesch et al., 2007) 
 
Spinal and bulbar 
muscular atrophy 
(SBMA) 
 
CAG 9 – 36 38 – 65 Exon (Orr and Zoghbi, 2007) 
 
Amyotrophic 
Lateral Sclerosis 
(ALS) 
(C9ORF72 gene) 
 
GGGGCC < 20 > 30 Intron 
(DeJesus-
Hernandez et 
al., 2011, 
Majounie et al., 
2012, Renton et 
al., 2011) 
Table adapted from Fondon et al. (2008) 
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1.6 Alternative structures of repetitive elements: G-Quadruplex 
In addition to the well known DNA double helix conformation there are other 
more unusual structures, where the organisation and stability of these alternative 
structures is highly dependent on nucleic acid composition and chemical properties. 
One of these alternative DNA conformations takes the name of G-Quadruplex. As 
the name suggests, high G-rich DNA or RNA strands could be rearranged into a 
more stable conformation depending on the length of the sequence (Huppert, 2010). 
The predicted core structure of G-Quadruplexes contains four runs of guanines also 
known as a G-tract, each of which contains at least three guanines, separated by any 
other nucleotides (G≥3NxG≥3NxG≥3NxG≥3) (Bochman et al., 2012).  
Furthermore, cations such as K+ or Na+, have been found to intercalate in the G-
Quadruplex structure stabilising it (Dapic et al., 2003).  
Initially thought to be a purely in-vitro artefact, these structures have been found 
in telomeres (Paeschke et al., 2005) and in near proximity to TSSs possibly able to 
modulate transcription (Huppert, 2008, Huppert et al., 2008). To highlight the 
importance of these G-Quadruplex structures have been demonstrated to be highly 
evolutionary conserved genetic regions even among yeast (Capra et al., 2010). 
Figure 1.5 - G-Quadruplex. G-quadruplex structures are built from a core of two or more G-quartets; 
on the left the atomic structure of a G-quartet. Image from: (Balasubramanian et al., 2011) 
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1.7 Gene environment interaction ( G x E ) 
Different variants of the same gene or genetic regions shape a substantial amount 
of people’s phenotypes. This is also true for diseases. The initiation and/or 
progression of these diseases and the increase of the risk or protective factors that a 
specific genetic variant can give. A perfect example is Huntington’s disease where a 
genetic expansion provides a non functional protein (Warby et al., 1993). However, 
for some conditions, genetic variations are not sufficient to explain the disease or 
condition onsets and often are not consistent with the Mendelian modes of 
inheritance within families. In addition to genetic factors, that can be considered risk 
genotypes for a certain condition, a broad range of environmental components, 
whether they are biological (e.g., infections), chemical (e.g., oxy radicals), physical 
(e.g., radiation), behavioural (e.g., smoking) or even life events (e.g., injury, job 
loss), are able to impact on the chances of disease development in people. 
What has become more important in the last decades is the fact that the interplay 
between genetic and environmental factors is something that might explain the 
different outsets of some conditions in people with the same genotype but exposed to 
different environments.  
This combined effect of environmental factors and genetic factors capable of 
influence people’s wellbeing is known as Gene – Environment Interaction (GxE) 
(Moffitt et al., 2005). 
It has been extensively demonstrated that polymorphic genetic variants can be 
differentially influenced by environmental stressors and act independently on gene 
expression, therefore they can be considered predisposing factors in neuropsychiatric 
disorders or inappropriate behavioural responses (Quinn et al., 2013). The MAOA 
gene, in this theses extensively discussed in chapters 3 and 4, is one of the most cited 
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example of gene-environment interaction. The previous defined low- and high-
activity variants of the MAOA VNTR (uVNTR: 2, 5 repetitions and 3, 3.5 and 4 
repetitions respectively), have been linked to several CNS conditions through case-
control studies (Table 1.4). 
Furthermore, environmental factors have also the potential to modify the cells’ 
ability to adapt through epigenetic processes.  
DNA methylation, histone modifications and X chromosome inactivation are 
some of the epigenetic mechanisms that cells use to regulate gene expression in order 
to develop and to adapt to the environment that surrounds them.  
These epigenetic modifications are essential for normal development but they are 
easily influenced by environmental factors such as nutrition, stress or drugs that can 
modify in the medium or long term, or even permanently, gene expression. 
For example, studies in both human and rodents proved that early life experiences 
can modify the epigenetic signatures that in turn can influence behaviour in 
adulthood which may also arise to neurological conditions depending on 
environmental stressors exposition (Hill et al., 2013, Murgatroyd and Spengler, 
2011, Murgatroyd et al., 2015). 
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1.8 The Monoamine Oxidase A (MAOA) gene promoter VNTRs 
Monoamine oxidases (MAO) are enzymes located in the outer mitochondrial 
membranes, in part responsible for the turnover of some of the most important 
neurotransmitters. Serotonin (5HT), dopamine (DA) and noradrenaline (NA) are, 
along with the dietary monoamines such as tryptamine and phenylethylamine, 
oxidised by these enzymes. The MAOA and the monoamine oxidase B (MAOB) 
genes have been mapped in the X Chromosome at 43.52 – 43.61 Mb and 43.63 – 
43.74 Mb respectively and exhibit a tail-to-tail configuration beside the same intron-
exon organisation (Chen et al., 1992, Grimsby et al., 1991). MAOs catalyse 
the oxidative deamination of monoamines acting in concert with the covalently 
bound cofactor flavin adenine dinucleotide (FAD). According to Chen et al. (1991) 
the FAD covalent binding site appears to be located in MAOA exon XII (Cys 406). 
More recent crystallography studies (De Colibus et al., 2005) identified the FAD 
binding domain in residues 13–88, 220–294, and 400–462. This requires extensive 
protein folding in order for the FAD to correctly interact with MAOA and produce a 
functional enzymatic activity. The substrate-binding domain resides in residues 89–
219 and 295–399 and the intramembrane region is located in the C-terminal of the 
protein in residues 463–506.  
In the oxidative reaction, an oxygen atom is used to remove an amine group from 
a substrate molecule, resulting in the corresponding aldehyde with the production of 
an ammonia molecule (Gaweska and Fitzpatrick, 2011). MAOA is afterward 
reoxidised by molecular oxygen, which forms H2O2 in the process (Figure 1.6).  
Human MAOA has been proven to crystallise as a monomer while the rat MAOA 
(92% of homology) and human MAOB (72% of homology) crystallise as dimers (De 
Colibus et al., 2005).  
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Figure 1.6 - Oxidation of monoamines catalysed by Monoamino Oxidases. Simplification of the 
oxidative reaction mediated by MAOA on the major monoamine neurotransmitters. 
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A single amino acid mutation has been found to be a possible explanation on the 
monomeric human MAOA state. It is a specific Glu 151  Lys mutation uniquely 
found in human MAOA. This residue in located in a specifically charged region 
involved in the dimerisation process (Andres et al., 2004).  
The MAOA promoter region lacks a TATA box, where usually the RNA 
polymerase II binds in order to initiate the transcription. However the promoter is 
CG rich and contains multiple binding sites for SP1 transcription factor which can 
initiate the transcription in the absence of a TATA box (Zhu et al., 1992). It has been 
demonstrated that MAOA can be positively regulated by both androgens and 
glucocorticoids acting through SP1 and that glucocorticoids are more powerful 
activators than androgens (Ou et al., 2006). PET (Positron emission tomography) 
scan images show that MAOA activity appears to be higher in depressed patients 
(Meyer et al., 2006), as well as mean cortisol concentrations which are generally 
higher than in normal control subjects (Barden, 2004). Furthermore, Manoli et al. 
(2005) found that in-vitro treatment with dexamethasone, a synthetic member of 
the glucocorticoid class of steroid drugs that is 25 times more potent than cortisol in 
its glucocorticoid effects, increases MAOA gene expression. In addition, two 
different VNTRs have been identified and proven able to drive expression in reporter 
gene constructs. The most studied is termed uVNTR and consists of a 30 base pair 
motif that can be repeated 2, 3, 3.5, 4 and 5 times. In 2004 Huang et al. (2004) 
described a 6 repetitions (R) variant of this same polymorphism. The 2, 3 and 5 
uVNTR are defined low expression variants (MAOA-L) whilst, conversely, with a 2 
to 10 fold increase in the expression, the 3.5 and 4R VNTRs are considered high 
expression variants (MAOA-H) (Sabol et al., 1998) (Figure 1.7 A). The most 
common variants in the population are represented by the 3R and the 4R variants.  
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Table 1.3 - Count of alleles and polymorphism for MAOA u-VNTR in different/ethnic 
populations 
Populations Sample Size 
2R   
(%) 
3R 
(%) 
3.5R 
(%) 
4R   
(%) 
5R   
(%) 
Han in Taiwan 
(Pai et al., 
2007) 
474 1     (0,2) 
307 
(64,7)   
165 
(34,8) 
1     
(0,2) 
Chinese Han in 
Taiwan (Lu et 
al., 2002) 
77 1     (1,3) 
42 
(54,5)   
34 
(44,2)   
Japanese 
(Kunugi et al., 
1999) 
125   78 (62)   
47    
(38)   
Asian/Pacific 
Islander (Sabol 
et al., 1998) 
82   50 (61) 
1     
(1,2) 
31 
(37,8)   
White/Non-
Hispanic (Sabol 
et al., 1998) 
1612   539 (33,1) 
8     
(0,5) 
1056 
(64,8) 
26   
(1,6) 
Note: Table adapted from Pai et al. (2007) 
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As illustrated in Table 1.3 (Pai et al., 2007), the trend between the most common 
alleles (4R and 3R) is opposite in western and eastern populations. Pai et al. (2007) 
in their study draw attention to the fact that MAOA uVNTR per se could be 
implicated in MAOA transcription and activity but may not be critical in modulating 
behavioural abnormalities. This is possibly due to the racial/ethnic differences in the 
genotype frequencies among world populations. 
In earlier versions of UCSC genome browser the uVNTR was located 1.2Kb 
upstream of the TSS, showing only one human splicing variant containing the 
uVNTR within the MAOA promoter region. At the time of writing this thesis, the 
latest version of the Hg19 database in UCSC genome browser, moved the MAOA 
TSS of the reference allele upstream of the uVNTR, ultimately including it into the 
transcript and making it the only variant. However, at the same time, the new Hg38 
database in UCSC genome browser and other online databases, such as AceView, 
kept separated the two TSSs of MAOA gene, describing two isoforms with two 
different 5ʹ UTRs. More details about the MAOA mRNA isoforms will be discussed 
in Chapter 4. 
The second VNTR in the MAOA promoter region, located ~500bp upstream of the 
uVNTR, is composed by two different decamers CCCCTCCCCG (Repeat A) and 
CTCCTCCCCG (Repeat B) that alternate themselves up to 7R (ABABABA); after 
that only the repeat A is present (ABABABAAAA). The 9 and 10 repetitions are the 
most common in the population, 8R, 11R and 12R have also been genotyped (Figure 
1.7 B). In gene reporter assays, similarly to the uVNTR, the 9R and 10R have 
opposite potency in driving the reporter gene expression, where the 9R is stronger 
than the 10R and the other genotypes fall in between them (Philibert et al., 2011). 
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Figure 1.7 – Monoamine Oxidase A (MAOA) promoter region VNTRs. Graphic representation of the MAOA u- and dVNTR. A. MAOA dVNTR genotyped alleles: 8R to 
12R. The structure forming the dVNTR is represented above the coloured squares, each representing a repetition. In green high expression, in red low expression, in blue the 
other copy variants as reported by Philibert et al. (2011). B. MAOA uVNTR genotyped alleles: 2R to 5R. The 30bp motif underneath the coloured squares. In red the low 
expression variants and in green the high expression variants as first reported by Sabol et al. (1998).  
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However, the vast majority of the literature refers only to the uVNTR as the major 
mediator of MAOA expression and a possible biomarker for stress-related illnesses, 
including major depressive disorder, addiction, and violent behaviour (Fan et al., 
2010, Philibert et al., 2011, Reif et al., 2014). For example, the high activity variant 
of the uVNTR has been associated with suicide attempts in female subjects with 
bipolar disorder (Ho et al., 2000) and with suicide in depressed male subjects (Du et 
al., 2002). Male children with the high expression variant, who experienced early life 
stressors, are less likely to develop antisocial behaviour compared to the children 
with the low activity variant (Caspi et al., 2002).  
Table 1.4 summarises some of the most recent or most relevant publications that 
associate, or try to associate, MAOA uVNTR to a wide range of CNS conditions and 
behavioural traits. Despite these efforts, the results are often inconclusive and 
conflicting. Limiting factors cited by the authors are often the small sample size, 
gender differences, ethnic differences in the case of genotype analysis or construct 
structure in case of the expression assays. An important factor that is usually 
excluded from meta-analysis and genotype analysis are female heterozygous for the 
uVNTR. MAOA is an X chromosome gene, therefore the ratio between males and 
females are different as different is the number of X chromosomes present in males 
and females. The female MAOA locus has been proposed as one of the loci that can 
escape X inactivation (Ji et al., 2015, Joo et al., 2014, Mugford et al., 2014).  
This could be consistent with the observation that XIST, a gene which contributes 
to the control of X chromosome inactivation, has recently been reported to be over 
expressed in major affective disorders in females (Ji et al., 2015). Differential X 
chromosome inactivation could therefore have significant influence on the regulation 
of MAOA in females.  
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This further layer of complexity in the regulation of the MAOA gene expression in 
females could in part explain why many studies of the MAOA G×E only report on 
males due to uncertainties with respect to which allele is active in heterozygous 
uVNTR females (Caspi et al., 2002, Fergusson et al., 2012, Kim-Cohen et al., 2006).  
Studies which have included both genders have had more complex findings often 
showing differences in the uVNTR association with behaviour (Aslund et al., 2011, 
Nikulina et al., 2012) such as pronounced effects on ADHD and anxiety only in 
females whereas the opposite is true for autism, bipolar disorder and aggressive 
behaviour only in males (Melas et al., 2013, Reif et al., 2012). 
 
Table 1.4- Summary of MAOA uVNTR in various conditions 
Condition Gender Associated MAOA genotype Reference 
ADHD and ADHD 
spectrum disorders 
M/F 3 - no association (Verma et al., 2014) 
M 3 (Wargelius et al., 2012) 
Aggression M 3 (Chester et al., 2015) 
Alcohol Consumption 
M/F M Low + - F High + + = sexual abuse (Nilsson et al., 2011) 
M 4 (Tikkanen et al., 2010) 
Anxiety disorder M/F 
3R more present in F 
with anxiety disorder - 
4R in F with agoraphobia 
(Samochowiec et al., 
2004) 
Autism Spectrum Disorder M 
Children 4 - mother's 4/4 
more present in ADHD 
children 
(Cohen et al., 2003) 
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Bipolar Affective Disorder M/F 3 in males  (Lin et al., 2008) 
Climacteric symptoms F no association (Grochans et al., 2013) 
Conduct behaviours M 3 (Caspi et al., 2002, Frazzetto et al., 2007) 
Depression F 3 + child adversities (Melas et al., 2013) 
Major Depressive Disorder 
M/F 4 [H] risk factor in F (Schulze et al., 2000) 
M/F 
3 [L] increase risk 
through cis-acting 
regulation 
(Zhang et al., 2010) 
M/F 
4 more frequent in F - F 3 
/3more responsive to 
fluoxetine 
(Yu et al., 2005) 
Mood disorder M/F no association (Kunugi et al., 1999) 
Panic Disorder M/F 4R only in females (Reif et al., 2012) 
Post-Partum Depression F MAOA 4/4 (Grochans et al., 2015) 
Psychiatric Disorders M/F no association (Liu et al., 2015) 
Schizophrenia M/F no association (Alvarez et al., 2010, Qiu et al., 2009) 
Suicide Behaviour M/F no association (Hung et al., 2012) 
 
Note: Gender: M=males; F=females; Genotype: with 3 and 4 are intended the 3R and 4R genotype of 
the uVNTR; H and L represent the High and Low expression genotype – High are 3.5R and 4R, Low 
are 2R, 3R and 5R
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1.9 The Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) 
gene 
Calcium channels are a category of ion channels selectively permeable to calcium 
ions. They can be divided in two categories: voltage- or ligand-gated depending on 
the activation methodology. The voltage-gated channels activate after a cellular 
depolarization while the ligand-gated channel activate after a ligand binds to the 
channel. The voltage-gated calcium channels are found in the membrane of excitable 
cells such as neurons and muscles. Of the protein complex that forms the functional 
voltage calcium channel, the α1 sub-unit forms the selective permeable pore. It also 
determines the activation speed of the channel and therefore the function that exerts. 
Ten different α1 sub-units have been identified, each of which is encoded by a 
different gene termed CACNA1 A to H and CACNA1S (Figure 1.8).  
However, the auxiliary sub-units α2, β, δ and γ are necessary to stabilise and make 
the channel fully functional. 
The CACNA1C gene is located on chromosome 12 and codes for the α1C sub-unit 
(Cav 1.2) of the L-type voltage-dependent calcium channel (LTCC). The Cav 1.2 
subunit is mainly expressed in the cardiac muscle tissue and in the brain (Christel 
and Lee, 2012, Striessnig et al., 2014). The inward calcium current that the activation 
of the LTTC brings, has been associated with formation of spatial memory and 
learning (Moosmang et al., 2005, White et al., 2008), neuronal differentiation, 
through the regulation of axonal growth and guidance (Rosenberg and Spitzer, 2011) 
and gene regulation through the activation of the transcription factor cAMP response 
element-binding protein (CREB) (Weick et al., 2003, Wheeler et al., 2008). 
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Figure 1.8 - Voltage-dependent calcium channel. Graphic representation of the high voltage-
activated calcium channel complex consisting of the main pore forming α1-subunit plus auxiliary 
subunits β-, γ-, and α2-δ. Image adapted from (Dolphin, 2012, Khosravani and Zamponi, 2006).  
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CACNA1C has been considered a potential candidate gene for several 
neurological disorders. An intronic SNP within the CACNA1C gene (rs1006737) has 
been initially associated with bipolar disorder (Sklar et al., 2008) followed by 
another intronic SNP (rs4765913) with an even stronger association (Gwas 
Consortium Bipolar Disorder Working Group, 2011). 
Subsequently, CACNA1C, has been associated to SCZ (Bigos et al., 2010) and the 
previous associated SNP (rs1006737), associated with bipolar disorder, has also been 
found as a possible risk factor for SCZ (Nyegaard et al., 2010) and possible regulator 
of dorsolateral prefrontal cortex activity (Paulus et al., 2014). 
It has been proposed that in SCZ modulation of Ca2+-mediated signalling caused 
by differential CACNA1C and glutamatergic transmission could lead to alterations in 
the rate of axon outgrowth and path finding, leading to the inefficient neuronal 
wiring observed in SCZ (Fromer et al., 2014, Purcell et al., 2014). 
Based on these specific and recurrent associations of the CACNA1C gene with 
neurological disorders and specifically with SCZ I performed a preliminary 
bioinformatic analysis on the CACNA1C promoter region and I identified two 
putative polymorphic VNTRs according to UCSC web browser that will be discussed 
in chapter 5. 
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1.10 The RE1-Silencing Transcription factor  (REST)  gene 
RE1-Silencing Transcription factor (REST) (Chong et al., 1995), also known 
as Neuron-Restrictive Silencer Factor (NRSF) (Schoenherr and Anderson, 1995) is a 
zinc finger transcription factor member of the Kruppel-type zinc fingers family. The 
gene maps to 4q12, the major transcript is composed of 4 exons and the translated 
protein contains 9 zinc-finger domains in its N-terminal (Chong et al., 1995). 
It exerts its activity by binding on a specific motif in the promoter region of its target 
genes (NRSE - Neuron-Restrictive Silencer Element) required for its activity as gene 
regulator (Bruce et al., 2004, Tapia-Ramirez et al., 1997). It acts indirectly by 
recruiting co-factors that in turn perform epigenetic changes on the target genes or 
recruit other proteins.  
The first co-factor was identified in 1999 by Andres et al. (1999), specifically 
binding at the C-terminal of the REST protein, CoREST. This factor was shown to 
be required to reduce the expression of the type II sodium channel gene (Andres et 
al., 1999, Ballas et al., 2001). Another co-factor, SIN3A, binds at the N-terminal of 
the REST protein (Huang et al., 1999, Naruse et al., 1999, Roopra et al., 2000) and 
in a complex with a histone deacetylase mediates gene repression. SIN3A has also 
been proven to bind in different development stages compared to CoREST 
suggesting a more dynamic repression pattern than previously thought (Ballas et al., 
2005, Grimes et al., 2000). An alternative mechanism by which REST regulates gene 
expression is through a complex with CoREST and MeCP2 (Lunyak et al., 2002) 
where it appears to be a silencing mechanism through methylation of the CpG islands 
across the genetic target region. The initial role given to REST was to act outside the 
CNS to repress neuronal genes in non-neuronal tissues (Chong et al., 1995, 
Schoenherr and Anderson, 1995).  
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However, REST mRNA has been found in adult neurons (Palm et al., 1998) and 
its levels respond to ischemic or epileptic insults (Calderone et al., 2003, Palm et al., 
1998). A study performed by our group also associated a REST exonic VNTR 
polymorphism in combination to a BDNF polymorphism in increased general 
cognitive ability (Miyajima et al., 2008). Furthermore it has been proven that REST 
negatively regulates hippocampal neurogenesis in adult rat brains. Its dysregulation 
leads ultimately to depletion of the neuronal stem cells (NSC) (Gao et al., 2011). A 
more recent study showed a protective effect of REST in the aging process of normal 
adult brains from age-related insults. A dysregulation of this process and REST loss 
from the neuronal nuclei has been observed in the early stages of Alzheimer’s 
Disease (AD) (Lu et al., 2014). Interestingly, a comparison of AD patients, all 
meeting the pathological criteria, showed significantly different levels of nuclear 
REST whether they displayed severe cognitive impairment or mild / no cognitive 
impairment (Lu et al., 2014). Other disorders such as fronto-temporal dementia 
(FTD) and dementia with Lewy bodies showed a depletion of REST from the nuclei. 
This depletion has been associated in autophagosomes together with other misfolded 
proteins (Lu et al., 2014). Another study (Goetzl et al., 2015) also confirms a 
reduction of the transcription factor REST in the plasma neuronal exosomes in AD 
patients.  
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1.11 Project Main Aim 
 Address the functional significance of genetic polymorphisms involved in 
transcriptional regulation within the promoter regions of candidate genes 
implicated in CNS dysfunction and/or as biomarkers for clinical predisposition to 
disease  
 
1.12 Specific Objectives 
 Investigate the MAOA gene polymorphic VNTRs and their potential role as gene 
expression regulators. 
 Investigate the GWAS candidate gene for schizophrenia CACNA1C for 
polymorphic variants within the promoter region and their possible implications 
in a GxE interaction contest. 
 Perform an association analysis of the novel polymorphic microsatellite in REST 
promoter region in case - control cohorts for schizophrenia, fronto-temporal 
dementia and Alzheimer’s disease. 
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Chapter 2 
 
Materials and Methods 
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2.1 Materials 
2.1.1 Commonly used Buffers and Reagents 
5X TBE Buffer was made adding 108 g Tris Base (Sigma), 55 g Boric acid 
(Sigma), 5.84 g EDTA (Sigma) and was made up to 2L using d.H2O. 
LB Agar was made adding  40 g/L in d.H2O (Fluka Analytical). LB agar was 
autoclaved the same day and stored at room temperature. 
LB Broth was made adding  25 g/L in d.H2O (Fluka Analytical). LB broth was 
autoclaved the same day and stored at room temperature. 
 
2.1.2 Chromatin Immunoprecipitation (ChIP) buffers 
Tris-EDTA (TE) buffer was made with 10 mM Tris and 0.1 mM EDTA (pH 8.0) 
made up to the final volume with sterile d.H2O. The pH was adjusted to be between 
7.5 and 8.0.  
Cell lysis buffer was made with 10 mM hepes (pH 7.9), 1.5 mM MgCl2, 10 mM 
KCl and 0.5% NP-40 and made up to the final volume with sterile d.H2O. it was 
supplemented with 10 µl/ml of 100X protease inhibitor cocktail (PIC, Sigma) 
immediately before use and stored on ice. 
Nuclear lysis buffer was made with 50 mM Tris-HCl (Tris was adjusted to pH 8.1 
with HCl), 1% SDS and 10 mM EDTA and made up to the final volume with sterile 
d.H2O. It was supplemented with 10 µl/ml 100X PIC immediately before use and 
stored on ice. 
Sonication buffer was made with 50 mM hepes (pH 7.5), 140 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate and 0.1% SDS 
and made up to the final volume with sterile d.H2O. It was supplemented with 10 
µl/ml 100X PIC immediately before use and stored on ice. 
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ChIP dilution buffer was made with 16.7 mM Tris–HCl, 167 mM NaCl, 1.1% 
Triton X-100, 0.01% SDS and 1.2 mM EDTA made up to the final volume with 
sterile d.H2O. It was supplemented with 10 µl/ml 100X PIC immediately before use 
and stored on ice. 
Low-salt wash buffer was made with 20 mM Tris–HCl, 150 mM NaCl, 0.1% 
SDS, 1% Triton X-100 and 2 mM EDTA and made up to the final volume with 
sterile d.H2O. 
High-salt wash buffer was made with 20 mM Tris–HCl, 500 mM NaCl, 0.1% 
SDS, 1% Triton X-100 and 2 mM EDTA and made up to the final volume with 
sterile d.H2O. 
LiCl wash buffer was made with 10 mM Tris–HCl, 250 mM LiCl from a 10M 
stock, 1% Igepal, 1% sodium deoxycholate and 1 mM EDTA and made up to the 
final volume with sterile d.H2O. 
Elution buffer was made with 50 mM Tris–HCl, 1 mM EDTA, 1% SDS and 50 
mM NaHCO3 and made up to the final volume with sterile d.H2O. 
RNAse: RNAse A: 20 mg/ml. (Sigma) 
SDS 10% :Sodium dodecyl sulfate (Sigma) 10% w/v made up to the final volume 
with sterile d.H2O. 
Proteinase K: Proteinase K solution (Qiagen) 
 
2.1.3 Drug Treatment Solutions 
Cortisone (Sigma) was dissolved in ethanol to make a 1 mM stock which was 
diluted in complete SH-SY5Y tissue culture media to a final concentration of 20nM, 
50 nM or 100 nM.  
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Lithium chloride (Sigma) was dissolved in sterile filtered d.H2O to make a 1 M 
stock solution which was diluted in complete SH-SY5Y tissue culture media to a 
final concentration of 1 mM (Hing et al., 2012, Roberts et al., 2007). 
Sodium valproate (Sigma) was dissolved in sterile filtered dH2O to make a 1 M 
stock solution which was diluted in complete SH-SY5Y tissue culture media to a 
final concentration of 5 mM (Pan et al., 2005, Zhang et al., 2003, Phiel et al., 2001). 
 
2.1.4 Human DNA Samples 
Schizophrenia cohort  
Genomic DNA samples from 823 patients with schizophrenia (mean age 37.66 
years, range 18-71) and 762 healthy controls (mean age 46.27, range 19-72) were 
kindly provided by our collaborator Prof. Dan Rujescu, Department of Psychiatry, 
University of Halle-Wittenberg. Subjects were all of German or central European 
descent and provided written informed consent. Schizophrenic patients were selected 
based on diagnosis under the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) and International Classification of Disease-10 (ICD-10). Detailed medical 
and psychiatric histories were collected for each patient, including the Structured 
Clinical Interview for DSM-IV (SCID), to evaluate lifetime Axis I and II diagnoses. 
Unrelated healthy controls were selected at random from the general population of 
Munich, Germany. To exclude any healthy volunteers with neuropsychiatric 
disorders, both the subjects and their first-degree relatives completed an initial 
screening process followed by detailed medical and psychiatric history assessment 
using a semi-structured interview. Participants that did not meet the exclusion criteria 
were invited to a comprehensive interview including the SCID I and SCID II to 
validate the absence of any lifetime psychotic disorder. All participants provided 
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written informed consent following a detailed and extensive description of the study, 
which was approved by the local ethics committee of Ludwig Maximilians 
University, Munich, Germany and carried out in accordance to the ethical standards 
outlined in the Declarations of Helsinki.  
 
2.1.5 Human cell lines 
SH-SY5Y 
Human-derived neuroblastoma cell-line obtained from the American Type Culture 
Collection (ATCC). 
 
HAP1  
HAP1 is a near-haploid human cell line that was derived from the male chronic 
myelogenous leukemia (CML) cell line KBM-7 (Carette et al., 2011).  
HAP1 cell line have been purchased from © 2017 Horizon Discovery Group plc, 
Company Registration Number 08921143 (https://www.horizondiscovery.com/) 
 
2.1.6 Cell culture media 
 
Complete media for SH-SY5Y cells  
Earle's modified Eagle's medium (Sigma) and HAM's F12 (Sigma) at a ratio of 
1:1, supplemented with 10% foetal bovine serum (Sigma), 1% 200 mM L-glutamine,  
1% 100 mM sodium pyruvate and 100 U/ml penicillin/ 100 ug/ml streptomycin. 
 
Complete media for HAP1 cells 
Iscove’s Modified Dulbecco’s Medium (IMDM) (GIBCO), supplemented with 
10% foetal bovine serum (Sigma) and 100 U/ml penicillin/ 100 ug/ml streptomycin. 
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Freezing media for SH-SY5Y 
90% foetal bovine serum (Sigma), 10% DMSO (Sigma). 
 
Freezing media for HAP1 
Medium A: IMDM + 20 % FBS 
Medium B: IMDM + 20 % FBS + 20 % DMSO
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2.1.7 PCR primers 
Table 2.1 - PCR primers used for gene expression profiling, genotyping and ChIP 
Gene Region Forward (5ʹ - 3ʹ) Reverse (5ʹ - 3ʹ) Product Size Template 
MAOA 
uVNTR TCCGAATGGAGCGTCCGTTC ACAGCCTGACCGTGGAGAAG  324 bp gDNA - cDNA 
 
dVNTR GGGTTAAGCGCCTCAGCTTG  CTGCTTCCTTAAGTCCACTCTTG 365 bp gDNA 
 
Exon I CGGGTATCAAAAGAAGGATCG   298 bp cDNA 
 
Exon IIA   CCAGGAGCTGCTTTCCTCTGATGC 
 
Exon III TACGTAGATGTTGGTGGAGCTT   440 bp cDNA 
 
Exon VI   AGAATATCCGAGTGGTGCCC 
CACNA1C 
P1 construct GCCCGATCCGAAACGAGACTCTG 
GGCTTCCTCGAATCTT 
350 bp gDNA 
 
P2 construct GCCACATCTGGAAGCGTTCAGC 600 bp gDNA 
 
P3 construct GCTCCCTTTGACAGCAGAGAGC 1039 bp gDNA 
REST VNTR GGCACTCCTTGCTTGGTAGAGG GTCCTGTGTTGGAATGTGCGGC 178 bp gDNA 
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2.1.8 DNA constructs and commercial vectors 
Table 2.2 - Reporter gene and expression constructs generated for use in in-vitro luciferase assays 
Name Vector Orientation 
RE sites of 
insertion 
Primers for amplification (5ʹ – 3ʹ) Application 
CACNA1C P1 pGL3B Forward HindIII 
Fw: GATCTGCGATCTAAGTGCCCGATCCGAAACGA 
Luciferase 
Rev: ACAGTACCGGAATGCCAAGATTCGAGGAAGCC  
CACNA1C P2 pGL3B Forward HindIII 
Fw: GATCTGCGATCTAAGTGCCACATCTGGAAGCG 
Luciferase 
Rev: ACAGTACCGGAATGCCAAGATTCGAGGAAGCC  
CACNA1C P3 pGL3B Forward HindIII 
Fw: GATCTGCGATCTAAGTGCTCCCTTTGACAGACA 
Luciferase 
Rev: ACAGTACCGGAATGCCAAGATTCGAGGAAGCC  
REST VNTR pGL3B Forward HindIII 
Fw: GATCTGCGATCTAAGTGGCACTCCTTGCTTG 
Luciferase 
Rev: ACAGTACCGGAATGCCGCCGCACATTCCAAC 
Note: Underlined sequences indicate vector overlapping sequences for direct cloning into the specified vector.  
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2.1.9 ChIP grade antibodies 
Table 2.3 - Antibodies used for ChIP in human SH-SY5Y cell line 
Antibody Host Species Species Reactivity Immunogen Company and Catalogue Number 
Anti-H3 Rabbit (Polyclonal) Human, mouse, rat Synthetic peptide corresponding to the carboxy-terminal of human Histone H3. Abcam, 1791 
Anti-H3K9me3 Rabbit (Polyclonal) Human, mouse, rat Synthetic peptide derived from within residues 1-100 of Human H3, trimethylated at lysine 9. Abcam, 8898 
Anti-RNA Pol II 
CTD phospho 
Ser5 
Rat (Monoclonal) Human Synthetic peptide containing the RNA pol II C-terminal domain (CTD)  Active Motif, 61085 
Anti-REST Rabbit (Polyclonal) Human, mouse, rat GST fusion protein corresponding to residues 801-1097 of full-length human REST/NRSF. Millipore, 07-579 
Normal rabbit 
IgG Rabbit (Polyclonal) - 
Unconjugated antibody not directed against any 
known antigen. Used as a non-specific IgG 
control  
NEB, 2729  
Anti-CTCF Mouse (Monoclonal) Human His-tagged recombinant protein corresponding to human CTCF. Millipore, 17-10044 
Anti-Nucleolin Mouse (Monoclonal) Human Human nucleolin protein from Raji cell extract. Abcam, ab13541 
Anti-hnRNPK Rabbit (Polyclonal)  Human, mouse 
Synthetic peptide corresponding to a sequence 
from the C-terminus of isoform a of human 
hnRNP K.  
Abcam, ab70492 
Anti-CNBP Goat (Polyclonal) Human, rat Synthetic peptide: GESGHLARECTIE, corresponding to C terminal of Human CNBP. Abcam, ab48027 
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2.2 Methods 
2.2.1 Designing PCR primers 
Polymerase chain reaction (PCR) primers were designed using the online primer 
designer software Primer3 (http://biotools.umassmed.edu/bioapps/ 
primer3_www.cgi) which generates a list of suitable PCR primers for amplification 
of the sequence of interest based on appropriate melting temperatures, GC% content 
and potential dimerisation and hairpin formation. In general, primers were designed 
to be 18-25 nucleotides in length, have a melting temperature of 50-65°C and a GC-
content between 40-60%. Primer specificity was determined using the In-Silico PCR 
and Pick Primers tools available from the UCSC Genome Browser 
(http://genome.ucsc.edu/index.html) and National Center for Biotechnology 
Information (NCBI) (http://www.ncbi. nlm.nih.gov/tools/primer-blast/). Primers 
were purchased from Eurofins MWG Operon and are listed in Table 2.1. 
 
2.2.2 General Cloning Methods 
PCR primer design for direct cloning into commercial vectors 
Primers were designed as outlined in section 2.2.1 with a minimum length of 15 
bp. Appropriate restriction sites (present in the multiple cloning site of the chosen 
vector but absent in the target sequence) were added to the 5ʹ end of the forward and 
reverse primers so that they are incorporated at the ends of the target DNA sequence 
following PCR amplification. To ensure efficient DNA cleavage by the restriction 
enzymes, a sequence of 15 bp overlapping the 5ʹ or 3ʹ plasmid’s arm was also 
included in the 5´ of the primer. Primers used for direct cloning is listed in Table 2.2 
and PCR methods outlined below. 
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PCR using a proof-reading polymerase 
Phusion High-Fidelity DNA Polymerase (NEB) was used in PCR for the 
amplification of DNA targets. The Phusion DNA Polymerase master mix is outlined 
below 
Component Volume (n=1) Final Concentration 
5X Phusion HF buffer 4 µl 1X 
PCR nucleotide mix (10 mM of each dNTP) 1 µl 200 µM 
Forward primer (10 µM) 1 µl 0.5 µM 
Reverse primer (10 µM) 1 µl 0.5 µM 
Phusion DNA polymerase (2 U/µl) 0.2 µl 0.4 U 
Nuclease free water X µl - 
DNA template X µl - 
Final volume 20 µl - 
 
PCR reactions were performed in a peqSTAR 2X (peqlab) thermocycler. The amount 
of DNA template used varied between primer sets depending on the abundance of the 
target for amplification. Thermal cycling conditions were as follows: initial denature 
at 98°C for 30 seconds, followed by 25 cycles of denature, annealing and extension at 
98°Cfor 10 seconds, X°C for 30 seconds and 72 °C for 30 seconds, respectively, with 
a final extension cycle at 72 °C for 10 minutes. The annealing temperature of each 
primer set was optimised using a gradient PCR and are listed in Table 2.1 along with 
primer sequences and expected product sizes. PCR products were analysed by 
agarose gel electrophoresis.  
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Analysis of DNA using agarose gel electrophoresis  
DNA fragments from PCR reactions or restriction digests were analysed by gel 
electrophoresis on 1-2.0% agarose gels supplemented with GelRed (1:10,000 
dilution) (Cambridge Bioscience) or 0.5 µl per 10 ml of ethidium bromide (Sigma 10 
mg/ml) and measured against a 100 bp or 1 Kb DNA ladder (Promega). The voltage 
(standard is 5 V/cm) and time for which the gel was run was dependent on the 
percentage of the gel and fragment size. The DNA was visualised using a UV 
transillumintor (BioDoc-it Imaging System).  
 
Recovery of DNA from agarose-gels 
Following separation through gel-electrophoresis, DNA fragments of the expected 
size were extracted from the agarose gel and column-purified using the QIAquick 
Gel Extraction Kit (QIAGEN), following manufacturer’s instruction. The purified 
DNA was eluted in 30 µl Elution Buffer. 
 
Restriction digest and DNA purification 
Restriction enzyme digests were used either to create specific nucleic acid 
overhangs for ligation or as a diagnosis tool for determining the presence and/or 
orientation of inserts. Restriction enzymes were purchased from Promega and digests 
performed using the following reaction components:  
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Nuclease free water X µl 
10X Buffer 2 µl 
Acetylated BSA (10 µg/µl) 0.2 µl 
DNA (1 µg) X µl 
Restriction Enzyme (10 U/µl) 0.5 µl 
Final volume 20 µl 
 
Recommended buffers for optimum enzyme activity were used, digestions were 
incubated at the appropriate temperature for the enzyme activity for 1-4 hours and 
fragments run on agarose gels to visualise their size (section 2.2.2). 
 
Ligation – Gibson Isothermal Assembly  
Gibson Isothermal Assembly is a high-efficiency DNA end-linking technique 
using three enzymes to join two or more sequences of blunt ended or 3ʹ overhang 
dsDNA in a single 1 hour reaction. 
A total of 0.02–0.5 pmols (weight in ng) x 1,000 / (base pairs x 650 daltons) of DNA 
fragments (blunt ended or 3ʹ overhang) were used when assembling 1 or 2 fragments 
into a vector and 0.2–1.0 pmoles of DNA fragments when assembling 4-6 fragments, 
with a 4 fold excess of insert to vector. DNA fragments were diluted in nuclease free 
water to a volume of 10μl and mixed with 10μl of 2X Gibson Assembly Master Mix 
(NEB Cat. No. E2611S) to a total volume of 20 μl, in a 50 μl PCR tube on ice, 
followed by 1 hr incubation at 50°C. 
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Transformation of chemically competent E. Coli cells  
Following ligation, the resulting plasmids were transformed into chemically 
competent E. Coli Sub-cloning Efficiency™DH5-α cells (Invitrogen), following 
manufacturer’s instruction. Briefly, 5 μl of the ligation reaction or 10 ng plasmid 
DNA was added to 50 μl of competent DH5-α cells and incubated on ice for 30 
minutes. The cells were then subjected to ‘heat-shock’ for 20 seconds at 42°C in a 
water bath followed by 2 minutes incubation on ice. Next, 950 μl of pre-warmed LB 
broth was added to the cells and the culture incubated with constant shaking (225 
rpm) at 37°C for 1 hour. Following this, 200 μl of the culture was spread evenly onto 
LB agar plates supplemented with 100 μg/ml ampicillin and incubated overnight at 
37°C. 
 
2.2.3 Isolation of plasmid DNA from bacterial cultures  
 
Mini-preparation of plasmid DNA 
In order to test plasmid DNA for inserts following molecular cloning, a small 
scale preparation of DNA (up to 20 μg) was undertaken. Individual colonies grown 
on LB agar plates (section 2.2.2) were transferred to 5 ml LB broth supplemented 
with 100 μg/ml ampicillin and cultured overnight at 37°C on a shaker at 225 rpm. 
DNA was isolated from the resulting bacterial culture using the QIAprep Spin 
Miniprep Kit (QIAGEN), according to manufacturer’s guidelines. Purified plasmid 
DNA was eluted in 50 μl nuclease-free water into fresh 1.5 ml microcentrifuge tubes 
and subject to restriction enzyme digestion to check for the correct size and 
orientation of the insert (section 2.2.2). 
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Maxi-preparation of plasmid DNA  
A Plasmid Maxi Kit (Qiagen) was used to purify high yields of plasmid DNA 
from transformed bacteria of greater purity than that generated from mini-
preparations for use in downstream applications such as in-vitro reporter gene assays. 
A 200 µl aliquot of the 5 ml starter culture from section 2.2.2 or starter culture grown 
from a small scraping of a glycerol stock (section 2.2.2) was grown overnight at 
37°C with shaking (225 rpm) in 100 ml of LB broth supplemented with the 
appropriate antibiotic to generate a sufficient quantity of bacteria for extraction of the 
plasmid DNA. DNA purification was carried out according to manufacturer’s 
instruction for high-copy plasmids. The resulting DNA pellet was resuspended in 
200-500 µl of EB buffer and quantified using a Nanodrop 8000 and then stored at -
80oC for long-term storage or at -20oC for working stocks. 
 
Sequencing 
Plasmid DNA with cloned inserts and PCR products were sequenced externally 
by Dundee DNA Sequencing and Service or Source Bioscience Life Sciences. The 
samples and primers were supplied as required by the companies. 
 
Glycerol stocks 
Glycerol stocks of transformed bacteria were made for long term storage. A 1.4 
ml volume of the overnight culture was transferred to a microcentrifuge tube and 
pelleted by centrifugation at 8,000 rpm for 3 minutes at room temperature. The 
supernatant was removed and the pellet resuspended in 0.5 ml of sterile 15% glycerol 
(v/v in LB broth) and transferred into a cryovial. This was then immediately frozen at 
-80oC. 
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pGL3-Basic (pGL3B) constructs 
REST VNTR fragments containing either the 7-copy 9-copy or 12-copy variant of 
the REST VNTR were amplified from human DNA and ligated into the pGL3B 
vector, which lacks a minimal promoter sequence, at the HindIII restriction sites with 
Gibson Isothermal Assembly.  
The same procedure applies for the CACNA1C promoter constructs. 
 
2.2.4 Cell Culture 
Culturing of SH-SY5Y and HAP1 cells  
Human SH-SY5Y neuroblastoma and human HAP1 cells were maintained in 
culture media outlined in section 2.1.6 at 37°C, 5% CO2, in T175 tissue culture flasks 
until 70-80% confluent. To passage cells, media was removed and the cells washed 
down with 1X sterile PBS (Sigma) pre-warmed at 37°C. Following removal of the 
PBS, 5 ml of pre-warmed 1X trypsin (Sigma) was washed over the cells and then 
removed, and the cells incubated at 37°C for approximately 3 minutes or until the 
cells began to detached from the bottom of the flask. To neutralise the trypsin, cells 
were washed down in 10 ml of pre-warmed complete tissue culture media and mixed 
into a single cell suspension through pipetting. Between 1-2 ml (approximately 1-2.4 
million cells depending on cell type) of the cell suspension was then transferred into 
a new T175 flask with 40 ml of the appropriate media for that cell line. Cell lines 
were tested for mycoplasm infection every six months using MycoAlert Mycoplasma 
Detection kit (Lonza). 
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Cell counts with a haemocytometer 
To determine the number of cells per ml of media cell counts were performed 
using a haemocytometer. Cells were passaged as described previously up to the cells 
being washed down with 10 ml of media. Prior to the coverslip being placed onto the 
counting surface of the haemocytometer both parts were washed with 70% ethanol. 
On the centre of the counting surface of the haemocytometer there are 25 squares 
(5x5) bounded by three parallel lines each containing 25 smaller squares (5x5). To 
perform the cell count, 20 µl of the cell suspension was introduced under the 
coverslip and the counting surface visualised under a light microscope on the 10X 
objective. The number of cells within the 25 larger squares bounded by three parallel 
lines were counted including cells touching the top or left hand borders of the 25 
squares and excluding those in contact with the bottom or right hand border. This 
area corresponds to 0.1 mm3 therefore the number of cells was multiplied by 1x104 
(10,000) to give the number of cells in 1 cm3 which is the equivalent of 1 ml. This 
gave the number of cells per ml of media used for calculating the density at which 
the cells were seeded.  
 
Freezing cells for storage in liquid nitrogen 
For long term storage, cell lines were frozen in freezing media in liquid nitrogen. 
The cells were grown in T175 flasks until 70-80% confluent and then passaged as 
described previously, but the cells were washed from the surface of the flask using 
10 ml of freezing media and the cell suspension split across cryovials with 1.8 ml in 
each. The cryovials were immediately placed into a Mr Frosty with isopropanol at -
800C for 24 hours and then transferred to liquid nitrogen. 
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Drug treatments 
Drug treatments were performed using concentrations previously optimised in our 
lab or reported in the literature to be effective in cell culture. These are detailed in 
section 2.1.3. Drugs were diluted in appropriate volumes of complete cell culture 
media and added to the cells for the specified time. For each drug treatment, n=4. 
Basal (untreated) and drug vehicle control cells were also included. For mRNA 
expression profiling (section 2.2.7), RNA extractions were performed immediately 
after the drug treatment. For luciferase and over-expression assays, drug treatments 
were performed 4 hours post-transfection. 
 
2.2.5 Delivery of plasmid DNA to cultured cells 
 
Single transfection assays 
SH-SY5Y cells were seeded into 6-well plates at approximately 400,000 cells per 
well and transfected with either 1 μg of the plasmid of interest using the TurboFect 
(Thermo Scientific) transfection reagent following the manufacturer’s guidelines. 
Cells were incubated for 48 hours before being processed for RNA extraction. 
 
Co-transfection assays 
For luciferase assays, SH-SY5Y cells were seeded in 24-well plates at 
approximately 100,000 cells per well and transfected with 1 μg plasmid DNA and 10 
ng pMLuc2 (Novagen) (internal control for transfection efficiency) using TurboFect 
(Thermo Scientific). Transfected cells were processed 48 hours post-transfection 
using the Dual-Luciferase Reporter Assay System (Promega).  
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2.2.6 Luciferase Reporter Gene Assays 
Cellular lysis 
At 48 hours post-transfection, tissue culture media was removed from the cells 
and the cells washed with 1X PBS. For cellular lysis, 100 µl of 1X passive lysis 
buffer (PLB) was added to each well of the 24-well plate and the plate incubated at 
room temperature on a rocking platform for 15 minutes. A 20 µl aliquot of the cell 
lysate was then transferred to an opaque 96-well plate for analysis.  
 
Measurement of reporter gene activity 
The appropriate amount of luciferase assay reagent II (LARII) and Stop and Glo 
reagent was prepared for the number of measurements required and allowed to reach 
room temperature. The opaque 96-well plate containing the cell lysate was placed 
into a Glomax 96 Microplate Luminometer (Promega) which had been setup under 
default settings for dual-luciferase reporter gene assays for experiments using two-
injectors. The injectors were first flushed with distilled water, 70% ethanol, distilled 
water and air to thoroughly clean them and then primed with the luciferase reagents 
(LARII in injector 1 and Stop and Glo in injector 2) before the Promega dual 
luciferase program is run, which measures the bioluminescence from the reaction 
catalysed by the firefly and renilla luciferase enzymes. The LARII is added first to 
measure the bioluminescence produced by the reaction catalysed by the firefly 
luciferase protein and then the Stop and Glo quenches this reaction and is used to 
measure the bioluminescence from the reaction catalysed by the renilla luciferase 
protein.  
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Statistical analysis 
Using the measurements recorded for the activity of the two co-transfected 
reporter gene constructs, the activity of the constructs across the different wells can 
be accurately compared as the internal control reduces experimental variability 
caused by differences in transfection efficiencies. Fold changes in firefly luciferase 
activity (normalised to renilla luciferase activity) supported by the reporter gene 
constructs over the pGL3 controls were calculated and significance determined using 
one-tailed t-tests. Significance was scored as follows */# P<0.05, **/## P<0.01, 
***/### P<0.001. For each transfection, a minimum of n= 4 was used. 
 
2.2.7 mRNA expression analysis 
In-vitro RNA extraction 
Total RNA was extracted using TRIzol reagent (Invitrogen) following 
manufacturer’s instruction. Briefly, SH-SY5Y and HAP1 cells were plated out into 
6-well plates at approximately 400,000 cells per well and incubated for 24 hours. The 
media from each well was removed and 1 ml of TRIzol was added per 10 cm2 and 
pipetted up and down to lyse the cells. The cell lysate/TRIzol mix was added to a 
nuclease-free microcentrifuge tube and incubated for 5 minutes at room temperature. 
To each sample 0.2 ml of chloroform (per 1ml of TRIzol reagent) was added, shaken 
vigorously by hand for 15 seconds and then incubated at room temperature for 2-3 
minutes. Samples were then centrifuged at 12,000 x g for 15 minutes at 4oC for phase 
separation into three layers: a colourless aqueous upper layer containing the RNA, a 
middle interphase layer and a lower red organic layer containing the DNA and 
protein. The upper colourless layer (approximately 500 µl) was carefully removed 
and transferred into a new microcentrifuge tube and 0.5 ml of 100% molecular grade 
isopropanol (per 1ml of TRIzol reagent) added to each sample and incubated for 10 
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minutes at room temperature. Samples were then centrifuged at 12,000 x g for 10 
minutes at 4oC and the resulting supernatant removed leaving behind the RNA pellet.  
To purify the RNA, 1 ml of 75% ethanol (per 1 ml of TRIzol reagent used in the 
initial step) was added and the sample vortexed and centrifuged at 7,500 x g for 5 
minutes at 4oC. The supernatant was removed and the pellet air dried for 5 to 10 
minutes before being resuspended in 20 µl of nuclease free water and incubated on a 
heat block at 55oC for 10-15 minutes. The RNA samples were kept on ice for 
quantification and first strand cDNA synthesis steps or stored at -80oC for later use.  
 
Measurement of RNA concentration by spectrometry 
RNA was quantified using a Nanodrop 8000. The Nanodrop was set to the RNA 
setting and calibrated with nuclease free water (the solvent the RNA was diluted in). 
A 1.5 µl aliquot of the RNA sample was loaded onto the pedestal and the absorbance 
measured. The amount of UV light absorbed at 260 nm by nucleic acids is dependent 
on their concentration. The Nanodrop measures the optical density (OD) of the RNA 
and then calculates its concentration (an OD260nm of 1 equals an RNA concentration 
of 40 µg/ml). The Nanodrop was also used to assess the quality of the RNA through 
measuring the 260/280 and 260/230 ratios; expected values for high quality RNA are 
approximately 2.0 and 2.0-2.2, respectively. The RNA was then stored at -80oC.  
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First strand cDNA synthesis 
cDNA was synthesised from total RNA, extracted using methods outlined in 
sections 2.2.5, using the GoScript Reverse Transcription System (Promega) 
following the recommended manufacturer’s protocol. For each sample in the 
experiment the same amount of RNA was used in the reverse transcriptase reaction, 
combined in a PCR tube with the following components:  
RNA (up to 5 µg) X µl 
Random Primers (0.5 µg/reaction) 1 µl 
Nuclease free water X µl 
Final volume 5 µl 
 
The mixture was denatured at 70oC for 5 minutes and then cooled on ice. The 
following reverse transcription mix was added to the RNA, random primers and 
nuclease free water and made up to a final reaction volume of 20 µl: 
 
Component Volume 
(n=1) 
Final 
Concentration 
Nuclease free water (to a final volume of 15 µl) Xµl - 
GoScript 5X reaction buffer 4 µl 1X 
MgCl2 (25 mM) 4 µl 5 mM 
PCR nucleotide mix (10 mM of each dNTP) 1 µl 0.5 mM 
Recombinant RNasin Ribonuclease inhibitor (40 U/µl) 0.5 µl 1 U/µl 
GoScript Reverse Transcriptase 1 µl - 
 
The reaction mixtures were incubated at 25oC for 5 minutes to allow primer 
annealing and then incubated at 42oC for 60 minutes for the extension step. The 
reverse transcriptase was inactivated by heating the reaction to 70oC for 15 minutes. 
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The cDNA was diluted appropriately (if 2 µg RNA was converted a 1:20 dilution 
was made) using nuclease free water and stored at -20oC. 
 
Semi-quantitative PCR analysis of mRNA expression 
For analysis of gene expression, cDNA generated as previously described was 
amplified using GoTaq DNA polymerase (Promega) following manufacturer’s 
guidelines. The GoTaq Flexi DNA Polymerase master mix is: 
 
Component Volume 
(n=1) 
Final 
Concentration 
5X Green GoTaq Flexi buffer 2.5 µl 1X 
MgCl2 (25 mM) 0.9 µl 4 mM 
PCR nucleotide mix (10 mM of each dNTP) 0.5 µl 0.4 mM 
Forward primer (20 µM) 0.1 µl 0.2 µM 
Reverse primer (20 µM) 0.1 µl 0.2 µM 
GoTaq DNA polymerase (5u/µl) 0.1 µl 0.05 U/µl 
Nuclease free water X µl - 
cDNA template (1:10 dilution) 1 µl - 
Final volume 12 µl - 
 
The PCR was performed in a thermocycler: QB-96 (Quanta Biotech) or peqSTAR 
2X (peqlab). The annealing temperature of each primer set was optimised using a 
gradient PCR and are detailed in Table 2.1. The amount of cDNA template used 
varied between primer sets depending on the abundance of the target for 
amplification. In general, 1 µl of a 1:20 dilution of cDNA generated from 2 µg of 
RNA was used for target genes and a 1:200 dilution of cDNA used for reference 
genes. Standard thermal cycling conditions were as follows: incubation at 95°C for 5 
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minutes, followed by 25 or 35 cycles (for reference and target genes, respectively) of 
95°C for 30 seconds, 57-65 °C for 30 seconds and 72 °C for 30 seconds, with a final 
cycle at 72°C for 10 minutes. Samples were kept at 4°C prior to gel electrophoresis 
(section 2.2.2.3) or at -20°C for long-term storage. 
 
2.2.8 Bioinformatic Analysis 
ECR (Evolutionary Conserved Regions) Browser 
Conservation of transcription factor consensus binding sequences were addressed 
based on the TRANSFAC 4.0 database (Matys, 2003) available through the rVista 
2.0 tool on the ECR Browser (http://ecrbrowser.dcode.org/) using the following 
parameters: minimum matrix conservation (similarity between the consensus binding 
site for a transcription factor and a potential binding site in the query sequence), 
70%; minimum number of homologous sites (the minimum number of sites of which 
a matrix is built), 4; factor class level (the classification of transcription factors in the 
TRASNFAC database is hierarchical and include 6 levels, from family of 
transcription factors to splice variants), 4; and similarity of the sequence to the 
matrix, 1. 
 
NCBI 
Sequence alignments between human and other species genomes were performed 
using the basic local alignment search tool of nucleotide databases (BLASTN) 
(Altschul et al., 1997), available at NCBI (http://blast.ncbi.nlm.nih.gov/ Blast.cgi). 
BLAST finds regions of local similarity between sequences through making 
comparisons of nucleotide or protein sequences to sequence databases, calculating 
the statistical significance of matches. BLAST can be used to infer functional and 
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evolutionary relationships between sequences as well as help to identify members of 
gene families. 
 
2.2.9 Genotyping 
VNTR analysis 
The REST VNTR was genotyped on a QIAxcel Advanced System (Qiagen) 
electrophoresis platform. DNA amplification was performed using 10 ng genomic 
DNA following the protocol described in section 2.2.5 and the human REST VNTR 
primer set detailed in Table 2.1. For analysis on the QIAxcel Advanced System 
platform, 12 µl of PCR product was subjected to capillary electrophoresis following 
the manufacturers’ protocol. The appropriate run method was the 0M800 associated 
with QIAxcel DNA High Resolution Gel Cartridge, with an injection time of 10 
seconds, a separation voltage of 3kV and separation time of 800 seconds. The 
QIAxcel DNA High Resolution Gel Cartridge is designed for high-resolution (3–5 
bp) genotypings. The gel cartridge can separate fragment sizes ranging from 15 bp to 
10 kb. For the runs the 15/600bp alignment marker was chosen in association with 
the 25/500bp ladder. 
Fragment analysis was performed using the Qiaxcel integrated software version 
4.0 (Qiagen) and validated using gel electrophoresis. For gel electrophoresis, PCR 
products were separated on a 2% agarose gel as described in section 2.2.2. Expected 
fragment sizes ranged between 178-190 bp. Sequenced samples for each genotype 
were included on each 96-well plate. Genotyping was performed blind to age and 
gender. Statistical analysis for genotype data is detailed in section 2.2.10. 
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2.2.10  Chromatin Immunoprecipitation (ChIP) 
In-vitro ChIP 
Cells were grown to 80% confluence in T175 flasks and treated for 1 hour under 
one of the following conditions: basal (untreated), 1 or 5 mM valproate (see section 
2.2.3). Samples were processed following methods described by Murgatroyd et al. 
(2012). ChIP buffers are listed in section 2.1.2. Immunoprecipitation was performed 
using ChIP grade antibodies detailed in Table 2.3. PCR analysis of the 
immunoprecipitated chromatin samples was performed using primers detailed in 
section 2.1.8, Table 2.1. 
 
For each immunoprecipitation (IP), 5 µg of the sheared chromatin was made up to 
250 µl using ChIP Dilution Buffer, supplemented with 10 µl/ml 100X PIC and 
incubated overnight at 4°C on a rotating wheel with antibodies raised against histone 
H3, H3-TriMetK9, NRSF, hnRNPK, CNBP, Nucleolin, SP1 and CTCF. Details of 
the antibody used per IP are outlined in Table 2.3. The protein–DNA complexes 
were added to 40 µl DynabeadsTM (Thermo Scientific), which were first pre-cleared 
by washing twice with 1 ml ChIP dilution buffer supplemented with PIC; the second 
wash step was left for 2 hours, and then incubated on a rotating wheel for 1 hour at 
4°C. The magnetic Dynabead™/protein–DNA complexes were captured by placing 
the tubes in a magnetic rack for 1 minute to separate the beads from the solution and 
the supernatant discarded. DNA bound magnetic beads were subjected to 5 minute 
wash steps (performed in a 4°C cold room) with rotation to remove non-specific 
DNA and proteins associated with the Dynabeads™. Firstly, the beads were washed 
with 1 ml of low-salt wash buffer, followed by high-salt wash buffer, LiCl wash 
buffer and finally TE buffer. The immune complex was eluted by adding 50 μl of 
elution buffer containing 50 μg/ml proteinase K to the magnetic bead/protein–DNA 
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complexes and the supernatant transferred to a new microcentrifuge tube and mixed 
at 65°C for 2 h to release the protein-bound DNA and reverse the cross-linking. The 
samples were then incubated at 95°C for 10 min to denture the proteins and 
inactivate the proteinase K and the DNA recovered from the sample through spin 
column purification using the Wizard® SV Gel and PCR Clean-Up System 
(Promega) in a volume of 20 µl. The DNA was quantified using a Nanodrop 8000 
and analysed by PCR (section 2.2.5).  
 
2.2.11  Methylated DNA Immunoprecipitation (MeDIP) 
Methylated double stranded DNA was isolated from genomic DNA samples using 
the CpG Methyl Quest DNA Isolation Kit (Merck Millipore), following 
manufacturer’s instruction. Briefly, a total of 300 ng of sonicated genomic DNA was 
incubated for 1 hour at room temperature on a rotating wheel with 5 µl of pre-cleared 
CpG MethylQuest glutathione paramagnetic beads, which are pre-coupled to a GST 
(glutathione-S-transferase protein)-MBD (methyl binding domain) fusion protein that 
specifically binds methylated double stranded DNA. Methylated sequences bound to 
the CpG Methyl Quest fusion-protein/bead complex were subjected to wash steps 
and the supernatant containing the non-methylated DNA was kept for comparison. 
The methylated DNA was eluted from the beads by heating the samples at 80°C for 
10 minutes with mixing in 100 µl TE buffer. The sample was separated from the 
beads by placing the tubes in a magnetic rack and transferred to a new 
microcentrifuge tube and the beads discarded. Samples were subjected to PCR 
analysis (section 2.2.5) and then stored at -20°C.  
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2.2.12  Statistical Analysis 
Clump analysis 
Significance-testing of allele frequency and genotype data for the REST VNTR 
between cases and controls of the schizophrenia cohort (Materials section 2.1.4) and 
AD and FTD cases and healthy controls was performed using Clump 24 analysis 
software which can be accessed from 
http://www.davecurtis.net/dcurtis/software.html.  
The Clump program assesses the significance of the departure of observed values 
from the expected values using a Monte Carlo-based approach. It does this by 
performing repeated simulations (10,000) to generate contingency tables (2 x N) that 
have the same marginal totals as the one under consideration and counting the 
number of times that a chi-squared value associated with the real table is achieved by 
the randomly simulated data. The Clump software also generates a novel chi-squared 
value (T4) by ‘clumping’ columns together into a new two-by-two table in a way 
which is designed to maximise the chi-squared value and directly tests the hypothesis 
that several alleles are more common among the cases than among the controls 
(Sham and Curtis, 1995). The Clump program generates four test statistics using 
Monte Carlo methods to evaluate the significance of chi-squared values by assessing 
how many times the observed value produced is exceeded by chance from the 
randomly generated simulated datasets. The four tables are as follows:  
T1: The raw 2-by-N table supplied by the user  
T2: The original table with columns containing small numbers ‘clumped’ together 
T3: The most significant of all 2-by-2 tables obtained by comparing each (non-rare) 
column of the original table against the total of all the other columns 
T4: A 2-by-2 table obtained by ‘clumping’ the columns of the original table to 
maximise the chi-squared value 
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Hardy-Weinberg Equilibrium (HWE) 
As a measure of quality control in our cohorts, we tested our genotype data for 
departure from HWE as this can be used as an indicator of genotyping errors and 
population stratification. For analysis of HWE, we used the Hardy-Weinberg 
equilibrium calculator (http://www.oege.org/software/ hwe-mr-calc.shtml) which 
implements the Pearson chi-square (X2) test statistic to assess goodness-of-fit of the 
observed genotype frequency against the expected under HWE (Rodriguez et al., 
2009).  
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Chapter 3 
 
Distinct chromatin structures at the MAOA promoter 
correlate with allele specific expression in female cells. 
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3.1 Introduction 
It is thought that the uVNTR acts as a classical transcriptional regulator in the 
promoter of the MAOA gene and that the distinct variants support differential MAOA 
expression, which mediates response to stress that the individual has, or is 
experiencing. This gene and the uVNTR polymorphism are the most often cited 
example of a genotype by environment interaction in which an individual’s genotype 
moderates the effect of environmental experience to alter mental health outcomes 
(Caspi et al., 2002). Simplistically the function of the uVNTR is modified by the 
complement of active transcription factors in the cell, altered in response to the 
environment, that are able to recognise and bind to the uVNTR thus allowing the 
domain to act as a transcriptional regulator. However two recent advances in 
understanding the regulation of this gene have questioned this simple hypothesis. 
Firstly, bioinformatic data now indicates that there are at least two transcriptional 
start sites (TSS) for the MAOA gene. Furthermore, the newly described 
transcriptional start site now places the uVNTR in the 5ʹ UTR (5ʹ untranslated 
region) of the MAOA gene (Figure 3.1). Secondly, the MAOA locus has been 
proposed as one of the loci that can escape X inactivation (Carrel and Willard, 2005, 
Joo et al., 2014, Mugford et al., 2014).  
To address the mechanisms which might underpin the sex differences in studies of 
MAOA G×E, we defined regulatory mechanisms at the MAOA promoter. One of the 
MAOA mRNA isoforms, according to UCSC web browser, now contains the uVNTR 
in the 5ʹ UTR. This allowed us to perform the analysis of allele specific expression 
and chromatin structure in the female cell line SH-SY5Y, which is heterozygous for 
this VNTR. We were able to demonstrate that both alleles, at least in the population 
of cells, can support expression of MAOA.  
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However, using chromatin immunoprecipitation (ChIP) analysis we demonstrate 
that each allele can support distinct transcription factor, histone binding and 
methylation patterns; the clear allelic difference in binding to the promoter and the 
expression from both alleles would be supportive of the model that the MAOA gene 
is within a genomic region that can escape X inactivation. 
 
 
 
 
3.2 Aims 
 
 
 Identify and assess the expression pattern of the MAOA mRNA in the 
neuroblastoma cell line SH-SY5Y 
 Analyse the differences in the expression led by the MAOA VNTRs  
 Analyse the GxE interaction in the SH-SY5Y cell line on both expression 
levels and chromatin interactions 
 Analyse the methylation pattern in the MAOA gene promoter region  
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3.3 Results 
3.3.1 Bioinformatic analysis 
3.3.1.1 Human MAOA Gene Promoter Architecture 
The uVNTR was originally described as being 1.2kb upstream of the TSS of the 
MAOA gene (Sabol et al., 1998), however bioinformatic analysis from data in Hg19 
and Hg38 of the human genome using ENCODE data on the USCS genome browser 
(http://genome.ucsc.edu) (Kent et al., 2002)(Kent et al., 2002) demonstrated an 
additional TSS which is upstream of the uVNTR. This now locates the uVNTR in the 
5ʹ UTR of the MAOA gene generating two possible MAOA isoforms, both active and 
that will encode for two different MAOA proteins (Figure 3.1). The ENCODE data 
shows those transcription factors determined by chromatin immunoprecipitation 
assay in a variety of cell lines to bind to this promoter region: of interest was the 
strong binding of CTCF, a transcription factor that we have previously implicated in 
regulation of the human serotonin transporter gene (SLC6A4) via in part regulatory 
VNTRs (Ali et al., 2010, Klenova et al., 2004, Stevens et al., 2012, Vasiliou et al., 
2012). These VNTRs in the SLC6A4 gene are associated with risk for 
neuropsychiatric disorders and respond to many pharmaceutical challenges such as 
lithium and cocaine in-vitro (Haddley et al., 2012, Klenova et al., 2004, Roberts et 
al., 2007, Vasiliou et al., 2012). Less than 500bp upstream from the uVNTR lies the 
dVNTR which has been demonstrated to have differential regulatory activity based 
on copy number of the repeat in reporter gene assay and different copy variants have 
been correlated to antisocial personality disorder (Philibert et al., 2011). 
Bioinformatic data suggests that MAOA locus has two different TSSs and that in part 
differential expression of MAOA gene may be directed by these distinct VNTR 
regulatory motifs. 
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Figure 3.1 – Monoaine Oxidase A (MAOA) promoter region. Graphic representation of MAOA promoter region based on UCSC genome web browser (Hg19). From top 
to bottom: reference gene sequence; previous version of UCSC genome; tandem repeats: from left to right dVNTR, uVNTR; CpG islands; ENCODE transcription factor 
data (Data version: ENCODE Mar 2012 Freeze) indicating those factors demonstrated to bind to this region in specific cell lines, in short the darker the line the more 
confidence in the association; ENCODE data for H3K27Ac mark (often found near active regulatory elements) on 7 cell lines; multi alignment (of 100 vertebrate) 
representing the degree of homology between primates and other species; vertebrate conservation (100 species).  
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However the primary sequence of both the u- and dVNTR are very different and this 
would suggest they could respond to different transcription factor pathways. 
Furthermore the dVNTR sequence predicts the formation of a G-Quadruplex 
structure as described in Chapter 1, section 1.6. As illustrated in Figure 3.2 the 
uVNTR sequence does not appear to contain potential binding sites for transcription 
factors while the dVNTR contains several binding motifs for SP1, hnRNPK and 
CNBP transcription factors overlapping the repeats of the copy number variation. 
A similar scenario has been proposed using the C-Myc gene as a model in which 
the double helix DNA would change its conformation modulating gene expression 
(Brooks and Hurley, 2009). Binding from the transcription factor SP1 would increase 
transcription of the gene, or at least promoting it, which in turn would increase the 
supercoiling upstream of the binding site allowing the downstream region to take 
single-stranded conformation. This would allow the formation of the G-Quadruplex 
in the purine rich strand and the i-motif in the pyrimidine rich strand potentially 
silencing the transcription (Sun and Hurley, 2009). Alternatively single strand DNA 
binding proteins such as hnRNPK and CNBP would bind to the purine rich and 
pyrimidine rich respectively maintaining the transcription active. Based on this 
assumption and on the presence of the binding motifs in the dVNTR core sequence 
we will test the hypothesis of a similar mechanism working on the MAOA promoter. 
Thus a different genotype, containing different copies of this VNTR, will modify the 
number of binding sites for these transcription factors which, in turn, might modulate 
the transcribed MAOA mRNA. 
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Figure 3.2 - Bioinformatic analysis on transcription factor binding sites over MAOA dVNTR and uVNTR genetic region. Genetic locus comprehensive of the MAOA 
dVNTR and uVNTR. Underlined in red the predicted SP1 binding motif (Raiber et al., 2012); in green the predicted hnRNPK binding motif (Michelotti et al., 1996) and in blue 
the predicted CNBP binding motif (Armas et al., 2013). 
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3.3.1.2 MAOA VNTRs conservation analysis 
DNA sequences of the genomic regions encompassing the MAOA u- and dVNTR 
were taken from UCSC browser through the Multi Alignment of 100 Vertebrates tool 
for each of species displayed in Figure 3.3 and aligned with Clustal Omega multiple 
sequence alignment online tool (http://www.ebi.ac.uk/Tools/msa/clustalo/). Figure 
3.3 A shows the dVNTR sequence in humans and non-human primates, the dVNTR 
is not present in rodents. The core sequences (A and B), as reported by Philibert et al. 
(2011), can be found in all species analysed except for marmoset which sets the 
separation line between the primates order in old world monkeys with the new world 
ones that we analysed. The described arrangement ABABABAAA can only be found 
in humans. In chimps, our genetic closest relatives in this analysis, it can be found 
two A sequences and one B with an A AB arrangement where between the A 
sequences is present an imperfect B sequence. Gorillas have an A B structure 
separated by a partial A sequence. Orangutans, surprisingly, show the higher number 
of copies after humans with a total of three A sequences and four B sequences with a 
structure B AB ABAB with a partial A sequence after each B copy variant (Table 
3.1). Both upstream and downstream flanking regions are highly conserved among 
species. Figure 3.3 B points out the MAOA uVNTR sequence in humans and non-
human primates. The complete 30bp MAOA uVNTR sequence that in human can be 
found from a minimum of 2 repetitions up to 6 repetitions (Huang et al., 2004, Sabol 
et al., 1998), goes back in time until chimps, where a single complete repeat can be 
found. Once again, the flanking sequences, upstream and downstream the repetitive 
element are highly conserved among species even in the most phylogenetic distant 
ancestors. These conservation data may be in line with a recent report affirming that 
diversity among great apes in the X chromosome is lower than in autosomes (Nam et 
al., 2015).  
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Figure 3.3 – Monoamine Oxidase A (MAOA) VNTRs conservation in human and non-human primates. A. Conservation analysis of the MAOA dVNTR. At the top graphic 
illustration of the MAOA gene. Underneath the alignment of the sequences for humans and non-human primates. B. Conservation analysis of the MAOA uVNTR. At the top 
graphic illustration of the MAOA gene. Underneath the alignment of the sequences for humans and non-human primates.  
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Table 3.1 - MAOA dVNTR conservation
 
Note: summary of the dVNTR repeats as present in humans and different non-human primates as 
illustrated in Figure3.3 
 
3.3.2 Allelic specific regulation of MAOA expression 
We used the human neuroblastoma cell line SH-SY5Y to address MAOA 
expression. SH-SY5Y is a well characterised cell line which was originally isolated 
from a four year old female. Genotyping of this cell line demonstrated that it was 
heterozygous for the uVNTR with 3 and 4 copies of the repeat element (Figure 3.4 
A). This allowed identification of allelic specific expression when initiated from the 
newly described TSS which places the uVNTR in the 5ʹ UTR. The MAOA uVNTR 
primer set that we used for the gDNA genotype can also be used to assess the mRNA 
expression since this genomic region, comprehensive of the uVNTR, has been 
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transcribed in the MAOA mRNA, thus converted into cDNA after the RT-PCR 
process.  
Under basal growth conditions we were able to detect mRNA corresponding to 
expression from both alleles using the uVNTR length as the distinguishing feature 
(Figure 3.4 A). Likewise, analysis of cDNA prepared from saliva from females 
heterozygous for the uVNTR demonstrated that in-vivo expression from both alleles 
could be observed in the same individual (Figure 3.4 B). In our experience PCR 
analysis of VNTRs can lead to different molar intensities of product from each allele. 
Therefore we made no attempt to correlate intensity of PCR product with expression 
levels, e.g the Longer (L – 4R) allele being more intense than the Shorter (S – 3R) 
allele or vice versa, in the same experiment. We observed a similar bias in the PCR 
of genomic DNA in several of our subsequent ChIP analysis. However we were able 
to compare intensity between experiments for the same primer set; this demonstrated 
that in SH-SY5Y cells in response to exposure to sodium valproate, a mood 
stabiliser, differential MAOA allelic expression was observed. Specifically the ratio 
of L- to S- allele expression was reversed (Figures 3.4 A - 3.5 A). Similarly to 
sodium valproate, exposure to ethanol, lithium chloride and cortisone at different 
concentrations (20, 50 and 100 nM) exerted a similar response. Figure 3.5 highlights 
the different expression levels obtained by the subsequent analysis of the treatments 
over the MAOA expression. This switch in relative levels of expression cannot be 
explained by PCR allele preference and reflects differential regulation of the alleles 
in response to the stimulus. As the MAOA gene is on the X chromosome the 
expression of both alleles could have been expected to be affected by the inactivation 
of one allele. The expression of both alleles does not have to be consistent with 
MAOA escaping X chromosome inactivation but could be construed as a mosaic 
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effect of random silencing of one allele in any particular cell and thus the population 
would appear to express both alleles. However there have been reports of large 
sections of the X chromosome escaping X inactivation which includes regions 
encompassing the MAOA gene (Carrel and Willard, 2005, Joo et al., 2014, Mugford 
et al., 2014).  
To explore the allelic expression further we analysed by ChIP, transcriptional and 
epigenetic variation at the MAOA promoter in SH-SY5Y cells in response to 
valproate using again the size difference of the uVNTR to identify allelic specific 
changes. RNA polymerase II was demonstrated to be present on both alleles, 
consistent with expression from both alleles (Figure 3.6 A). This was in stark 
contrast to histones which were found only on the promoter of the shorter, 3 copy 
repeat, uVNTR allele (Figure 3.6 B). The lack of histones on the 4 copy uVNTR 
promoter was observed with two different antibodies, H3 which identifies all histone 
3 proteins and H3K9me3 which is indicative of an inactive histone complex 
consistent with promoter inactivation and heterochromatin formation (Hublitz et al., 
2009). The methylation status of both alleles was addressed by their ability to 
associate with methylation binding domain protein (MBD). This demonstrated, under 
basal growth conditions, a clear allelic specificity in that the 4 copy uVNTR 
promoter, which did not associate with the active histone mark, was predominantly 
methylated whereas the 3 copy uVNTR promoter was unmethylated (Figure 3.7). 
We observed a small unmethylated proportion of the 4 copy allele. The methylation 
pattern was altered when the cells were exposed to sodium valproate, most 
noticeably in the methylated fractions, in that there was now a significant proportion 
of the 3 copy allele which was methylated.  
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Figure 3.4 - 1.5% agarose gel of Monoamine Oxidase A (MAOA) uVNTR PCR amplification. Amplicon size 324bp for 3R VNTR, 354bp for 4R VNTR. A. SH-SY5Y 
cell line cDNA: lanes from left to right: 100bp ladder marker; basal condition; vehicle control: H2O 1 hour ; sodium valproate treatment 1 hour; PCR negative control. B. 
human female samples cDNA: lanes from left to right: 100bp ladder marker; 2x homozygous 3R/3R; 3x heterozygous 3R/4R. 
95 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 - Monoamine Oxidase A (MAOA) cDNA expression. A. Line graph illustrating the 
MAOA mRNA fold expression level comparing the uVNTR 3R vs uVNTR 4R. The table represent the 
Student’s T-Test (two-tailed type 2). B. The agarose gels illustrate a sample of the PCRs used to 
generate the graph. At the top MAOA uVNTR, right below the housekeeping gene β-Tubulin. Values 
for both 3R and 4R uVNTR have been normalised for β-Tubulin before calculating the fold increase. 
For each condition N=3. * = p<0.05. 
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Figure 3.6- ChIP analysis of the Monoamine Oxidase A (MAOA) VNTRs alleles. Amplicon size 
324bp for 3R VNTR, 354bp for 4R VNTR. A. In-vivo interaction of active RNA pol II (CTD phospho 
Ser5) under basal conditions, lanes from left to right: 100bp ladder marker; input DNA (1% sheared 
chromatin) acts as a positive control for PCR; IgG: –ve control for non-specific background binding; 
active RNA pol II (CTD phospho Ser5) 10ug DNA. B. In-vivo interaction of Histone 3 and active 
Histone mark H3K9me3 with the MAOA alleles under basal conditions. Lanes from left to right: 
100bp ladder marker; input DNA (1% sheared chromatin); IgG; Histone 3; active Histone mark 
H3K9me3. C. ChIP analysis of the in-vivo interaction of factors associated with alternative DNA 
structure formation with MAOA alleles. Under Basal conditions (top) , following 1hr exposure to H₂0 
(middle), following 1hr exposure to 2 µM sodium valproate (bottom). Lanes from left to right: input 
DNA (1% sheared chromatin); IgG; Histone 3; active Histone mark H3K9me3; Single Stranded DNA 
(ssDNA) binding protein hnRNP K; ssDNA binding protein CNBP; G4 binding protein nucleolin; 
transcription factor CTCF; transcription factor Sp1. 
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Figure 3.7- Methylation at the Monoamine Oxidase A (MAOA) promoter. PCR amplification of sheared gDNA post CpG MethylQuest treatment. Amplicon size 324bp 
for 3R VNTR, 354bp for 4R VNTR. Lanes from left to right: 100bp ladder marker; basal condition; vehicle control: H2O ; sodium valproate treatment of unmethylated 
DNA: not bound to methyl domain binding protein (CpG MethylQuest™ Protein). Basal condition; vehicle control: H2O ; sodium valproate treatment of methylated DNA 
bound to methyl domain binding protein (CpG MethylQuest™ Protein). 
98 
 
 
To complement the distinct epigenetic marks on the MAOA alleles we addressed the 
potential binding of transcription factors to the promoter (Figure 3.6 C). The 
selection of transcription factors for analysis was based mainly on a) the CpG island, 
and b) our previous study on CTCF and Sp1 interactions on VNTRs in several genes, 
including the SLC6A4 gene (Haddley et al., 2012, Klenova et al., 2004, Roberts et 
al., 2007, Vasiliou et al., 2012). We therefore addressed the binding to the promoter 
by ChIP analysis of 4 transcription factors: CTCF, Sp1, HnRNP K, CNBP and the 
transcriptional coactivator protein nucleolin. These proteins have previously been 
shown to bind similar sites or affect the binding of one another to regulatory regions 
(Lobanenkov et al., 1990, Michelotti et al., 1995, Witcher and Emerson, 2009). As 
for histones, under basal growth conditions, transcription factor binding was only 
observed on the short, 3 copy uVNTR allele (Figure 3.6 C). Upon exposure to 
sodium valproate two major changes were observed; 1) binding of the single 
stranded nucleic acid binding proteins hnRNP K and CNBP on the longer 4 copy 
uVNTR and 2) a significant increase in the intensity (equated to binding) for the 
inactive histone (H3K9me3), nucleolin and Sp1 to the short allele.  
Previous models of chromatin structure have proposed that constitutively active 
genes have proximal promoters with no or few nucleosome which allows access for 
transcription factors to initiate the transcriptional event (Choi and Kim, 2008), 
whereas transcription of stimulus inducible genes would require movement or 
removal of well-positioned nucleosomes from the promoter to allow the transcription 
factor to interact with the consensus binding site (Li et al., 2007). Based on this 
hypothesis and the findings presented above, our data would be consistent with the 
short 3 copy allele being at least in part, stimulus inducible in our cell model. We 
undertook preliminary testing of this hypothesis by exposing SH-SY5Y cells to 
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challenges we have previously used to elicit responses in modulation of transcription 
factors and methylation state of cell lines (Haddley et al., 2012, Roberts et al., 2007, 
Vasiliou et al., 2012).  
 
3.4 Discussion 
The MAOA uVNTR is one of the most studied GxE interactions in the literature 
and the accepted hypothesis is that the different repeat copy numbers regulate the 
differential expression of MAOA in response to the environment. This is a relatively 
straightforward explanation for the male gender which has only one allele for this 
gene. However, the situation is more complex in females for several reasons 
including a) gene dosage, b) the potential for MAOA to escape X-inactivation and c) 
the female, unlike the male, can be heterozygous at this locus which could correlate 
with distinct expression profiles to differentially modulate MAOA gene expression. 
The MAOA gene is one of the approximately 15% of X chromosome genes which 
may escape X inactivation (Carrel and Willard, 2005, Joo et al., 2014, Mugford et 
al., 2014). However there is still much debate about X inactivation in-vivo and there 
may be no reason why X-inactivation of the second allele in females itself is not 
dependent on GxE interactions. Consistent with this, the gene termed a master 
regulator of X chromosome inactivation, XIST, is over expressed in females with 
major affective disorders (Ji et al., 2015). This would help, in part to explain, the 
differences in association seen for specific mental health issues when male and 
females are compared when the uVNTR is assessed as a risk factor, such examples 
include: MAOA uVNTR moderating the relationship between childhood 
maltreatment and dysthymia only in females, gender differences including 
pronounced effects on ADHD and anxiety in females whereas the opposite is true for 
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autism, bipolar disorder and aggressive behaviour in males (Melas et al., 2013, Reif 
et al., 2012). Indeed many studies of MAOA G×E report only on males due to 
compounding effects including female heterozygosity for the uVNTR (Caspi et al., 
2002, Fergusson et al., 2012, Kim-Cohen et al., 2006). Thus, it is likely that both 
sex-based and disorder-based differences exist. 
We investigated the molecular mechanisms underlying MAOA expression in the 
human neuroblastoma cell line SH-SY5Y which is both female and heterozygous for 
the uVNTR. This heterozygosity was crucial for our study to correlate mRNA 
expression from each individual MAOA allele with transcription factor binding and 
epigenetic marks at the proximal promoter. Our data suggested that the MAOA gene 
might escape X inactivation in SH-SY5Y cells and that both alleles were active, 
albeit by very distinct molecular mechanisms. Most noticeably although both alleles 
had different chromatin structures (methylation and transcription factor interactions), 
when ChIP was performed for an active RNA polymerase (anti-RNA pol II CTD 
phospho Ser5 antibody) binding was observed at both alleles which was consistent 
with the cDNA studies. This demonstrates that both alleles were active despite the 
distinct chromatin architectures (Figure 3.6 A). The methylation of one allele which 
apparently did not repress MAOA expression (Figure 3.7) would be consistent with 
recent work on the X chromosome which indicated that methylation does not 
necessarily correlate with gene repression but rather functions as a parameter 
affecting a region’s ability to escape X inactivation (Joo et al., 2014). Our data adds 
to the importance of gender in regulation of MAOA expression via epigenetic 
mechanisms, e.g. the gender specific changes of methylation in a longitudinal study 
of twins (Wong et al., 2010) and hypomethylation in the pathogenesis of panic 
disorder particularly in female patients (Domschke et al., 2012). 
101 
 
 
To further investigate the regulation of the MAOA promoter we analysed binding 
for CTCF, Sp1, hnRNP K, CNBP and nucleolin. Our data provided evidence that 
these proteins recognise the proximal MAOA promoter and more importantly 
demonstrated distinct patterns of binding over each specific allele which could be 
modulated by inducible gene expression (Figure 3.6 C). Our transcription factor 
binding profile to the promoter is consistent with our previous findings of distinct 
chromatin architecture over the heterozygous alleles which correlated with 
differential expression in response to sodium valproate (Figure 3.4). That mRNA 
expression is increased from the 3 copy allele in response to multiple challenges 
(ethanol, cortisone, sodium valproate and lithium - Figure 3.5), might represent the 
fact that this allele is the one most likely to respond initially to transcription factor 
changes as minimum methylation is present so allowing ease of access for the 
transcription factors to recognise their DNA binding sites. However the complex 
genomic architecture at each MAOA allele remains to be resolved in future 
experiments.  
In females the differences in epigenetic marks and transcription factor binding 
over the MAOA promoter in-vivo, which we have defined in-vitro, may be generated 
by inconsistent X-inactivation and the action of other environmental challenges that 
modulate promoter activity including the uVNTR. This would be consistent with the 
over expression of XIST in major affective disorders in females (Ji et al., 2015). 
Combined the data suggests a requirement for the reappraisal of the regulation of X 
chromosome gene expression, and specifically MAOA in females that might 
contribute to mental health issues. However we have demonstrated with valproate 
exposure and other challenges that the level of expression could still be altered. In 
this manner GxE interactions in females could be quite distinct from those in males 
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in which a more conventional chromatin structure over the promoter might be 
expected. Therefore females may be even more variable with respect to both X-
linked gene expression and subsequent GxE interactions. Our data reappraises the 
regulatory mechanisms operating at the MAOA promoter to control gene expression 
and furthermore whether a gene dosage model is important for gender effects on 
mental health. The gender effect could modulate CNS function and development at 
any time in the foetus, child or adult as it would still be dependent on transcription 
factor expression to modulate the regulator functions of the proximal MAOA 
promoter. The same mechanism may operate on other genes on the X chromosome 
implicated in mental health disorders. It may also be relevant in conditions such as 
Klinefelter Syndrome (XXY) and triple X syndrome as in general these patients 
show an increased incidence of psychiatric conditions (DeLisi et al., 2005, Otter et 
al., 2010). The complexity of X inactivation to modulate the action of risk factors 
involved in predisposition to a disorder may also have significant consequences for 
genome wide association studies on the X chromosome. 
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Chapter 4 
 
MAOA isoforms in the haploid HAP1 cell line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
 
4.1 Introduction 
The MAOA gene expresses at least two mRNA isoforms that are reported in the 
major online web browsers. These two isoforms lead to translation of two distinct 
MAOA proteins whose function might be modified by the difference in the amino 
acid sequence that these two isoforms possess (Figure 4.1). The effect and activity of 
the minor MAOA isoform has not previously been reported to our knowledge and we 
will try to address its mRNA and protein expression in this chapter.  
The HAP1 cell line we utilised for these experiments is a semi-haploid cell line 
derived from KBM7 cell line. The HAP1 cell line possess a single set of 
chromosomes with the exception of a 30 Mbs (megabases) fragment of chromosome 
15 which is integrated on the long arm of chromosome 19. Carette et al. (2011) in an 
unsuccessful attempt to induce pluripotency in KBM7 cells for their experiment, 
generated the HAP1 cell line. This haploid cell model is used as a tool by the 
company Horizon that through genome editing with Clustered Regularly Interspaced 
Short Palindromic Repeat (CRISPR) - Cas9 technique is able to knockout (KO) 
specific genetic sequences. 
The single set of chromosomes possessed by this cell line makes it ideal to 
completely and specifically knock out genomic regions of interest either to assess 
gene expression or protein function and interested pathways in which these proteins 
might be involved. 
We exploited this major advantage of the HAP1 cell line purchasing from Horizon 
MAOA KO cell lines for the uVNTR, the dVNTR and both VNTRs, in order to 
assess the effect that the two VNTRs in the MAOA promoter region, might have in 
the expression of the two different isoform start sites.  
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4.2 Aims 
 
 Identify and assess the expression pattern of the MAOA mRNA and protein 
isoforms due to the different TSSs in the HAP1 cell line clones 
 Analyse the differences in the expression led by the MAOA uVNTR and 
dVNTR in the different KO cell lines for the two TSSs 
 Validate the GxE interaction, observed for the MAOA gene in Chapter 3, in 
the HAP1 cell line 
 
 
 
4.3 Results 
4.3.1 Bioinformatic analysis on MAOA gene 
4.3.1.1 MAOA isoforms description 
Different accredited web browser such as UCSC (https://genome.ucsc.edu/), 
AceView (http://www.ncbi.nlm.nih.gov/ieb/research/acembly/), UniProt 
(http://www.uniprot.org/) and Ensemble (http://www.ensembl.org/) report two major 
isoforms of the MAOA mRNA which in turn translate two different MAOA protein 
isoforms, along with different unspliced and untranslated oligonucleotides.  
Figure 4.1 defines these mRNAs (Figures 4.1 A and 4.1 C) along with a novel 
isoform identified in this study (Figure 4.1 B). We will refer to these isoforms as 
Long MAOA (L), Medium MAOA (M) and Short MAOA (S) isoforms according to 
the expected protein weight.  
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Figure 4.1 - Monoamine Oxidase A (MAOA) isoforms. Graphic representation of the MAOA gene as reported in UCSC genome browser Hg38 and the most recent version of 
the Hg19. Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes the exons. Curved black arrow sets the translational start site. Gray bars are the dVNTR and 
the uVNTR from left to right respectively. A. Major MAOA isoform (Long). B. MAOA splicing variant missing Exon IV (Medium). C. MAOA minor isoform (Short).  
107 
 
 
The MAOA L variant (Figure 4.1 A) represents the MAOA major isoform, it is 
comprised of a 4090 bp mRNA and is composed of 527 amino acids (AA). The 
Hg19 database and AceView web browser, at the time of writing, identify the 5ʹ 
UTR of this isoform as identical to the isoform S, where the mRNA sequence 
comprehensive of the 5ʹ UTR is 5330 bp long (Figures 4.2 – 4.3). In the older 
database versions this spanned from bp +1 to +181. Therefore MAOA uVNTR, since 
its first characterization in 1998 (Sabol et al., 1998) was considered more than 1kb 
away from the first, shorter, transcriptional start site.  
On the contrary the MAOA isoform S (Figure 4.1 C) has a longer 5ʹ UTR 
(1446bp), thus contains the uVNTR within the UTR. The major feature of this 
isoform is the presence of an alternative exon (Exon IIA) that produces a truncated 
version of the MAOA protein, exactly 133 AA shorter than the Long isoform. As 
illustrated in Figure 4.1 C, the alternative Exon IIA contains a (TGA) stop codon in 
the reading frame which makes the translational start site shift to Exon IV where the 
next in frame methionine codon (ATG) is located. The resulting expected protein is 
394 AA long. The MAOA S isoform lacks residues 1-133, thus an important piece of 
the FAD binding domain. Because the cofactor FAD is necessary to the MAOA 
protein to exert its activity, this protein should be inactive. Unfortunately the 
literature does not report any evidence for this particular protein isoform. Only the 
mRNA has been confirmed for this isoform and the putative protein sequence 
deduced.  
Finally the MAOA M isoform (Figure 4.1 B) has been identified in my current 
studies by PCR of cDNA (Figure 4.21). This isoform lacks Exon IV, from residue 
102 to 137, which overlaps with a section of the substrate binding domain. Again no 
literature on this isoform is present and not even the splicing variant has been 
identified before.  
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Figure 4.2 - Monoamine Oxidase A (MAOA) mRNA Long isoform. mRNA sequence of the 
canonical MAOA protein. Long isoform in this manuscript. NCBI Accession number: BC008064 
(Version BC008064.2) (http://www.ncbi.nlm.nih.gov/nuccore/BC008064). At the top illustration of 
MAOA gene as reported in UCSC genome browser Hg38 and the most recent version of the Hg19 
(GENECODE v24 track). Black boxes represent 5ʹ and 3ʹ UTRs, white boxes the exons. Curved black 
arrow sets the translational start site for the conventional MAOA protein (long isoform). 
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Figure 4.3 - Monoamine Oxidase A (MAOA) mRNA Short isoform. mRNA sequence of the short 
MAOA protein. Short isoform in this manuscript. NCBI Accession number: AK293926 (Version 
AK293926.1). At the top illustration of MAOA gene as reported in UCSC genome browser Hg38 and 
the most recent version of the Hg19 (GENECODE v24 track). Black boxes represent 5ʹ and 3ʹ UTRs, 
white boxes the exons. Curved black arrow sets the translational start site for the short MAOA protein 
(short isoform). 
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A 3D representation of the putative MAOA protein isoforms is illustrated in 
Figure 4.4 B – D. The reconstruction for each isoform has been obtained from 
http://raptorx.uchicago.edu website. The input sequences can be found in the Figures 
4.5 – 4.5 – 4.6. Figure 4.4 A illustrate the representation of MAOA protein obtained 
after crystallisation (De Colibus et al., 2005) highlighting in blue the FAD binding 
domains and in red the substrate binding domains.  
The comparison between the Figure 4.4 A and 4.4 B both representing the major 
MAOA isoform (L) shows high level of similarity which increase the reliability 
about the possible structure of the other MAOA isoforms deduced in our study.  
As expected, several structural changes can be seen in the M and S isoform 
(Figure 4.4 C – D). In the M isoform the FAD binding domain appear intact whilst 
the structural change can be seen in the substrate binding domain appearing 
substantially reduced compared to the L isoform. On the contrary the S isoform 
(Figure 4.4 D) suffered a radical structural change undergoing the deletion of a third 
of the residues that compose the FAD binding domain. 
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Figure 4.4 - Prediction of Monoamine Oxidase A (MAOA) protein isoforms. 3D predicted protein 
molecular structures of MAOA protein based on the mRNA sequences obtained from online databases 
(B-D) or sequencing data (C) using http://raptorx.uchicago.edu website. A. Image from De Colibus et 
al. (2005): in blue the FAD binding domain, in red substrate binding domain, membrane region (C-
terminal) in green. In yellow and cyan ball-and-stick representation are FAD and clorgyline 
respectively. Black coil is the active site loop. B. Representation of the MAOA L isoform. C. D. 
Putative reconstruction of isoform M and S respectively. 
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Figure 4.5 - Monoamine Oxidase A (MAOA) Protein Long isoform. Amino acid sequence of the 
MAOA long isoform protein used also to generate the image in Figure 4.4. At the top illustration of 
MAOA gene as reported in UCSC genome browser Hg38 and the most recent version of the Hg19 
(GENECODE v24 track). Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes 
the exons. Curved black arrow sets the translational start site for the long MAOA protein (long 
isoform). 
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Figure 4.6 - Monoamine Oxidase A (MAOA) protein Medium isoform. Amino acid sequence of 
the MAOA medium isoform protein used also to generate the image in Figure 4.4. At the top 
illustration of MAOA gene as reported in UCSC genome browser Hg38 and the most recent version of 
the Hg19 (GENECODE v24 track). Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), 
white boxes the exons. Curved black arrow sets the translational start site for the medium MAOA 
protein (medium isoform). 
 
 
 
 
  
 
 
114 
 
 
 
Figure 4.7 - Monoamine Oxidase A (MAOA) protein Short isoform. Amino acid sequence of the 
MAOA short isoform protein used also to generate the image in Figure 4.4.At the top illustration of 
MAOA gene as reported in UCSC genome browser Hg38 and the most recent version of the Hg19 
(GENECODE v24 track). Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes 
the exons. Curved black arrow sets the translational start site for the short MAOA protein (short 
isoform). 
 
 
 
4.3.1.2 Conservation analysis of MAOA isoforms – interested exons  
I performed a conservation analysis on the Exon IIA region (chrX:43,517,110-
43,517,217) and the 5ʹ and 3ʹ flanking regions in humans, non-human primates and 
rodents. The sequences from each species were extrapolated from UCSC web 
browser Hg19.  
The alignment of the sequences obtained from the 100 vertebrates conservation 
tool in UCSC web browser shows few differences in non-human primates compared 
to the human sequence (Figure 4.8). Thus the TGA stop codon in the human Exon 
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IIA sequence, that generates the truncated MAOA protein, could be expressed in 
these species as well. However in non human primates, according to UCSC and ECR 
web browser, this genomic region is not considered an exon that can be spliced in the 
MAOA sequence.  
In rodents this sequence appears significantly different. Both mouse and rat 
sequences do not show the TGA stop codon in their reading frame and the overall 
sequence presents significant changes compared to human and non-human primates.  
MAOA Exon IV, as illustrated in Figure 4.9, shows a very high degree of 
conservation among species. Some point mutations are present in the DNA 
sequences but they are all synonymous mutations except for one that in rodents and 
marmoset encode for a methionine instead of an isoleucine. As stated before, this 
exon is part of the substrate binding domain in the fully functional MAOA protein. In 
order to maintain its activity it has to be expected an high degree of conservation of 
this genomic region among species.  
This analysis is in accordance with Andres et al. (2004), where the MAOA gene 
sequence has been compared in human and non human primates. Specifically for one 
of the regions analysed, comprising Exons IV – V and Exons VII – VIII, humans 
show divergence levels from other species no higher than 1.55% and the lower level 
is with chimpanzees for a 1.06% divergence. This is also in accordance with 
Ebersberger et al. (2002), where in their study they analysed divergence levels of 
parts of all the chromosomes in humans and chimpanzees and they concluded that 
the whole X chromosome has accumulated the least amount of differences (1.0%) 
compared to the autosomes. 
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Figure 4.8 - Monoamine Oxidase A (MAOA) Exon IIA conservation analysis. At the top graphic representation of the MAOA gene. White boxes: exons, black boxes: 
untranslated regions (UTRs), gray boxes: dVNTR and uVNTR from left to right respectively. Underneath alignment of MAOA Exon IIA in different species. Alternate codons are 
highlighted in gray or black. Amino acids translation is represented by corresponding letters underneath DNA sequences. TGA stop codon is termed as Stop.  
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Figure 4.9 - Monoamine Oxidase A (MAOA) Exon IV conservation analysis. At the top graphic representation of the MAOA gene. White boxes: exons, black boxes: 
untranslated regions (UTRs), gray boxes: dVNTR and uVNTR from left to right respectively. Underneath alignment of MAOA Exon IV in different species. Alternate codons are 
highlighted in gray or black. Amino acids translation is represented by corresponding letters underneath DNA sequences. ATG codons are termed as Met.  
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4.3.2 HAP 1 cell lines characterisation 
In total we obtained 9 cell line clones from Horizon. As explained in Figure 4.10 
from the parental cell line (P) were generated, after a first CRISPR/Cas9 deletion, 
four different single KO cell lines. Two of them have the uVNTR deleted from the 
MAOA promoter region and still possess the dVNTR. These are clone 9_F4 and 
9_E2 termed A and B respectively for simplicity. The other two clones have the 
dVNTR deleted and still possess the uVNTR and they are clones 13_B5 and 13_B1 
termed C and D respectively.  
Using clones B and C as parental cell line to generate a second mutation, the 
double KO clones du_B5 (E), du_F3 (F), ud_D8 (G) and ud_F3 (H) were generated 
applying a second, de-novo, CRISPR/Cas9 deletion. These second deletion clones 
are E and F using clone B as parental cell line and clones G and H using clone C as 
the parental cell line.  
The deletions were confirmed by PCR using the primer sets for MAOA uVNTR 
and dVNTR respectively as shown in Figure 4.12 A – B. SH-SY5Y cell line has 
been used as positive control for the PCR and also to identify the genotype of the 
HAP1 cell line for both VNTRs since SH-SY5Y carries the two most common 
alleles for both VNTRs. The 3R and 4R for the uVNTR and the 9R and 10R for the 
dVNTR. HAP1 cell line, after the comparison with SH-SY5Y, turned out to carry the 
3R and 10R polymorphism for uVNTR and dVNTR respectively. 
Both the agarose gel and the virtual gel generated by the Qiaxcel confirmed the 
deletion for all the cell line for both uVNTR and dVNTR single KO and the four 
double KO cell lines.  
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Figure 4.10 - HAP1 cell line genetic tree. Genetic tree explaining the different HAP1 cell line clones. Parental cell line (P) at the top has been used to generate the single KO 
cell lines for uVNTR, on the left side (blue branch) and for dVNTR on the right side (red branch). Clones B and C has been used as parental cell line to generate a second KO that 
brought to the double KO cell lines (E to H) which lack both uVNTR and dVNTR.  
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Figure 4.11 confirms that the DNA deletion has been successful and the actual sizes 
in the gels correspond to the expected ones (data file information from Horizon). 
However, a substantial difference of 43 bp can be observed between clones E, F and 
clones G, H for the uVNTR locus whilst there is no difference in the dVNTR one. 
The sequences alignment in Figure 4.12 confirms this difference between clones 
observed in the gel, thus excluding the possibility of the agarose gel artefact.  
The most plausible explanation is the parental cell line that each double KO set 
derives from. Again, regarding the uVNTR locus, clones G and H show a difference 
of 4 bp between themselves while clones E and F have the same sequence. No 
difference has been observed in the dVNTR locus among any of the clones. 
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Figure 4.11 - HAP1 cell line genotype. Genotype of HAP1 cell line clones confirming the deletion of 
the interested genetic region. A - PCR reaction amplifying uVNTR genetic region. B - reaction 
amplifying dVNTR genetic region. Letters on top refer to Figure 4.1 for the clones. 
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Figure 4.12 - HAP1 double KO alignment. Alignment of the HAP1 double KO clones E, F, G and H 
after sequencing of each clone. 
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4.3.3 MAOA gene expression 
To assess any effect of uVNTR and dVNTR deletions on the MAOA expression in 
HAP1 cell line, the RNA has been extracted and converted to cDNA. Different 
primer sets have been used in order to assess the expression of the different predicted 
MAOA mRNA isoforms. The primer set that amplifies from Exon III to Exon VI of 
MAOA cover the expression of both long and short MAOA isoforms, thus giving 
insight on the total MAOA RNA that has been expressed. 
The comparison between the parental cell line and the uVNTR single KO, 
illustrated in Figure 4.13 A, highlights a slight difference in the expression 
supported by the two different clones: clone A shows a slight increase of the MAOA 
expression while clone B presents a small reduction. Both of them are not 
significantly different from the expression of the parental cell line according to the 
Student’s T-Test. However, the difference between the two single KO clones is 
statistically significant (p<0.05). Figure 4.13 B with its representation of a cartoon 
mechanism model summarises the effect of the uVNTR deletion on the expression of 
this mRNA which appears to be completely neutral.  
However, the dVNTR KO clones C and D appear to support MAOA expression 
differently from the uVNTR KO clones. Both cell lines display a significant 
reduction (p<0.05) of expression compared to the parental cell line (Figure 4.14 A). 
This trend strongly suggests a major role of the dVNTR in the regulation pattern of 
this MAOA isoform expression compared to the major accredited risk factor uVNTR. 
The model represented in Figure 4.14 B displays the positive regulatory effect of the 
dVNTR on this MAOA isoform. 
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Figure 4.13 – Monoamine Oxidase A (MAOA) expression in HAP1 cell line – uVNTR deletion 
clones. A. Relative expression level of MAOA mRNA at basal condition. At the top illustration of 
MAOA gene as reported in UCSC genome browser Hg38 and the most recent version of the Hg19 
(GENECODE v24 track). Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes 
the exons. Curved black arrow sets the translational start site (TSS) for the conventional MAOA 
protein (long isoform). Black straight arrows show the forward and reveres primers respectively. P is 
the parental cell line, A and B are the uVNTR single deletion clones: 9_F4 and 9_E2 respectively. The 
table at the side provides the p-values obtained with the two-tailed type 2 Student’s T-Test. *p<0.05, 
**p<0.01, ***p<0.001. For each clone N=4. All values were normalised to β-Actin.  B. Illustration of 
the MAOA promoter gene and the effect on the isoform expression of the uVNTR. Curved black line 
represents the TSS. 
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Figure 4.14 - Monoamine Oxidase A (MAOA) expression in HAP1 cell line – dVNTR deletion 
clones. Relative expression level of MAOA mRNA at basal condition. At the top illustration of MAOA 
gene as reported in UCSC genome browser Hg38 and the most recent version of the Hg19 
(GENECODE v24 track). Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes 
the exons. Curved black arrow sets the translational start site (TSS) for the conventional MAOA 
protein (long isoform). Black straight arrows show the forward and reveres primers respectively. P is 
the parental cell line, C and D are the dVNTR single deletion clones: 13_B5 and 13_B1 respectively. 
The table at the side provides the p-values obtained with the two-tailed type 2 Student’s T-Test. 
*p<0.05, **p<0.01, ***p<0.001. For each clone N=4. All values were normalised to β-Actin.  B. 
Illustration of the MAOA promoter gene and the effect on the isoform expression of the dVNTR. 
Curved black line represents the TSS. 
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In all the four double KO cell lines that have been tested, there is a significant 
reduction (p<0.01) on the MAOA mRNA expression compared to parental cell line 
and the expression trend among them is equal as illustrated in Figure 4.15 A.  
Figure 4.16 shows the expression patterns of the single KO clones B and C and 
the double KO clones that have been generated from them, compared to the parental 
cell line. In Figure 4.16 A it can be observed the effect of the uVNTR deletion 
compared to the double KO clones. As also reported in Figure 4.19 A the uVNTR 
deletion does not modify the MAOA expression, however when also the dVNTR is 
deleted from the promoter sequence, the MAOA expression obtained from the double 
KO cell lines is significantly reduced (p<0.05) compared to both the parental cell line 
and the uVNTR deletion clone according to the Student’s T-Test. 
In Figure 4.16 B the deletion of the dVNTR is sufficient to significantly reduce 
(p<0.01) the expression of MAOA which is comparable to the expression obtained 
from the double KO cell lines.  
 The MAOA uVNTR has always been considered a positive regulator of the 
MAOA gene since Sabol et al. (1998) characterised this polymorphism with 
expression constructs, although the 3R VNTR was considered low expression 
compared to the 4R (high expression). In their experiment they compared the ability 
of the different polymorphic variants of the MAOA uVNTR to drive the luciferase 
expression.  
However in our cell line model, the uVNTR deletion does not modulate the 
expression of this particular MAOA isoform, it is in fact neutral and not a positive 
regulator.  
These data altogether give more insight on the complexity of the MAOA promoter 
region where a single element like the uVNTR or the dVNTR alone are not sufficient 
to explain the expression of this gene. In fact, the deletion of both does not preclude 
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the expression of the gene, although the amount of mRNA is significantly reduced 
compared to parental cell line.  
To support this fact has also to be reminded that rodents do not possess the human 
(or primate) specific VNTRs but they are able to express MAOA. Unfortunately, the 
major advantage we exploited of this cell line is also a major limitation on the 
experiments. The haploid genotype of the HAP1 cell line is perfect to assess the 
function of a genetic variant such as MAOA u- or dVNTR, but it also does not allow 
us to compare the expression of MAOA with different copy variant of u- or dVNTR. 
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Figure 4.15 - Monoamine Oxidase A (MAOA) expression in HAP1 cell line – double deletion 
clones. Relative expression level of MAOA mRNA at basal condition. At the top illustration of MAOA 
gene as reported in UCSC genome browser Hg38 and the most recent version of the Hg19 
(GENECODE v24 track). Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes 
the exons. Curved black arrow sets the translational start site (TSS) for the conventional MAOA 
protein (long isoform). Black straight arrows show the forward and reveres primers respectively. P is 
the parental cell line, E, F, G and H are the MAOA VNTRs double KO clones: du_B5, du_F3, ud_D8 
and ud_F3 respectively. The table at the side provides the p-values obtained with the two-tailed type 2 
Student’s T-Test. *p<0.05, **p<0.01, ***p<0.001. For each clone N=4. All values were normalised to 
β-Actin.  B. Illustration of the MAOA promoter gene and the effect on the isoform expression of the 
dVNTR and uVNTR. Curved black line represents the TSS. 
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Figure 4.16 - Monoamine Oxidase A (MAOA) expression in HAP1 cell line – single deletion 
clones and related double KO clones. Relative expression level of MAOA mRNA at basal condition. 
At the top illustration of MAOA gene as reported in UCSC genome browser Hg38 and the most recent 
version of the Hg19. Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes the 
exons. Curved black arrow sets the translational start site (TSS) for the conventional MAOA protein 
(long isoform). Black straight arrows show the forward and reveres primers respectively. A. P is the 
parental cell line, B single uVNTR deletion clone, E and F are the MAOA VNTRs double KO clones 
generated from Clone B: du_B5, du_F3 respectively. B. P is the parental cell line, C single dVNTR 
deletion clone, G and H are the MAOA VNTRs double KO clones: ud_D8 and ud_F3 respectively. 
The tables on the side provide the p-values obtained with the two-tailed type 2 Student’s T-Test. 
*p<0.05, **p<0.01, ***p<0.001. For each clone N=4. All values were normalised to β-Actin.   
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4.3.4 MAOA gene expression (Short isoform) 
The element that allows us to differentiate between the long and short MAOA 
mRNA isoforms is the presence of the Exon IIA that contains a stop codon in the 
reading frame thus stopping the translation of the canonical MAOA protein 
generating a shorter protein. 
The primer set that amplifies from Exon I to Exon IIA allow us to address only 
the expression of the short isoform since Exon IIA is present only in this isoform and 
not in the long one. This is illustrated in Figure 4.17 A for the uVNTR deletion 
clones. A complete opposite trend can be observed from the analysis of the short 
isoform expression where the parental cell lines express a low level of this mRNA 
(~8% of the total mRNA).  
The expression obtained from the uVNTR single KO clones A and B is 
significantly higher compared to the parental cell line. No significant difference can 
be seen between the two clones. Similarly as observed for the uVNTR KO clones, 
the expression of both dVNTR KO clones, C and D, is significantly higher than the 
parental cell line as illustrated in Figure 4.18 A.  
The deletion of either the uVNTR or the dVNTR seems sufficient to increase the 
expression of the MAOA short mRNA isoform highlighting the possibility of a 
positive regulatory element in both VNTRs specific for this mRNA isoform which in 
contrast can not be seen for the long isoform where only the dVNTR appears to be 
necessary to modulate the expression.  
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Figure 4.17 - Monoamine Oxidase A (MAOA) short isoform expression in HAP1 cell line – 
uVNTR deletion clones. Relative expression level of MAOA mRNA at basal condition. At the top 
illustration of MAOA gene as reported in UCSC genome browser Hg38 and the most recent version of 
the Hg19. Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes the exons. Curved 
black arrow sets the translational start site (TSS) for the MAOA protein (short isoform). Black straight 
arrows show the forward and reveres primers respectively. P is the parental cell line, A and B are the 
uVNTR single deletion clones: 9_F4 and 9_E2 respectively. The table at the side provides the p-
values obtained with the two-tailed type 2 Student’s T-Test. *p<0.05, **p<0.01, ***p<0.001. For 
each clone N=4.  All values were normalised to β-Actin.  B. Illustration of the MAOA promoter gene 
and the effect on the isoform expression of the uVNTR. Curved black line represents the TSS. 
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Figure 4.18 - Monoamine Oxidase A (MAOA) short isoform expression in HAP1 cell line – 
dVNTR deletion clones. Relative expression level of MAOA mRNA at basal condition. At the top 
illustration of MAOA gene as reported in UCSC genome browser Hg38 and the most recent version of 
the Hg19. Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes the exons. Curved 
black arrow sets the translational start site (TSS) for the MAOA protein (short isoform). Black straight 
arrows show the forward and reveres primers respectively. P is the parental cell line, C and D are the 
dVNTR single deletion clones: 13_B5 and 13_B1 respectively. The table at the side provides the p-
values obtained with the two-tailed type 2 Student’s T-Test. *p<0.05, **p<0.01, ***p<0.001. For 
each clone N=4. All values were normalised to β-Actin.  B. Illustration of the MAOA promoter gene 
and the effect on the isoform expression of the dVNTR. Curved black line represents the TSS. 
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Figure 4.19 - Monoamine Oxidase A (MAOA) short isoform expression in HAP1 cell line – single 
deletion clones and related double KO clones. Relative expression level of MAOA mRNA at basal 
condition. At the top illustration of MAOA gene as reported in UCSC genome browser Hg38 and the 
most recent version of the Hg19. Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white 
boxes the exons. Curved black arrow sets the translational start site (TSS) for the conventional MAOA 
protein (long isoform). Black straight arrows show the forward and reveres primers respectively. A. P 
is the parental cell line, B single uVNTR deletion clone, E is the MAOA VNTRs double KO clone 
generated from Clone B: du_B5. B. P is the parental cell line, C single dVNTR deletion clone, G is 
the MAOA VNTRs double KO clone ud_D8. The tables at the side provide the p-values obtained with 
two-tailed type 2 Student’s T-Test. *p<0.05, **p<0.01, ***p<0.001. For each clone N=4. All values 
were normalised to β-Actin.  C. Illustration of the MAOA promoter gene and the effect on the isoform 
expression of the dVNTR and uVNTR. Curved black line represents the TSS. 
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The difference between single and double KO, as illustrated in Figure 4.19, shows 
an additive effect of the two VNTRs in the short isoform expression when the double 
KO clones derived from clone C are assessed (Figure 4.19 B). However, although 
the same trend can be observed for the clones derived from clone B (Figure 4.19 A) 
they do not show a significant increase compared to clone B. 
Surprisingly the expression data obtained using the uVNTR primer set (Figure 
4.20) displays extremely similar values to the ones obtained with the primer set Exon 
I – Exon IIA.  
These similarity in contrast with the expression data obtained by the expression 
analysis of the long and short isofom together (primer set Exon III – Exon VI) allow 
us to differentiate the 5ʹ UTR of the MAOA pre-mRNA, where currently, UCSC web 
browser excludes the shorter 5ʹ UTR from its database erasing this difference among 
isoforms.  
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Figure 4.20 - Monoamine Oxidase A (MAOA) short isoform expression in HAP1 cell line – single 
deletion clones and related double KO clones. Relative expression level of MAOA mRNA at basal 
condition. At the top illustration of MAOA gene as reported in UCSC genome browser Hg38 and the 
most recent version of the Hg19. Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white 
boxes the exons. Curved black arrow sets the translational start site (TSS) for the MAOA protein 
(short isoform). Black straight arrows show the forward and reveres primers respectively. A. P is the 
parental cell line, B single uVNTR deletion clone, E and F are the MAOA VNTRs double KO clones 
generated from Clone B: du_B5, du_F3 respectively. B. P is the parental cell line, C single dVNTR 
deletion clone, G and H are the MAOA VNTRs double KO clones: ud_D8 and ud_F3 respectively. 
The table at the bottom provides the p-values obtained with the two-tailed type 2 Student’s T-Test. 
*p<0.05, **p<0.01, ***p<0.001. For each clone N=4. All values were normalised to β-Actin.   C. 
Illustration of the MAOA promoter gene and the effect on the isoform expression of the dVNTR and 
uVNTR. Curved black line represents the TSS. 
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4.3.5 MAOA gene expression (Medium isoform) 
For this MAOA isoform we were able to distinguish the expression of both the 
medium and long MAOA isoforms as Exon IV is completely missing from this 
transcript. This isoform splices out Exon IV from the coding sequence, 
hypothetically this encoded protein is unable to exert its normal function due to the 
fact that it is unable to bind the substrate because its binding site has been disrupted. 
The expression data obtained from this assay were extremely low compared to the 
total MAOA expression. The amount of this isoform did not exceed 3% of the total 
MAOA mRNA. As illustrated in Figure 4.21 the deletion of either the uVNTR or 
dVNTR nor the double deletion clones generated any alteration of the expression 
when compared to the parental cell line.  
It is possible that this spliced isoform is an aberration of the normal MAOA Long 
mRNA and completely independent from the MAOA VNTRs.  
Unfortunately the implication of this protein isoform and its mRNA remains 
unexplained at the moment but it would be interesting pursuing the research on this 
novel MAOA mRNA isoform. 
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Figure 4.21 - Monoamine Oxidase A (MAOA) medium isoform expression in HAP1 cell line – 
single deletion clones and related double KO clones. Relative expression level of MAOA mRNA at 
basal condition. At the top illustration of MAOA gene as reported in UCSC genome browser Hg38 and 
the most recent version of the Hg19. Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), 
white boxes the exons. Curved black arrow sets the translational start site (TSS) for the MAOA 
protein (medium isoform). Black straight arrows show the forward and reveres primers respectively. 
For each clone N=4. A. P is the parental cell line, B single uVNTR deletion clone, E is the MAOA 
VNTRs double KO clone generated from Clone B: du_B5. B. P is the parental cell line, C single 
dVNTR deletion clone, G is the MAOA VNTRs double KO clone ud_D8. C. P is the parental cell line, 
E, F, G and H are the MAOA VNTRs double KO clones: du_B5, du_F3, ud_D8 and ud_F3 
respectively. The tables at the side provide the p-values obtained with the two-tailed type 2 Student’s 
T-Test. All values were normalised to β-Actin.   
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4.3.6 MAOA gene expression – valproate treatment 
In chapter 3 we demonstrated that the MAOA 3R uVNTR was responsive to 
external stimuli in the neuroblastoma cell line SH-SY5Y, making this polymorphic 
region a target for a strong GxE interaction.  
We therefore set to validate our previous results in the HAP1 cell line model, 
which possesses the MAOA 3R uVNTR, the most responsive VNTR in SH-SY5Y. 
Figure 4.22 shows the expression level of the total MAOA mRNA that encodes 
for the canonical MAOA protein, representing more than 90% of the total MAOA 
mRNA, also including the mRNA that encodes for the short MAOA protein isoform.  
The PCR amplification uses the primer set from Exon III to Exon VI of the 
MAOA mRNA. After the Student’s T test was performed, no significant difference 
among any of the analysed clones was found. The absolute expression levels, at basal 
condition, of this assay confirms the ones illustrated in Figure 4.13 generated in a 
separate experiment for the parental cell line and uVNTR deletion clones A and B, 
where no differences between the parental cell line and the deletion clones were 
found. The addition of 5mM sodium valproate for 1 hour to the working media did 
not produce a visible effect on the MAOA expression.  
On the contrary, the use of the MAOA uVNTR primer set, targeting the longer 5ʹ 
UTR containing the uVNTR in it, illustrated in Figure 4.23, shows in the parental 
cell line a 3-fold increase in the expression of this mRNA isoform after 1h treatment 
with 5mM sodium valproate. At basal condition the uVNTR KO clones showed the 
increase we observed in the previous experiment represented in Figure 4.20 with a 
3-fold increase in the expression compared to parental cell line.  
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Surprisingly, when the sodium valproate was administrated to the KO cell lines, 
we no longer observed the 3-fold increase displayed by the parental cell line after the 
same treatment.  
It is possible that the deletion of the uVNTR, removing the repression exerted by 
the uVNTR itself on this isoform, brings the expression to its maximum level. 
However, it is also possible that the sodium valproate specifically acts in the uVNTR 
locus for this particular mRNA isoform, therefore the deletion of the uVNTR, makes 
the sodium valproate unable to exert its regulative mechanism.  
These results add another distinction on the two MAOA mRNA isoforms where 
the longer mRNA, encoding for the full length protein, is not affected by the mood 
stabiliser sodium valproate, while the isoform with the longer 5ʹ UTR is responsive 
to external stimuli, according to our previous results in chapter 3 (Figure 3.3).  
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Figure 4.22 - Monoamine Oxidase A (MAOA) expression in HAP1 cell line after 1h exposure to 
sodium valproate – uVNTR deletion clones. Relative expression level of MAOA mRNA at basal 
condition and after 1h exposure to 5mM sodium valporate. At the top illustration of MAOA gene as 
reported in UCSC genome browser Hg38 and the most recent version of the Hg19. Black boxes 
represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes the exons. Curved black arrow sets the 
translational start site (TSS) for the conventional MAOA protein (long isoform). Black straight arrows 
show the forward and reveres primers respectively. P is the parental cell line, A and B are the uVNTR 
single deletion clones: 9_F4 and 9_E2 respectively. The table at the bottom provides the p-values 
obtained with the two-tailed type 2 Student’s T-Test. *p<0.05, **p<0.01, ***p<0.001. For each clone 
N=3. All values were normalised to β-Actin.   
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Figure 4.23 - Monoamine Oxidase A (MAOA) expression in HAP1 cell line after 1h exposure to 
sodium valproate – uVNTR deletion clones. Relative expression level of MAOA mRNA at basal 
condition and after 1h exposure to 5mM sodium valporate. At the top illustration of MAOA gene as 
reported in UCSC genome browser Hg38 and the most recent version of the Hg19. Black boxes 
represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes the exons. Curved black arrow sets the 
translational start site (TSS) for the short MAOA protein. Black straight arrows show the forward and 
reveres primers respectively. P is the parental cell line, A and B are the uVNTR single deletion clones: 
9_F4 and 9_E2 respectively. The table at the bottom provides the p-values obtained with the two-
tailed type 2 Student’s T-Test. *p<0.05, **p<0.01, ***p<0.001. For each clone N=3. All values were 
normalised to β-Actin.   
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Due to time limitation I was unable to assess the other HAP1 clones for the dVNTR 
deletion and the double deletions. An hypothesis can however be formulated. If the 
sodium valproate acts exclusively through the uVNTR we would expect at least a 3-
fold increase in the expression for the dVNTR clones, as we can observe for the 
parental cell line (Figure 4.19). This expression increase will be added to the already 
increased expression level due to the dVNTR deletion which (Figure 4.16) is 3-4- 
fold compared to the parental cell line. Whenever the sodium valproate would have a 
regulative effect on the dVNTR as well we might expect the same expression as 
basal condition. At the same time the double KO clones would not be affected by 
sodium valproate since they do not possess the uVNTR nor the dVNTR. Their 
expression level should remain the same as basal condition. 
 
4.3.7 MAOA protein 
The relative expression of the MAOA protein has been performed in the lab by 
Miss Andrea McKavanagh, a master student currently under the supervision of Dr. 
Jill Bubb. The western blot analysis on the parental cell line (P), the uVNTR single 
KO clones (A and B) and the double KO cell line ud_B5 (E) is in line with the 
mRNA expression data: no differences can be observed in the protein expression 
levels between the parental cell line and the two uVNTR KO cell lines A and B 
(image not shown).  
However, despite a significant reduction in the mRNA expression between the 
parental cell line and the double KO cell line (E), the protein level of the latter shows 
no significant difference compared to parental cell line. This partially unexpected 
result may be due to the long turnover of the MAO proteins. 
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In-vivo studies on baboon’s brains on MAOB determined a half-life turnover of 
the protein to be 30 days (Arnett et al., 1987). Similar studies in rat liver determined 
the half-life of the protein to be close to 3 days (Della Corte and Tipton, 1980).  
More recently, an experiment conducted on mpkCCD cells, mouse derived renal 
cortical collecting duct cells, Sandoval et al. (2013) assessed the half-life of the 
expressed protein in this cell model and specifically set the MAOA protein half-life 
to 78.5 hours. In addition, a different MAOA mRNA/protein level has been 
previously reported in rat hippocampus (Morishima et al., 2006), and is in line with 
our results in HAP1 cell line model, where a reduction in the mRNA does not 
correspond to a reduction in the protein. Furthermore, the monoclonal MAOA 
antibody which specifically targets the C-terminus of the MAOA protein, will be 
unable to detect short isoform of the MAOA protein as well as the medium one.  
It has been observed that long 5ʹ UTRs can interfere with the translational 
processes through post transcriptional modification that can modify the translational 
efficiencies (Mignone et al., 2002, van der Velden and Thomas, 1999) or weaken the 
start context (Rogozin et al., 2001). This might explain the reason of the short MAO 
protein absence.  
However, in a previous experiment, the protein analysis in the neuroblastoma cell 
line SH-SY5Y, showed two bands that are consistent with the expected size of the 
MAOA protein isoforms and the ratio RNA:protein. As illustrated in Figure 4.24 C 
the amount of the normalised values for the isoform M and S does not exceed 10% of 
the total MAOA protein. 
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Figure 4.24 - Monoamine Oxidase A (MAOA) protein expression in SH-SY5Y cell line. A. 
Illustration of MAOA gene as reported in UCSC genome browser Hg38 and the most recent version 
of the Hg19. Black boxes represent 5ʹ and 3ʹ untranslated regions (UTRs), white boxes the exons. 
Colored lines represent the exons translated for each protein isoform: green for the Long, red for the 
Medium and blue for the short respectively. B. Expected sizes of the three MAOA protein isoforms 
based on amino acid sequence translation. Image if the western blot representing in red the MAOA 
protein, in green β-actin. C. Densitometric analysis of the three isoform after normalization to β-actin.  
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4.4 Discussion 
All the major online web browsers such as NCBI or UCSC recognise and accept 
two distinct isoforms of the MAOA gene. These isoforms can be easily distinguished 
at several levels. The “canonical” MAOA isoform is composed of 15 exons with short 
5ʹ and 3ʹ UTRs. The second isoform has 16 exons and long 5ʹ and 3ʹ UTRs. In 
addition, in the 5ʹ UTR of this latter isoform, the polymorphic variant, termed 
uVNTR (Sabol et al., 1998), is part of the sequence.  
The extra exon present in this isoform, which here has been termed as Exon IIA, 
contains a TGA stop codon in the sequence reading frame that would now allow the 
first ATG codon for the protein translation to be within Exon IV (Figures 4.1 – 4.4). 
The N-terminus of the resulting protein is missing in this isoform and the enzyme is 
133AA shorter than the canonical one. As a consequence, the FAD binding domain 
is disrupted, as the N-terminus residues contribute to this domain; thus hypothetically 
this leaves this shorter isoform unable to break down monoamine neurotransmitters.  
The evolutionary analysis of Exon IIA (Figure 4.8) and Exon IV (Figure 4.9) do 
not highlight particular differences between humans and non human primates for 
both exons, which is in agreement with previous studies on the MAOA gene (Andres 
et al., 2004) and the X chromosome (Ebersberger et al., 2002) conservation in 
humans and non human primates. However Exon IIA appears to be less conserved in 
rodents. In fact rodents do not seem to have the TGA stop codon in the reading 
frame. It has to be noted that UCSC web browser does not consider this sequence 
part of the transcript in any species other than human although the overall sequence 
appears to be highly conserved when aligned.  
Extending our results on MAOA expression, reported in Chapter 3, we attempted 
to further analyse the expression pattern of the MAOA gene. The major aims were to 
assess differences of the three MAOA isoforms and the effect of the two polymorphic 
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VNTRs may have on the expression. In order to accomplish our goals we exploited 
the semi-haploid cell line HAP1 that has been engineered to remove either the 
uVNTR, the dVNTR or both from the MAOA promoter sequence.  
We obtained a total of 9 cell lines. From the parental cell line (P) four single KO 
cell lines have been made after a CRISPR/Cas9 deletion; of these, two clones had the 
uVNTR deleted from their genome (clone A and B) and still maintain the dVNTR, 
and two clones had the dVNTR deleted (clones C and D) maintaining the uVNTR. 
The four double KO cell line (E, F, G and H) have been created with a second, de-
novo, CRISPR/Cas9 deletion using a single KO cell line as a start point. Clones E 
and F derived from clone B and clones G and H from clone C (Figure 4.10). 
To analyse the expression pattern of the MAOA mRNAs we designed different 
primer sets that allowed us to distinguish the expression of the short MAOA isoform 
from the total MAOA mRNA. For the latter the primers spanned from Exon III to 
Exon VI. These exons are present in both mRNA isoform sequences, thus this will 
measure the total amount of MAOA mRNA expressed.  
To isolate the short MAOA isoform from the total MAOA mRNA, we used a 
primer set that amplifies from Exon I to Exon IIA. In addition the primer set that 
amplifies the uVNTR has be used for comparison and a possible feature to 
distinguish and confirm the length difference in the 5ʹ UTRs of the two MAOA 
mRNA isoforms. 
The first difference to be noted is the total amount of PCR product reported for the 
different isoforms. The Qiaxcel System (Qiagen), used for these experiments, at the 
end of its analysis provides the concentration (ng/ul) of peaks corresponding to the 
bands of an agarose gel. Since the RNA converted into cDNA and the amount of 
cDNA used for the analysis has been the same for all samples and every single 
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amplification, it can be assumed that the absolute expression levels of each assay can 
be compared.  
A comparison of the Qiaxcel system and the intensity analysis obtained from the 
agarose gel is reported in the Figure 4.25 and no difference between the two systems 
has been found. 
Comparing the expression level of the total amount of MAOA mRNA (Exon III – 
Exon VI primers) and the second (short) isoform (Exon I – Exon IIA) in the parental 
cell line we go from a concentration of 1.90 ng/ul to 0.16 ng/ul respectively which 
sets the short isoform to 8% of the total MAOA mRNA (Figures 4.13 – 4.17). 
Similarly, using the uVNTR primer set we obtained a concentration of 0.13 ng/ul 
(7% of the total). This similarity strongly suggests, consistent with NCBI 
(http://www.ncbi.nlm.nih.gov/nuccore/AK293926.1), that the longer 5ʹ UTR, 
containing the uVNTR in it, is associated to the short MAOA isoform and its 
expression is less than 10% of the total MAOA mRNA at basal condition (Figures 
4.19 – 4.20).  
The expression of the MAOA isoforms are also affected differently by the two 
polymorphic VNTRs present in the MAOA promoter region. The uVNTR 
polymorphism is the most often cited example of a genotype by environment 
interaction (G×E) in which an individual’s genotype moderates the effect of 
environmental experience to alter mental health outcomes and has always been 
considered a positive regulator of the MAOA gene but, as shown in Figure 4.13, its 
deletion from the promoter region does not affect the overall expression of the total 
amount of MAOA mRNA.  
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Figure 4.25 - Expression comparison. mRNA expression comparison between two different methods. In white is the densitometric analysis with the ImageJ software, in dark 
gray the results obtained with the Qiaxcel software. The same sample set has been used for both methods.  
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However, a significant difference is observed in the expression levels of the short 
isoform where the uVNTR appears to be a negative regulator (Figures 4.17 – 4.20 
A). The expression of the short isoform in the absence of the uVNTR has a 3-4 fold 
increase in comparison to the parental cell line.  
In addition when the cells are subjected to the mood stabiliser sodium valproate 
the uVNTR plays a major role, once again, only in the short isoform expression. As 
illustrated in Figure 4.22, sodium valproate does not affect the expression of the total 
MAOA mRNA in any HAP1 cell line while we can observe a 3-fold increase in the 
parental cell line after 1h treatment with sodium valproate (Figure 4.23) when only 
the short isoform is assessed with the uVNTR primer set.  
The fact that the uVNTR deletion clones do not report the same increase as the 
parental cell line, but the expression level is the same as basal condition, suggests 
that the valproate exerts its effect through the uVNTR itself.  
Unfortunately we were not able to clarify the mechanisms through which the 
uVNTR regulates the MAOA expression, nor the sodium valproate role in the MAOA 
gene expression regulation. It might be possible that post-translational mechanisms 
take place in presence of the uVNTR, thus its deletion increases the amount of this 
mRNA in the cells perhaps making it more resistant to degradation.  
Conversely the dVNTR affects the expression of both MAOA isoforms, long and 
short, in the opposite direction. In fact its deletion significantly reduces the 
expression of the total amount of MAOA mRNA (Figure 4.14) giving it a positive 
regulator role with respect to the mRNA with the short 5ʹ UTR. On the contrary it 
acts as a negative regulator on the mRNA isoform with the long 5ʹ UTR. Its deletion, 
as shown in Figures 4.18 and 4.20 B significantly increases the expression. 
As might be expected, the effect on the expression of the canonical MAOA 
isoform in the double KO cell lines is significantly lower than the parental cell line 
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(Figure 4.15) and at the same time significantly lower than the uVNTR deletion 
clones (Figure 4.16 A). However if we compare the expression of the double KO 
clones to the single dVNTR deletion clones we do not find any significant difference 
(Figure 4.16 B). This result strengthens the role for the dVNTR in driving the 
expression of the MAOA gene at the expense of the most studied uVNTR. 
In the double KO clones G and H, in both Figures 4.19 and 4.20 B, an additive effect 
of the uVNTR and dVNTR over the expression of the short MAOA isoform can be 
observed but the same result does not appear for the clones E and F.  
 
Table 4.1 – Summary of Monoamine Oxidase A (MAOA) isoforms expression 
 
Note: effect on the expression of the MAOA isoforms in the different HAP1 KO cell 
lines. “L” = full length MAOA; “M” = medium isoform; “S” = short isoform 
 
Level of expression vs 
basal condition 
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This difference encountered between clones E – F and G – H, might be identified 
in the 43bp difference between the clones in the uVNTR locus (Figure 4.11 A). 
Further analysis will be required to identify the role of these specific 43 bp in the 
regulation of this MAOA isoform expression. However these data highlight further 
the role of the uVNTR in this short MAOA isoform expression and the primary role 
that it might have over people’s mental health outcomes.  
Table 4.1 summarises the expression patterns at basal condition and after sodium 
valproate treatment for the parental cell line, the uVNTR deletion cell lines and 
where possible the dVNTR and double KO cell lines. 
These findings together identify the MAOA dVNTR as major positive regulator of 
the MAOA canonical isoform and at the same time set its role as a negative regulator 
on the short MAOA isoform. A model of the regulation exerted by the two 
polymorphic VNTRs in MAOA promoter region is summarised in Figure 4.26. 
The MAOA uVNTR, a well established risk factor for several CNS disorders and 
conditions, appears to have a neutral effect on the expression of the MAOA canonical 
mRNA encoding for the full length MAOA protein, a role which instead is assigned 
to the less studied dVNTR, positive regulator of this isoform. Even when both 
VNTRs are deleted from the MAOA promoter, the expression is comparable to the 
dVNTR deletion alone. However, in the short MAOA isoform expression, both 
VNTRs display a negative regulatory activity which becomes additive when both are 
deleted from the promoter region. 
 
The work in this chapter, including tissue culture, cell treatments, RNA extraction, 
cDNA conversion, PCRs and data analysis is all in collaboration and shared with 
Mrs Veridiana Pessoa.  
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Figure 4.26 - Monoamine Oxidase A 
(MAOA) expression model chart. A. 
MAOA major isoform. B. MAOA 
secondary isoform. C. Graphic 
representation of the MAOA promoter 
region and the regulatory effect 
exerted by the u- and dVNTR on the 
two MAOA isoforms. White box Exon 
I, grey bars represent MAOA dVNTR 
and uVNTR from left to right 
respectively. Curved black lines 
represent the transcriptional start sites 
(TSSs) of the two MAOA isoforms. 
Underneath the curved lines are 
represented the 5ʹ untranslated regions 
( UTRs) of the two MAOA isoforms.  
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Chapter 5 
 
The promoter of the schizophrenia GWAS gene CACNA1C 
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5.1 Introduction 
Schizophrenia is a devastating neuropsychiatric disorder that affects 
approximately 1% of the worldwide general population (Guan et al., 2014). Recent 
research strongly suggests that both environmental and genetic factors are causative 
in the predisposition to the disorder (Schizophrenia Psychiatric Genome-Wide 
Association Study, 2011) and term this interaction the G x E mechanism. The latter 
is particularly apparent in twin studies which establish a high heritability for SCZ 
(64%). The exact aetiology and genetic mechanism of SCZ is still unknown, 
however it is believed to be developmental in origin and involve multiple candidate 
genes, which deregulate and accumulate to cause nervous system dysfunction in 
response to environmental challenge (Karlsgodt et al., 2010). 
The CACNA1C gene has, in the last years, gained the attention of many scientists 
as it has been associated to SCZ by several genome wide association studies 
(GWAS). Along with other genes such as ANK3, ITIH3-ITIH4 and MIR-137, 
CACNA1C association has been the most widely reproduced (Schizophrenia 
Psychiatric Genome-Wide Association Study, 2011). The consistency of its 
association with SCZ has led to it being one of the most established and studied SCZ 
risk loci (Obermair et al., 2004). 
It has recently shown that the SNP (rs1006737) located in the third intron of 
CANCA1C gene and strongly associated with SCZ (Nyegaard et al., 2010), is able to 
modulate CANCA1C expression. Specifically, the risk allele for this SNP, with AA 
genotype, has been associated with a reduction in the mRNA expression of the gene 
(Eckart et al., 2016). 
CACNA1C promoter region contains, within 1Kb of its transcriptional start site 
(TSS), two tandem repeats, making the overall structure of the CACNA1C gene 
promoter region similar to the one in the MAOA gene. 
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It has been established that the MAOA uVNTR modulates gene expression in an 
allele-dependent manner (also see Chapters 3 and 4) and a preliminary bioinformatic 
analysis of the human CACNA1C gene demonstrated two possible repetitive DNA 
domains, within 1kb upstream of the proximal promoter (Figure 5.1). 
We therefore set out to address the hypothesis that the CACNA1C TRs may too be 
polymorphic and may differentially support gene expression. 
 
 
 
 
5.2 Aims 
 Determine the polymorphic nature of the TRs in the CACNA1C locus in 
proximity to its promoter region 
 Validate the effect of these TRs on gene expression through gene expression 
constructs 
 Assess the effect of external stimuli and their ability to modulate the 
expression through the CACNA1C TRs 
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Figure 5.1 - Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) promoter region. Schematic showing the CACNA1C gene described in UCSC Genome 
Browser, Assembly GRCh37/hg19. Initial Bioinformatic analysis of the CACNA1C proximal promoter identified two tandem repeats approximately 1kb upstream of the TSS 
(marked by grey vertical lines). Primers were designed using in silico PCR analyses ran by UCSC Genome browser. The white box indicates CpG island. The black box indicates 
the start of the CACNA1C coding gene. The coverage of each reporter gene construct is illustrated by the black boxes labelled: P1 (chr12:2,162,269-2,162,618) P2 
(chr12:2,162,019-2,162,618) and P3 (chr12:2,161,580-2,162,618). 
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5.3 Results 
5.3.1 Bioinformatic analysis 
Due to its similar genetic architecture compared to MAOA we hypothesised that 
the proximal STR within the CACNA1C proximal promoter may be polymorphic and 
therefore a VNTR. Yet initial bioinformatic analysis using both UCSC genome 
browser and STR web browser (http://strcat.teamerlich.org) failed to determine 
polymorphism in the tandem repeat. UCSC genome browser did not identify any 
SNPs within the proximal promoter region and when the STR was inputted into the 
STR viewer (a catalog of human STR variation), it failed to identify the TR as 
polymorphic.  
However more recent data has now supported our hypothesis and determined that 
the proximal STR is in fact variable in copy number and therefore a VNTR. Recently 
updated UCSC data has determined that there are two in-dels (Insertion-Deletion) 
within the proximal TR: rs530020760 (chr12:2162060-2162067 Hg19) which is a 
deletion of the “CGGG,CGGG” repeat motif seen in 2.08% of the population and 
rs548465087 (chr12:2162068-21620670 Hg19) which is an insertion of the “CGGG” 
repeat motif seen in 97.92% of the normal population. UCSC calls the STR as a 4bp 
repeat motif of “CGGG” therefore as recently updated SNP data reveals that an 
individual can have this motif either inserted or deleted the copy number is variable 
and the STR is in fact, like initially hypothesised a VNTR. 
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5.3.2PCR amplification of CACNA1C TRs 
The primer design and PCR amplification of both the TRs genetic region within 
the CACNA1C proximal promoter was highly difficult due to the high GC content of 
the regions, just below 80% for both TR1 and TR2.  
After a long optimization process with different enzymes and PCR protocols we 
were able to successfully amplify TR2 out of human genomic DNA. The genotype of 
TR2, a sample is illustrated in Figure 5.2, shows no polymorphic nature in any of the 
analysed samples. 
Even more difficult was the optimization of CACNA1C TR1. Since bioinformatic 
analysis of the CACNA1C promoter region with UCSC web browser reported the 
polymorphic nature of the region, present only in the 2% of the population, we 
therefore decided to drop the optimization process and genotyping of CANCA1C 
TR1 genetic region. 
 
 
Figure 5.2 - Amplification of Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) 
TR2. Schematic representation of the CACNA1C gene described in UCSC Genome Browser, 
Assembly GRCh37/hg19. The white box indicates CpG island. The black box indicates the start of the 
CACNA1C coding gene. Gray boxes represent the TRs. Black arrows are the forward and reverse 
primers used for the amplification from left to right respectively. The gel shows PCR amplification of 
10 human samples for the TR2 genetic region enclosed within the forward and reverse primers 
highlighted in the graph at the top. 
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5.3.3 Luciferase Reporter Gene Expression 
To characterise the CACNA1C proximal promoter activity we generated three 
reporter gene constructs; P1 from -149bp to +201bp, P2 from -399bp to +201bp and 
P3 from -838bp to +201bp where +1 is considered the first nucleotide of the 
CACNA1C mRNA transcript (Figure 5.1). Initial bioinformatic analysis identified 
two STR’s 1kb upstream of the CACNA1C proximal promoter. Therefore the 
constructs were designed accordingly to include/exclude the STR’s to observe any 
possible regulatory properties. As illustrated in Figure 5.3 the minimal CACNA1C 
promoter P1 shows a similar expression to the empty vector pGL3B. The second 
construct, P2, containing the “CGGG” in-del previously described, supported a large 
increase in reporter activity (increase close to 11 fold), which resulted in a significant 
difference in activity compared to the pGL3B backbone (*** p<0.001) and P3 
supported a slight, although non-significant increase in the expression of the 
luciferase gene over the pGL3B plasmid. 
These data all together strongly suggest that at least in the in-vitro model 
neuroblastoma cell line SH-SY5Y, CACNA1C proximal promoter contains a 
minimum of two regulatory domains -399 to -250 and -838 to -399, which can 
function as positive and negative regulator of the expression respectively.  
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Figure 5.3 - Validation of CACNA1C promoter region in SH-SY5Y cells. Schematic representation of CACNA1C promoter region constructs cloned in the pGL3B (Basic) 
reporter vectors in forwards orientation aligned to the CACNA1C gene. Average fold change in luciferase activity supported by the CACNA1C constructs over vector controls in 
SH-SY5Y cells. N=3. *Significant changes in luciferase activity over backbone control and between experimental conditions. *P<0.05, **P<0.01, ***P<0.001. 
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To determine if regulation behaved in a stimulus-induced manner, the SH-SY5Y 
cells were treated with a mood stimulant (cocaine) or a mood stabilizer (lithium). 
Both drugs have been shown to modulate signaling pathways in SH-SY5Y cells 
previously at the transcriptional and/or post-transcriptional level (Fernandez-Castillo 
et al., 2015, Nciri et al., 2015). Our analysis of reporter gene assays determined that 
gene expression is directed by the minimal promoter region (P1) and responds either 
positively or negatively in response to drug challenge, i.e. in a stimulus-inducible 
manner in all reporter gene constructs. Exposure to 1mM of lithium resulted in an 
approximate 1.5-fold increase in reporter gene activity in P2 compared to basal, 
whereas exposure to 10µM cocaine resulted in an approximate 3-fold decrease in 
reporter gene activity in P2. Overall the data also validates the previous finding that 
the P2 region contains a positive regulator and the P3 region contains a negative 
regulator. However the drug challenge data suggests that P1, the minimal CACNA1C 
promoter region directs gene expression, as it follows the same pattern of expression 
when exposed to drug challenge (Figure 5.4). 
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Figure 5.4 - Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) promoter region 
constructs in SH-SY5Y cells in a GxE environment contest. Schematic representation of 
CACNA1C promoter region constructs cloned in the pGL3B (Basic) reporter vectors in forwards 
orientation aligned to the CACNA1C gene. Average fold change in luciferase activity supported by 
the CACNA1C constructs over vector controls in SH-SY5Y cells at basal condition and after 1h 
treatment with 10uM cocaine and 1mM lithium. N=3. *Significant changes in luciferase activity over 
backbone control and between experimental conditions. *P<0.05, **P<0.01, ***P<0.001. 
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5.4 Discussion 
We set out to address differential CACNA1C expression as it has been proposed 
that in SCZ modulation of Ca2+-mediated signalling caused by differential 
CACNA1C and glutamatergic transmission could lead to the inefficient neuronal 
wiring observed in the disorder (Fromer et al., 2014, Purcell et al., 2014). 
Furthermore it has been proved that a SNP within intron 3 of the CACNA1C gene is 
able to modulate the expression of this gene (Eckart et al., 2016). Thus, addressing 
further differential CACNA1C regulation could underpin another pathway 
modulating SCZ. Initial bioinformatic analysis identified tandem repeats within 1kb 
upstream of the CACNA1C proximal promoter according to UCSC web browser. 
Using the MAOA gene as a model, we hypothesised that the TRs in the CACNA1C 
proximal promoter region may be polymorphic. The primer design, optimization 
process and amplification of the two TR regions proved difficult due to the very high 
GC content. Within the designed primers, 80% of the entire sequence is GC rich. 
Amplification of the TR2 region in human genomic DNA proved this region not to 
be polymorphic (Figure 5.2).  
Recently updated SNP data in the last UCSC web browser version (Hg19) has 
now validated our hypothesis and MAOA model, determining that the proximal TR 
(TR1) can be variable and therefore is a VNTR. However, the reported deletion of 
the “CGGG,CGGG” repeat motif can only be observed in 2% of the screened 
samples. Therefore, due to the difficulties encountered in the optimization and 
amplification processes and the very low abundance of this in-del in the population 
we decided to abandon the screening of this genetic region.  
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We characterised the CACNA1C proximal promoter, identifying an enhancer in 
the region of -399 to -250 (P2 construct) and a repressor in the region of -838 to -399 
(P3 construct), interestingly the former contains CACNA1C VNTR (Figure 5.3).  
We further determined that gene expression is directed by the minimal promoter 
region (P1 construct: -149 to +201) and have also supported the GxE mechanism 
proposed in SCZ by demonstrating in SH-SY5Y neuroblastoma cell line, CACNA1C 
expression can be differentially modulated by environmental stimuli i.e. positively in 
response to lithium and negatively in response to cocaine.  
Bioinformatic analysis of the CACNA1C promoter region is of particular interest 
as ENCODE (Encyclopedia of DNA Elements) ChIP-Seq data set predicts 
transcriptional binding sites for several transcription factors (TFs). Among the TFs 
that bind to the region, PAX5 overlap with TR1 inside the P2 construct sequence. 
PAX5 is member of the paired box (PAX) family. These proteins are believed to 
be important regulators in early development. PAX5 has been implicated in SCZ as it 
is influential in neuronal development. Furthermore, recent postmortem studies have 
demonstrated that PAX5 is downregulated in GABAergic neurons of patients that 
displayed neuropsychiatric and/or neuro-developmental disorders (Ohtsuka et al., 
2013). 
The transcription factor Engrailed 1 (EN1) binds within the P1 construct, 
CACNA1C minimal promoter. EN-1is a homeobox gene that primarily helps to 
regulate developmental processes in the dorsal midbrain and anterior hindbrain 
(cerebellum and colliculi) of humans. Additionally EN-1 has been strongly 
associated with SCZ and with antipsychotic response (Webb et al., 2008). EN-1 is 
fundamental in brain development which has been demonstrated by a team that 
generated a knockout mouse model with the En1 homeobox, which resulted in death 
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less than 24 hours after birth as the mice refused to eat, despite having the physical 
ability to. Post-mortem examination of the mice discovered that due to the absence of 
the En1 TF the majority of the cerebellum, colliculi and cranial nerves were missing 
(Wurst et al., 1994). 
Furthermore, the Enhancer of zeste homolog 2 (EZH2) TF binds throughout the 
CACNA1C promoter region. 
EZH2 is an important regulator of several developmental processes, including 
neurodevelopment, and it has been found dysregulated in several cancer types 
(Ronan et al., 2013). It is considered a transcriptional repressor as its activity 
increases DNA methylation of its target genes acting in concert with DNA 
methyltransferases (Vire et al., 2006). EZH2 has also been shown to interact with the 
REST-signalling complex and function as a co-repressor of neuronal gene expression 
(Dietrich et al., 2012). 
Taken together our data suggests that the CACNA1C minimal promoter is a stimulus 
inducible regulatory domain. This region could modulate CACNA1C expression in 
response to environmental factors, such as stress, in the medium to long term in 
addition to the immediate changes observed in our SH-SY5Y cell model, which 
would support the proposed GxE mechanism of SCZ. Bioinformatic analysis allowed 
us to identify the CACNA1C proximal TR (TR1) as variable in copy number and 
thereby a VNTR. Future analysis of this VNTR and the interaction that the two 
variants may have with TFs such as EZH2, EN1 and PAX5 over the expression of 
the gene may be important to a better understanding of SCZ aetiology. 
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Chapter 6 
 
Characterisation of a VNTR polymorphism in the REST 
promoter; a biomarker for Alzheimer’s disease? 
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6.1 Introduction 
Alzheimer’s disease (AD) is today one of the major cause of dementia in late 
adulthood affecting 24 million people worldwide (Hurd et al., 2013). AD is a 
progressive degenerative disorder which involves anatomical, molecular and 
psychological changes in patients’ brains (Sperling et al., 2011). Memory loss, 
disorientation, depression and confusion are some of the symptoms presented to AD 
patients (Alzheimer's Association, 2015).  
Genome-Wide Association Study (GWAS) studies have identified several genetic 
factors that have been associated to the early and late onset of this degenerative 
disorder, among these the Apolipoprotein E (APOE) which was the first genetic 
factor recognised as susceptibility gene for AD (Reitz, 2015b).  
Recently, loss of transcription factor REST/NRSF has been described in patients 
with AD whilst healthy aged controls showed an increase of this protein compared to 
young control and AD patients, highlighting among other things a possible 
neuroprotective effect exerted by this transcription factor (Goetzl et al., 2015, Lu et 
al., 2014). Neuronal loss, which is thought to be a contributing cause of 
neurodegenerative disorders, including AD, might be contrasted by REST activity in 
normal brains since has been shown to repress pro-apoptotic genes and promote 
expression of genes that mediate oxidative stress resistance (Tothova et al., 2007).  
Despite the great advance of science and technology in recent years and all the 
genetic association studies that have been made, the processes that underlie most of 
the biological changes in AD still remain unexplained. Nevertheless they are 
postulated to be a combination of genetic and environmental factors (Reitz, 2015a).  
Other well established genes, such as MAOA (chapters 3 and 4), that contain 
polymorphic genetic sequences in their promoter regions, have been extensively 
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proven to be able to modify gene expression and to be biomarkers for other CNS 
dysfunctions and/or behavioural traits. On these premises, we will try to identify a 
novel polymorphic biomarker that might regulate REST expression and be involved 
in the onset of AD, FTD or other CNS conditions such as schizophrenia, through the 
construction of expression vectors and genotyping REST VNTR in case vs control 
cohorts. 
 
6.2 Aims 
 
 Validate if the polymorphic region in REST promoter might regulate the 
expression of the gene through both in silico and experimental analysis 
 Validate the potential to modify expression of this polymorphic VNTR in 
REST promoter through expression assays 
 Genotype the REST VNTR to determine whether it can be used as a 
biomarker for predisposition to AD or other conditions such as schizophrenia, 
in which REST has been implicated 
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6.3 Results 
6.3.1 Bioinformatic analysis of REST promoter locus 
The undoubted importance of REST/NRSF and its involvement in a vast variety 
of regulatory pathways from childhood until late age, in both physiological and 
pathological environments, encouraged us to investigate possible biomarkers in 
proximity of its promoter region that might affect its expression. Following the study 
performed on the MAOA promoter region where two polymorphic VNTRs have been 
proven able to affect expression of the gene (Chapters 3 and 4), we performed a 
similar bioinformatic analysis on the REST gene.  
A first look on UCSC genome browser gave us insight of a tandem repeat (TR) 
mapped right before the first of the three possible REST Transcriptional Start Sites. 
UCSC reports this TR as 2 copies of a 35bp sequence.  
According to UCSC web browser several transcription factors bind in REST 
promoter region (Figure 6.1).  
The ENCODE ChIP transcription factors database in UCSC shows that POLR2A 
strongly binds to the region encompassing all the three possible TSSs and that REST 
might self regulate the expression from the second and third TSSs. The histone 
activation marks also provide information on the activation of these TSSs.  
The first one, starting on the 5ʹ end of the region, does not seem particularly active 
although the ENCODE data reports activation in embryonic cell lines. In addition, 
the overlap of this TSS with a CpG island suggests the presence of a promoter in this 
region (Figure 6.1 A).  
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Figure 6.1 - Characterisation of REST promoter region. A. Schematic representation of REST gene as described in the UCSC Genome Browser, assembly GRCh37/hg19, 
Feb 2009. Exons represented as white boxes; introns as connecting lines. Scale bar is represented at the top. Three different transcriptional start sites are identified by a 
different first exon. Vertical grey lines highlights putative variable regions according to UCSC Genome Browser. The green bar identifies a CpG island. Transcription factor 
binding and histone marks over the REST promoter from ENCODE V2 data B. Enlargement of the transcriptional start site containing the polymorphic microsatellite. From 
the top: scale bar, black arrows highlighting the relative position of the forward and reverse primers used for the genotype, green bar representing the CpG island. The white 
box is the first exon, each grey box represent a repetition of the microsatellite, grey bar show the putative VNTR according to UCSC Genome Browser. Number of repetitions 
and length in base pairs are shown for each variant. Underneath is shown the alignment of the sequences for each variant.  
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Meanwhile, a distinct bioinformatic resource, Short Tandem Repeat (STR) web 
browser (http://strcat.teamerlich.org/), provides evidence of a polymorphic 
microsatellite. This variant has been identified after sequencing a total of 24 human 
samples. Information from STR web browser are highlighted in Figure 6.2. 
The most common allele, used as reference allele in STR web browser, is 
composed of 22bp, although being a repetition of 3bp the motif should be 21bp (7 
copies of the CGG motif). The same can be said for a minor variant of 19bp (18bp – 
6 copies) and a third variant of 28bp (27bp – 9 copies).  
Interestingly this VNTR has been reported to be 2474bp upstream from the TSS. 
From our bioinformatic analysis, and according to UCSC web browser, this VNTR 
overlaps with the 5ʹ Untranslated Region (5ʹ UTR) of the first possible TSS (Figure 
6.1 A). AceView web browser directly includes this polymorphism in a putative 
protein translation, marking this region as part of a fully functioning protein.  
This last statement has to be handled carefully as AceView browser does not 
report the first ATG codon as it should be for all the proteins. The first ATG in the 
reading frame is around 300bp upstream of this VNTR according to AceView web 
browser. However, the first available ATG codon would be exactly 36bp 
downstream of this polymorphism, excluding it from the translated protein. 
According to STR web browser, out of the 24 analysed samples, 14 American 
samples showed a single 6-copy variant of this polymorphism, 8 samples a 7-copy 
variant and 5 samples a 9-copy variant. In the European population only 8 samples 
have been sequenced for this locus and only the 7-copy and 9-copy variants have 
been identified with a 75-25% ratio (6 samples and 2 samples respectively) and 
demonstrating 35% of heterozygosity. A single African and a single Asian sample 
are homozygous for the 7-copy variant.  
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Figure 6.2- Snapshot of STR web 
browser for REST VNTR. Top left is a 
table summarizing the VNTR 
characteristics; on its left a bar chart 
showing the heterozygosity in the 
sequenced samples. Bottom left a chart 
with the relative genotype of the VNTR. 
On its right the frequency of each allele in 
all the analysed populations. Red bar is 
African population, orange bar American 
population, light blue bar Asian 
population, dark blue bar European 
population. 
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We decided to pursue the analysis of this already identified polymorphic region in 
addition to the NTR sequence that UCSC highlighted as possible polymorphism 
(Figure 6.1 B).  
The PCR amplification of the region of interest in human neuroblastoma cell lines 
and human genomic DNA (Promega) is illustrated in Figure 6.3 and it clearly appear 
polymorphic, although the 35bp difference of the NTR suggested by UCSC web 
browser appears not to be involved due to the very small bp difference in the agarose 
gel. This region has been subsequently purified, cloned and sequenced to confirm the 
nucleotide composition. The analysis of the human DNA samples performed in our 
laboratory also showed the presence of a previously unreported variant of 12 copy as 
illustrated in Figure 6.4. 
 
 
 
 
Figure 6.3 - Cell line genotype for REST VNTR. M: size marker 100bp (promega), lane 1: SK-n-
AS, lane2: Be2C, lane 3: Kelly, lane 4:SH-SY5Y, lane 5 human gDNA, lane 6: PCR negative control. 
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Figure 6.4 - REST VNTR polymorphism in human samples. PCR amplification of REST VNTR 
locus. A. Virtual gel generated from Qiaxcel of 6 homozygous samples for the 7 copy variants, 6 
homozygous samples for the 9 copy variants and 6 homozygous samples for the 12 copy variants. 
Underneath 2% agarose gel of the same PCR reactions. B. Virtual gel generated from Qiaxcel 
highlighting the allelic genotype combinations. On the right side the table summarises the genotype 
relative to each sample. 
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6.3.2 REST VNTR supports reporter gene expression in the SH-SY5Y 
neuroblastoma cell line 
To assess a possible regulatory function of REST VNTR, the 7-copies, 9-copies 
and 12-copies variants were cloned into the pGL3-Basic (pGL3B) luciferase reporter 
gene vector which lacks promoter and enhancer sequences.  
The constructs included -119 to +60 bp, of the reference genome (7 copies), of the 
REST first TSS promoter using the first base of the pre-mRNA sequence as +1, 
which incorporated the entire VNTR sequence, the 9 copies and 12 copies constructs 
were -119 to +66 and -119 to +75 respectively.  
The assay demonstrated the ability to modify the expression levels of the different 
REST VNTR constructs compared to the empty vector, showing a 6.21, 3.75 and 2.9 
fold increase for the 7-copies, 9-copies and 12-copies respectively (Figure 6.5; 
***p<0.001 for the average fold difference of luciferase activity supported by all the 
alleles of the REST VNTR over the pGL3B control).  
A significant difference (***p<0.001) has been found in the expression driven by 
these polymorphisms where the most common variant (7-copies) appears to be more 
capable to drive the expression of the luciferase gene followed by the 9-copies and 
the 12-copies. 
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Figure 6.5 - Validation of REST VNTR potential to regulate gene expression in SH-SY5Y cells. 
Schematic representation of REST VNTR constructs aligned to the REST gene showing the 7-copy, 
REST VNTR, 9-copy REST VNTR and 12-copy REST VNTR, variants of the REST VNTR ± the 
proximal flank region in the pGL3B (Basic) reporter vectors in forwards orientation. Average fold 
change in luciferase activity supported by the REST VNTR constructs over vector controls in SH-
SY5Y cells. N=3. *Significant changes in luciferase activity over backbone control and between 
experimental conditions. *P<0.05, **P<0.01, ***P<0.001. 
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6.3.3 Genotype Variation of the REST VNTR in Alzheimer’s disease 
The REST VNTR has been demonstrated to support differential reporter gene 
expression in the SH-SY5Y cell line model. We therefore hypothesised that this 
polymorphism might be a risk factor in the development of CNS diseases such as 
Alzheimer’s disease, especially because the dramatic change in expression of this 
protein found in AD vs Control brains (Lu et al., 2014). The genotype of this 
repetitive element was carried out in 225 AD patients, 71 age matched controls and 
340 healthy controls representing the ageing population. Three different alleles of the 
3bp REST VNTR were identified in our analysis including a 7-copies, 9-copies and 
12-copies polymorphism. 
 
Figure 6.6 - Allele distribution in comparison with STR web browser. Analysis of REST VNTR 
comparing AD, Aged Controls, Ageing Controls cohorts and STR web browser European sequenced 
samples. 
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The allele distribution for our analysed cohorts and STR web browser is 
summarised in Figure 6.6. Consistent with STR web browser the most common 
alleles in our cohorts are the 7-copies and 9-copies with an average of 45% and 35% 
respectively. The 12-copies is represented in 19% of our population.  
Interestingly STR web browser does not report the 12 copies polymorphism 
whilst we were unable to find any 6-copy variant in our cohorts highlighting the 
possibility of the 6 copies REST VNTR to be an extremely rare variant.  
This demonstrate that the allele frequency is comparable within the cohorts but 
the difference in the heterozygosity of the AD cohort and the two control cohorts 
might represent the real difference in the representation of a risk factor.  
Hardy–Weinberg (H-W) test was performed on each of the cohorts to evaluate 
whether the genotypes were in equilibrium. Figure 6.7 illustrates the expected 
genotypes beside the observed ones for each of the tested groups. 
In the control groups, whether analysed separately or together, no significant 
differences were found. In the AD cohort, however, the χ2 = 11.48 and the p-value 
with 3 df has been found <0.01 meaning less than a 1% chance that the discrepancy 
is due to chance or sampling error. Therefore, the assumption that the population is 
in H-W equilibrium (HWE) can be rejected.  
The results given by the HWE analysis strengthen our hypothesis of an 
association between the REST VNTR and AD. This association may lie in the 7_7 or 
12_12 genotype, both overrepresented in the AD cohort in comparison to the control 
groups, especially in the age matched controls where the 12_12 genotype is more 
present than in the ageing controls. 
To validate our hypothesis, however, we performed the clump statistical analysis 
(sham and Curtis 1995). The Clump 24 analysis software, which has been used for 
179 
 
 
our study, assesses the significance of the observed values from the expected values 
using a Monte Carlo-based approach, as also explained in the Material and Method 
chapter. 
 
 
 
Figure 6.7 - Hardy–Weinberg prediction for expected genotypes. Comparison of the expected  and 
observed REST VNTR genotypes in AD, aged control, ageing control and pooled control cohorts. 
Each table on the left side represent the observed genotypes for each cohort, on the right side the 
expected genotypes. The graphs underneath report the expected and observed genotypes. 
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The comparison of the genotype and allele frequencies between AD samples and 
aged controls are outlined in Table 6.1. Despite the significant association given by 
the HWE for the AD cohort, the clump analysis test, whose results are highlighted in 
the table on the left side of Table 6.1 does not report any significant difference 
between the AD and aged control groups.  
 
Table 6.1 - Genotype and allele frequencies of REST VNTR in AD cohort and matched aged 
controls.
 
Note: AD = Alzheimer’s disease. Tables at the top report the genotypes in the two different cohorts 
with count and percentage to the total. Tables below report the allele frequencies for REST VNTR. On 
the right, the clump analysis table with the χ2 and p value. Refer to section 2.2.12 for details on clump 
analysis.    
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Although the clump analysis was not able to detect any significant difference 
between the groups, it is notable that a difference of 8.4% increase in the 7_7 
genotype, a 3% increase in the 12_12 genotype and a reduction of 6.7% in the 7_12 
genotype was observed for AD compared to controls.  
The small sample size, especially for the control group, might represent a reason 
for the lack of power in the test. Moreover, increasing the sample size as in Table 
6.4, where the aged and ageing controls were pooled together, resulted in the p-value 
by the clump analysis dramatically falling in all the 4 available tests.  
We therefore decided to compare the two control cohorts in order to evaluate any 
possible difference between the groups. These two groups represent two different 
kind of healthy populations: the first, aged population, which are less likely to 
develop AD and the second, a population that due to the wider age range still has 
some possibility to develop AD in the future.  
Our hypothesis in this case would be to find a protective genotype that might be 
present in the aged population that has not developed AD. The results of this analysis 
are summarised in Table 6.2. 
The aged control group on the left and the ageing control group on the right 
respectively, although having different age range, are very similar between each 
other. The allelotype between the groups does not show any difference, however 
some slight, non significant, differences can be found in the genotypes.  
The most notable difference, once again, is in the 12_12 genotype with 2.8% and 
4.1% for aged and ageing cohort respectively and in the 9_9 genotype appearing 
more represented in the aged controls (16.5% vs 10.9%).  
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Table 6.2 - Genotype and allele frequencies of REST VNTR in aged and ageing controls. 
 
Note: Tables at the top report the genotypes in the two different control cohorts with count and 
percentage to the total. Tables below report the allele frequencies for REST VNTR. On the right, the 
clump analysis table with the χ2 and p value. Refer to section 2.2.12 for details on clump analysis.    
 
As there are only small differences between the control groups, we decided that it 
was appropriate to pool them together in attempt to give more strength to the clump 
analysis. The results are summarised in Table 6.3. 
Despite this, the clump analysis was not able to detect any significant difference 
between the groups, but now a trend can be delineated. It can still be observed that 
there was a 8.2% difference in the 7_7 genotype (higher in AD) which remained the 
same as in the previous analysis. The 7_12 genotype is still lower in the AD cohort 
although only by 4.7% and the 12_12 genotype difference lowered to 1.9%. The 7_9 
genotype is also lower in AD compared to controls.  
In every analysis performed the allelotype does not show any notable difference 
between the groups.  
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Table 6.3 - Genotype and allele frequencies of REST VNTR in AD cohort and pooled controls. 
 
Note: AD = Alzheimer’s disease. Tables at the top report the genotypes in the two different cohorts 
with count and percentage to the total. Tables below report the allele frequencies for REST VNTR. On 
the right, the clump analysis table with the χ2 and p value. Refer to section 2.2.12 for details on clump 
analysis.    
 
 
6.3.4 Genotype Variation of the REST VNTR in FTD and schizophrenia 
In addition to the AD cohort, a small FTD cohort and a schizophrenia cohort, 
made available for the study, have been genotyped for the REST VNTR. In FTD 
there is a depletion of REST in neuronal nuclei (Lu et al., 2014). As illustrated in 
Table 6.4, the genotype for the FTD cohort does not show any particular difference 
compared to the aged controls except for a 2.1% increase in the 12_12 genotype and 
a 2.4% reduction in the 9_9 genotype. The p value, close to 1, obtained from the 
Clump analysis confirms that there is no difference between the 2 cohorts. For FTD 
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as well as for AD the allelotype does not show any difference, giving more strength 
to our hypothesis that a particular genotype will be more influential than the presence 
of a particular allele alone. 
Table 6.4 - Genotype and allele frequencies of REST VNTR in FTD cohort and age matched 
controls 
 
Note: FTD = Fronto temporal dementia. Tables at the top report the genotypes in the two different 
cohorts with count and percentage to the total. Tables below report the allele frequencies for REST 
VNTR. On the right, the clump analysis table with the χ2 and p value. Refer to section 2.2.12 for 
details on clump analysis.    
 
In the schizophrenia cohort we can observe an inversion in the trend for the 7_7 
genotype with a slight reduction, an increase of 6.7% and 2.3% in the 9_9 and 12_12 
genotype respectively in comparison to the healthy controls. The heterozygosity of 
this group (59%) is between the AD and control groups.  
Finally in Table 6.6 are represented the three cases cohorts that we have genotyped 
for a direct comparison. Once again, the clump analysis does not show any 
significant differences among any of the cohorts. 
185 
 
 
 
Table 6.5 - Genotype and allele frequencies of REST VNTR in schizophrenia cohort and age 
matched controls 
Note: SCZ = schizophrenia. Tables at the top report the genotypes in the two different cohorts with 
count and percentage to the total. Tables below report the allele frequencies for REST VNTR. On the 
right, the clump analysis table with the χ2 and p value. Refer to section 2.2.12 for details on clump 
analysis.    
However, the 7_7 genotype is overrepresented in the AD group, with an increase 
of 9.1% and 8.8% compared to FTD and schizophrenia respectively.  
The heterozygous 7_9 genotype is increased in the FTD cohort by 5% compared 
to the other cohorts. In the 7_12 genotype it can be observed a reduction of 6% in the 
AD cohort, whilst in FTD and SCZ cohort there is no difference. 
The 9_9 genotype is 4% higher in the schizophrenia cohort than in AD and FTD. 
Finally no difference is observed in the 9_12 genotype and a very small difference is 
present in the 12_12 genotype among the groups. In conclusion the major difference 
(8.4%) in the 7_7 genotype appear to be specific for the AD.  
The 12_12 genotype is increased in the AD and schizophrenia cohorts compared 
to the relative controls. 
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Table 6.6 - Comparison for the genotype of REST VNTR in AD, FTD and schizophrenia cohorts. 
 
 
Note: AD = Alzheimer’s disease; FTD = Fronto temporal dementia; SCZ = schizophrenia. Tables at the top report the genotypes in the three different cohorts with count and 
percentage to the total. Tables below report the clump analysis with the χ2 and p value. Refer to section 2.2.12 for details on clump analysis.   
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6.4 Discussion 
The REST gene has been recently associated with AD, in particular REST protein 
levels have been found dramatically reduced in AD CNS (Goetzl et al., 2015, Lu et 
al., 2014). Bioinformatic analysis on the REST locus highlighted the presence of 
three possible TSSs. Two of these TSSs overlap with a CpG island and ENCODE 
data suggest that POLR2A binds across them, suggesting the presence of a promoter. 
The ENCODE database also gives information about the binding of REST itself to 
the second and the third TSSs.  
Several other genes such as MAOA, 5HTT-LPR, STIN2 (Hill et al., 2013, 
Guindalini et al., 2006, Haddley et al., 2008, Ali et al., 2010, Vasiliou et al., 2012, 
Galindo et al., 2011, Roberts et al., 2007) have been identified to possess 
polymorphic copy variants comprised of repetitive elements within their promoters 
which have been linked to CNS conditions, diseases or behavioural traits, both by 
themselves or in the Gene x Environment interaction.  
The data generated from the reporter gene constructs indicate that REST VNTR 
can significantly modulate reporter gene expression. In addition the length of the 
repetitive element differentially modulates the expression, the 7-copy REST VNTR 
having the highest power of driving the expression, while the 12-copy has the lowest. 
 To test our hypothesis of REST VNTR as a potential biomarker for AD, we 
genotyped an AD cohort with age matched and non-matched control cohorts. In the 
analysed samples 3 different variants have been found consisting in 7 copies, 9 
copies and 12 copies of a CGG triplet.  
The first 2 variants have been previously reported by the STR web browser while 
the third, unreported previously, has been experimentally found in our study. 
Another variant, consisting in 6 copies, has been reported by STR web browser in 
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just one sample but we were unable to find it in our cohorts suggesting to be a very 
uncommon variant.  
Our cases and control groups differ is heterozygosity; the AD samples show an 
average reduction of 10% compared to controls either aged matched or not (Figure 
6.5). Furthermore, the allele distribution does not differ among the groups suggesting 
that the specific individual genotype would be more important than the presence of a 
particular allele.  
Comparing the AD cohort with its age matched controls we find a reduction 
(8.8%) in heterozygosyty especially in the 7_9 and 7_12 alleles which is 
compensated by an increase (8.4%) of the homozygous 7_7 genotype in the AD 
group (Table 6.1). At the same time they also show an increase of 3% in the 12_12 
genotype and a reduction of 3% in the 9_9 genotype.  
Considering both the genotype and the reporter gene data we could draw some 
predictions. 
The 7_7 genotype, which provides the highest reporter gene expression in our 
assays might actually result in an overall down-regulation of REST, since REST 
might inhibit its own expression, whilst the 12_12 genotype, with the lowest reporter 
gene expression, might bring an overabundance of it.  
Therefore, the thousands of genes regulated by REST will be dramatically 
affected (Bruce et al., 2009, Johnson et al., 2007).  
In addition these genotypes might be linked to the different cognitive impairment 
seen by Lu et al. (2014) where patients with severe cognitive impairments have been 
found with an even lower REST nuclear expression compare to those with mild or no 
cognitive impairment. Unfortunately we were unable to prove this hypothesis in our 
cohorts because we have been unable to access the relevant clinical data.  
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The 9_9 genotype is 5% more abundant in the aged control group, this might be a 
sign of an optimal expression rate that might reveal itself to be a protective trait at 
least for AD, although this same genotype has been found particularly high in the 
schizophrenia cohort compared to the healthy controls (16.9% vs 10.9%). The ageing 
population might still develop this condition while the aged controls have less 
chances to have a late onset for AD. 
Finally, consistent with our initial hypothesis of an association between AD and 
REST VNTR, the Hardy–Weinberg prediction highlights unexpected genotype 
combinations in our AD cohort (p<0.01 df=3). In particular the 7_7 and the 12_12 
genotypes are higher and at the same time the 7_9 and 7_12 genotypes are lower than 
what we would expect to find in the general population.  
On the contrary, in our aged cohort the only difference between the observed and 
the expected values, is the 12_12 genotype with a slight reduction in the observed 
samples. This difference is not present in the ageing cohort and that is concealed in 
the pooled control cohort.  
Unfortunately due to the relatively small sample size we have not been able to 
show enough statistical power to validate our genotype in AD. 
However a clear trend can be observed especially when we increased the control 
samples size pooling together the aged and ageing control groups, although no 
statistical difference can be observed (Table 6.2). 
REST has been also recently indirectly linked to schizophrenia, either as a 
regulator of a Genome-Wide Associated Gene MIR137 (Warburton et al., 2015) or 
negatively regulating the normal developmental switch of the 2B subunit in the N-
methyl-D-aspartate (NMDA) receptor which is thought to be responsible for a 
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greater hippocampal excitement and consequently source of the psychosis symptoms 
in schizophrenia (Tamminga and Zukin, 2015).  
In the first case a VNTR in mir137 promoter region has been proven to be 
differentially regulated by REST where overexpression of REST reduces mir137 
expression, which is positively linked to schizophrenia.  
In the second case, REST will be necessary for the REST-mediated subunit switch 
in the NMDA receptors. Failure of this switch will result in a greater expression and 
presence of GluN2B in the NMDA receptors with an immature phenotype which is 
more observed in the CA3 of humans with schizophrenia.  
Once again the relatively small sample size, and the lack of clinical information, 
does not allow us to clarify REST involvement in this condition, although 
homozygosity seems to play an important role in this condition as well as for AD.  
Given the importance of this protein from the early development to the late 
adulthood an imbalance of its expression, either too high or too low, could represent 
a tangible risk and a really important biomarker for detecting this condition way 
before its onset, thus could provide the basis for a tailored genetic treatment in 
patients.  
Further analysis will be required and these data will have to be repeated in a much 
larger cohort to prove statistical power, nevertheless this finding might give great 
insight in the future of this pathology. 
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Chapter 7 
 
Final Conclusions 
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7.1 Project overview 
In this investigation we have given new insights into the role of novel genetic 
polymorphisms and we expanded the knowledge of other already known and well 
established GxE susceptible loci.  
Their localisation in highly CNS disease-sensitive gene promoter regions further 
increases their importance in their role as gene regulators in response to 
environmental stimuli.  
In relation to our initial project aims and objectives the following observations can 
be made: 
 In the neuroblastoma cell line SH-SY5Y the MAOA promoter region is 
susceptible to chromatin modifications that allow single stranded binding 
factor to bind DNA after exposure to sodium valproate (Figure 3.6) and at 
the same time displayed a variable methylation pattern in the same genetic 
region (Figure 3.7) 
 We have been able to differentiate the expression of the two MAOA mRNA 
isoforms by basing our measurements on an alternative splicing exon within 
the second isoform and comparing it to the 5ʹ UTR where the uVNTR is 
located (Figures 4.13 – 4.14) 
 The MAOA VNTRs KO cell line model HAP1 proved, through our 
experiments, that the uVNTR is a negative regulator of the second MAOA 
isoform and it doesn’t have any activity on the primary MAOA isoform, 
despite the fact that it has always been defined as positive regulator (Figures 
4.13 – 4.17) 
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 The major role in MAOA gene expression is attributed to the less studied 
dVNTR that proved itself to be a positive regulator of the primary MAOA 
isoform and a negative regulator of the second isoform (Figure 4.24). 
 Our data strongly suggest that the mood stabiliser, sodium valproate, exerts 
its function through the uVNTR (Figure 4.23)  
 The GWAS candidate gene for schizophrenia CACNA1C contains a VNTR in 
its promoter region that, through bioinformatic analysis, has been shown to be 
present in less than 2% in the population 
 The VNTR (TR1) in the CACNA1C promoter has been proven to contain a 
positive regulator while the TR2 contains a negative regulator (Figure 5.3)  
 CACNA1C minimal promoter directs gene expression in our reporter gene 
constructs and it responds in a stimulus-inducible manner when subjected to 
either cocaine or lithium chloride (Figure 5.4)  
 We identified a novel polymorphic microsatellite within the REST gene 
promoter region. Each variant, compared to each other, has been proven to 
drive expression gene constructs significantly (Figure 6.5) 
 No significant difference can be found among the genotyped FTD, SCZ or 
AD cohorts. However the Hardy–Weinberg prediction show a significant 
difference within the AD cohort (Figure 6.7) strongly suggesting a 
correlation within this condition and the REST VNTR genotype.  
However, because of the relatively small sample size we analysed, we were 
not able to prove statistical significance. 
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7.2 The role of VNTR polymorphisms 
It is now widely accepted that both genetic and environmental factors shape our 
own individuality and our behaviours and are able to create the basis for CNS 
diseases and conditions. It was already common knowledge that genetic polymorphic 
variants within the population may represent either protective or risk factors for 
several conditions. However the deep relation between genes and environment is still 
not completely understood.  
Microsatellites and VNTRs constitute 3% of the entire human genome (Lander et 
al., 2001) and they have been widely involved in gene regulation processes (Gymrek 
et al., 2016, Li et al., 2007). Furthermore, a wide range of microsatellites and VNTR 
have been associated to just as many diseases (Table 1.2), CNS conditions and 
behavioural traits (Table 1.1).  
However, despite their importance, VNTRs and microsatellites are often poorly 
studied due to the peculiar difficulties that these genetic regions possess. The high 
CG content that usually constitute them and the repetitive nature per-se of these 
regions, are among the factors that persuade scientists to go for easier ways.  
SNPs are often better candidates in terms of efficiencies and effectiveness in 
scientific studies. Several equipments have been developed and a wide range of 
bioinformatic tools have been designed in order to facilitate SNP studies. 
In the last decade, however, the advancement in DNA-sequencing technologies 
and better bioinformatic tools, made possible a deeper understanding of these 
repetitive and polymorphic genetic regions (Treangen and Salzberg, 2012).  
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7.3 The MAOA VNTRs 
The MAOA uVNTR has been implicated, as a risk factor, in a wide range of 
behavioural processes and CNS conditions (Table 1.4). However, our data in 
Chapters 3 and 4 strongly suggest a primary role of the less studied dVNTR in the 
MAOA canonical protein expression, while the uVNTR appears to not be involved in 
regulating this isoform expression.  
Both VNTRs negatively regulate the expression of a secondary MAOA isoform, 
containing the uVNTR within the longer 5ʹUTR (Figure 4.26), and generating a 
shorter protein that hypothetically loses the ability to break down monoamine 
neurotransmitters, as the FAD binding domain is disrupted.  
 Furthermore, as reported in Chapter 3, the mRNA containing the uVNTR in the 
longer 5ʹUTR, appears to be more responsive to external stimuli, in particular the 3R 
variant of the MAOA uVNTR in comparison to the 4R variant. In Chapter 4, I 
validated the responsiveness to external stimuli of this isoform and the 3R uVNTR in 
the haploid cell line HAP1 (Figure 4.23). 
Overall, these results reveal a dual role of the dVNTR, as it can be an activator or 
a repressor depending on the isoform that is going to be transcribed. In addition, 
these data point to a previously ignored MAOA mRNA isoform that could be 
responsible for the association that has been made between the MAOA gene and CNS 
conditions from several association studies. 
Data generated from our group strongly suggest linkage disequilibrium between 
these VNTRs, with a further layer of stratification in the behavioural traits that 
specific genotypes generate in response to environmental stimuli (data not 
published). If taken into consideration, the expression data on the longer 5ʹUTR 
MAOA isoform, and the behavioural traits associated with a particular genotype, 
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might represent the explanation of the strong GxE interaction that the MAOA gene 
displays.   
 
7.4 The CACNA1C gene 
The association between the CACNA1C gene and SCZ is one of the most 
reproduced by GWAS studies (Schizophrenia Psychiatric Genome-Wide Association 
Study, 2011). Several SNPs within CACNA1C introns have been repeatedly linked to 
SCZ (Eckart et al., 2016, Nyegaard et al., 2010). However, linkage disequilibrium 
analysis on these SNPs and the two CACNA1C promoter region’s TRs, on which we 
focused our attention, failed to produce any significant association (data not shown).  
The analysis on the TR located on the far 5ʹ side of the CACNA1C promoter 
region (TR2 – Figure 5.2) revealed no polymorphic nature. Bioinformatic analysis 
on TR1, however, showed a polymorphic in-del: rs530020760 (chr12:2162060-
2162067 Hg19) which is a deletion of the “CGGG,CGGG” repeat motif seen in 
2.08% of the population and rs548465087 (chr12:2162068-21620670 Hg19), which 
is an insertion of the “CGGG” repeat motif seen in 97.92% of the normal population. 
Reporter gene construct assays revealed that TR1 contains a positive regulator 
while the TR2 contains a negative regulator (Figure 5.2). Furthermore, the 
expression from the reporter gene constructs is directed by the CACNA1C minimal 
promoter and it is able to respond in a stimulus-inducible manner when subjected to 
either cocaine or lithium chloride (Figure 5.3). 
The calcium current directed by the calcium channels is fundamental in both 
cardiac muscle tissue and in the brain (Christel and Lee, 2012, Striessnig et al., 
2014). These data on the CACNA1C promoter region and the GxE interaction 
displayed represent a step forward, although little, in the understanding of this gene 
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expression and its relation to external stimuli. In the future, the data presented in this 
thesis might be of great relevance for personalised medicine and shed light into the 
functioning and regulation of this elaborate gene. 
 
7.5 The REST VNTR 
The activity and levels of REST have been associated with several pathological 
conditions as previously highlighted in section 1.10. Recently, Lu et al. (2014) and 
Goetzl et al. (2015) reported a marked reduction of REST in AD patients. 
In this investigation we reported a novel polymorphic microsatellite within the 
REST promoter region. Two variants of this microsatellite have been previously 
reported by the STR web browser and a third one has been experimentally found in 
our study. The reporter gene constructs, generated with the three variants, proved to 
be able to support expression. In addition, the expression can be differentially 
modulated depending on the copy variant (Figure 6.5).  
Our genotype data suggest an association of this microsatellite with AD according 
to the Hardy–Weinberg (H-W) test. However, the relatively small sample size did 
not show enough statistical power to prove a significant association with AD through 
the clump test.  
Nonetheless, these results, if further investigated, might be able to open a new 
path in the understanding of this pathology, better chances of a early diagnosis and 
better prevention strategies, if not a personalised genetic therapy. 
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7.6 Limitations of the work 
In chapter 3 we have verified the expression of the MAOA mRNA utilising the 
uVNTR primer set in order to target the 5’UTR of this specific isoform. However, 
we have only been able to assess the presence of this MAOA mRNA in few human 
samples. As shown in Figure 3.4, clear differences are present in the expression of 
MAOA associated to different VNTRs (3R – 4R). An association of the cortisol 
levels for each sample to a possible differential expression would have strengthen the 
finding in the cell line model where the different MAOA alleles responded in a 
specific allelic manner (Figure 3.5)   
In chapter 4, three distinct mRNA isoforms have been isolated utilising different 
primer sets that allowed us to distinguish each isoform. However, a deeper analysis 
at the protein level would be necessary in order to definitely prove the translation of 
these mRNA isoform into proteins. In addition, an activity study of the different 
MAOA isoforms would be necessary. If the FAD binding domain lacking in the 
short (Figures 4.1 C – 4.3 – 4.7) and medium (Figures 4.1 B – 4.6)  MAOA is 
absolutely necessary for a correct activity of these isoforms the resulting proteins 
would be inactive. In addition a quantitative PCR of the different isoforms would 
strengthen the mRNA expression profile analysed in the chapter.  
In chapter 6 the relative small cohort did not allow us enough statistical power for 
the REST VNTR analysis. The study should be repeated in a much larger cohort.  
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7.7 Future studies 
For a complete analysis of MAOA, methylation and expression profile analysis in 
human samples associated to clinical data should be preferential. This will confirm 
and clarify a differential allelic expression due to the different uVNTR alleles. 
After overexpression of the MAOA isoforms (short and medium) the activity should 
be assessed. In alternative to the overexpression, MAOA could be enriched through 
antybody precipitation. It would be important to confirm the transcription factor 
binding in the HAP1 KO cell lines through ChIP analysis and correlate these to the 
expression profile, preferentially with qPCR specifically targeting the different 
MAOA isoforms 
In chapter 5 an activator and a repressor have been found in close proximity of the 
CACNA1C TSS in the P2 and P3 constructs respectively. The reporter gene 
expression assay with the different constructs should be repeated in association with 
EZH2 overexpression. Being EZH2 an important regulator of several developmental 
processes and its specific binding sequence present in several calcium channels, it 
might give insights for a better understanding of the CACNA1C and other calcium 
channels dysregulation found in schizophrenic patients.  
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